(S1 (S (NP (NN Gene) (NN expression) (NN analysis)) (VP (VBD indicated) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (NNS genotypes)) (PP (IN of) (NP (NP (DT the) (NN drug1) (NN variant)) (CC and) (NP (NN CHRNA5) (NN expression))))))) (PP (PP (IN in) (NP (NP (NN brain)) (CC and) (NP (JJ peripheral) (NN drug2)))) (, ,) (CC and) (PP (IN with) (NP (NP (DT the) (NP (NP (NN rs16969968)) (CC and) (NP (NN rs17477223))) (NNS variants)) (PP (IN in) (NP (NN brain))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NP (DT the) (NN intake)) (PP (IN of) (NP (NP (JJ saturated) (JJ fatty) (NNS acids)) (PRN (-LRB- -LRB-) (NP (NNS SFA)) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NN drug2)))) (PP (IN on) (NP (NP (NN serum) (NN lipid) (NNS levels)) (PP (IN in) (NP (JJ Lithuanian) (JJ adult) (NN population))))))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NP (NN drug1)) (, ,) (NP (NN SFA) (NN intake)) (, ,) (CC and) (NP (NN drug2))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (NN blood) (NN lipid) (NNS levels)) (PP (IN in) (NP (JJ Lithuanian) (JJ adult) (NN population)))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Analysis)) (PP (IN of) (NP (ADJP (ADJP (JJ gene-diet)) (CC and) (ADJP (JJ gene-obesity))) (NNS interactions)))) (VP (VBD did) (RB not) (VP (VB confirm) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN diet)) (CC and) (NP (NN drug2)))) (PP (IN on) (NP (NP (NN TC)) (CC and) (NP (NN LDL-C)) (NP (NN level))))) (ADVP (RB significantly)) (VP (VBD depended) (PP (IN on) (NP (NN drug1))))))))) (. .)))
(S1 (S (PP (IN Inside) (NP (NP (DT this) (NN region)) (PP (IN of) (NP (CD 16.3) (NN kb))))) (, ,) (NP (NP (NP (NN LD)) (PRN (-LRB- -LRB-) (NP (ADJP (NN r2) (JJ =)) (CD 0.14)) (-RRB- -RRB-))) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NN drug3))) (, ,) (PP (CC but) (PP (RB not) (IN in) (NP (NN drug4))) (CC and) (PP (IN in) (NP (NNS controls)))))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (PP (IN In) (NP (DT the) (NN discovery) (NN population))) (, ,) (NP (PRP we)) (VP (VBD observed) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (NN SIRT2) (NN drug1) (NN T) (NN allele)) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (VBN adjusted) (NNS odds)) (ADJP (NN ratio) (NN -LSB-OR) (-RRB- -RSB-) (JJ =) (NP (CD 1.23)))) (, ,) (NP (CD 95) (NN %) (ADJP (RB confidence) (JJ interval)) (NN -LSB-CI) (-RRB- -RSB-) (: :) (CD 1.02-1.50)) (, ,) (S (NP (NN P)) (VP (JJ =) (NP (NN .02)) (, ,) (PP (IN after) (NP (NP (NN correction)) (PP (IN for) (NP (NP (NN sex)) (, ,) (NP (NN age)) (, ,) (CC and) (NP (NN APOE) (NN e4) (NN genotype)))))))) (-RRB- -RRB-)))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN association)) (PP (IN between) (NP (NP (NN drug2)) (CC and) (NP (NN SIRT2) (NN drug1) (NN T) (NN allele))))) (VP (VBD was) (ADJP (RB only) (JJ present) (PP (IN in) (NP (NN APOE) (NN e4) (NNS noncarriers)))) (PRN (-LRB- -LRB-) (NP (NP (VBN adjusted)) (CC OR) (NP (ADJP (JJ =) (NP (CD 1.29) (, ,) (CD 95) (NN %) (CD CI))))) (: :) (NP (CD 1.03-1.61)) (, ,) (NP (ADJP (NN P) (JJ =)) (CD .03)) (-RRB- -RRB-)))) (. .)))
(S1 (S (PP (IN Over) (NP (NP (DT an) (JJ average) (NN period)) (PP (IN of) (NP (CD three) (NNS years))))) (, ,) (NP (NP (NNS participants)) (PP (IN with) (NP (NP (DT the) (JJ risk-conferring) (NN TT) (NN genotype)) (PP (IN at) (NP (NN drug1)))))) (VP (VBD were) (ADJP (RBR more) (JJ likely)) (S (VP (TO to) (VP (VB have) (NP (NP (NN progression)) (PP (IN from) (NP (NN drug2))) (PP (TO to) (NP (NN drug3)))) (SBAR (IN than) (SINV (VBD were) (NP (NP (JJ CC) (NNS homozygotes)) (PRN (-LRB- -LRB-) (NP (NN hazard) (NN ratio)) (, ,) (NP (CD 1.55)) (: ;) (NP (NP (CD 95) (NN percent)) (ADJP (RB confidence) (JJ interval))) (, ,) (NP (CD 1.20) (TO to) (CD 2.01)) (: ;) (NP (NN P<0.001)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NP (DT The) (NN frequency)) (PP (IN of) (NP (NN drug1)))) (VP (VBD did) (RB not) (VP (VB differ) (PP (IN between) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNS drug2)) (CC and) (NP (NNS controls))))))))) (. .))))
(S1 (S (S (NP (DT The) (NNS results)) (VP (VBD indicated) (SBAR (IN that) (S (NP (NP (JJ homozygous) (NN drug1) (NNS carriers)) (ADJP (JJ aged) (NP (NP (CD 35) (NNS years)) (CC or) (NP (JJR older))))) (VP (VBD had) (NP (JJR worse) (NN drug2)) (PP (IN than) (NP (NP (JJ heterozygous) (NNS carriers)) (CC and) (NP (NNS noncarriers))))))))) (. .)))
(S1 (S (NP (CD Nine) (NNS loci)) (VP (VBD were) (ADVP (RB statistically)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ incident) (NN drug10) (NNS events)) (PP (IN in) (NP (NP (NP (NP (NP (JJ white) (NNS participants)) (: :) (NP (NP (NN 9p21)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (: ;) (NP (CD P=4.7) (NN *) (CD 10) (-LRB- -LRB-) (CD -41) (-RRB- -RRB-)) (-RRB- -RRB-))) (, ,) (NP (NP (CD 16q23.1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (: ;) (NP (NN P=0.0004)) (-RRB- -RRB-))) (, ,)) (NN 6p24.1)) (PRN (-LRB- -LRB-) (NP (NN drug3) (: ;) (CD P=0.0002)) (-RRB- -RRB-))) (, ,) (NP (CD 2q36.3) (PRN (-LRB- -LRB-) (NP (NN drug4)) (: ;) (NP (CD P=6.7) (NN *) (CD 10) (-LRB- -LRB-) (CD -6) (-RRB- -RRB-)) (-RRB- -RRB-))) (, ,) (NP (NP (NN MTHFD1L)) (PRN (-LRB- -LRB-) (NP (NN drug5)) (, ,) (NP (NP (NN P=5.1) (NN *) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD -10)) (-RRB- -RRB-))) (-RRB- -RRB-))) (, ,) (NP (NP (NN APOE)) (PRN (-LRB- -LRB-) (NP (NN drug6)) (: ;) (NP (CD P=2.7) (NN *) (CD 10) (-LRB- -LRB-) (CD -18) (-RRB- -RRB-)) (-RRB- -RRB-))) (, ,) (NP (NN ZNF627) (PRN (-LRB- -LRB-) (NP (NN drug7)) (: ;) (NP (CD P=5.0) (NN *) (CD 10) (-LRB- -LRB-) (CD -8) (-RRB- -RRB-)) (-RRB- -RRB-))) (, ,) (NP (NP (NN CXCL12)) (PRN (-LRB- -LRB-) (NP (NN drug8)) (: ;) (NP (CD P=1.4) (NN *) (CD 10) (-LRB- -LRB-) (CD -6) (-RRB- -RRB-)) (-RRB- -RRB-))) (CC and) (NP (NP (NN LPL)) (PRN (-LRB- -LRB-) (NP (NN drug9)) (: ;) (NP (CD P=2.7) (NN *) (CD 10) (-LRB- -LRB-) (CD -17) (-RRB- -RRB-)) (-RRB- -RRB-)))))))))))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (NP (NP (NP (NP (NN Apolipoprotein) (NN E)) (PRN (-LRB- -LRB-) (NP (NN APOE)) (-RRB- -RRB-))) (JJ functional) (NNS haplotypes)) (VP (VBN determined) (PP (IN by) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (NP (NNS SNPs)))))) (VP (VBP have) (VP (VBN been) (ADVP (RB extensively)) (VP (VBN studied)) (CC and) (VP (VBN found) (S (VP (TO to) (VP (VB be) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (JJ consistent)) (NN association)) (PP (IN in) (NP (JJ human) (NN drug3) (NNS studies))))))))))))) (. .))))
(S1 (S (S (NP (EX There)) (VP (VBD were) (ADVP (RB also)) (NP (NP (DT no) (JJ significant) (NNS effects)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN E4)) (NP (NNS carriers)))) (PP (IN on) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN drug2)))))))) (, ,) (CC but) (S (NP (JJ multivariate) (JJ logistic) (NN regression) (NN testing)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NP (NP (NN triglyceride)) (CC and) (NP (NN hemoglobin) (NN A1c))) (NNS concentrations))))) (VP (VBD had) (NP (JJ independent) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN drug4)))))))))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (NP (JJ Significant) (NNS associations)) (PP (IN with) (NP (NN drug4)))) (VP (VBD were) (VP (VBN observed) (PP (IN for) (NP (NNS genotypes) (NP (NP (NP (NP (NN drug1) (NN A/T)) (PRN (-LRB- -LRB-) (NP (NNS odds) (NP (NP (NN ratio)) (NP (NN -LSB-OR)))) (-RRB- -RSB-) (, ,) (NP (NP (NP (QP (CD 2.1) (: ;) (CD 95)) (NN %)) (ADJP (RB confidence) (JJ interval))) (NP (NN -LSB-CI))) (-RRB- -RSB-))) (PRN (, ,) (NP (CD 1.0-4.5)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug2) (NN T/C)) (PRN (-LRB- -LRB-) (NP (NP (NN OR)) (, ,) (NP (CD 4.4) (: ;) (CD 95) (NN %) (CD CI)) (, ,) (NP (CD 1.9-10.2))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN drug3))))) (PRN (-LRB- -LRB-) (CC OR) (, ,) (NP (CD 4.1)) (: ;) (NP (CD 95) (NN %) (NN CI)) (, ,) (NP (CD 1.6-10.9)) (-RRB- -RRB-))))))))
(S1 (S (S (NP (NP (NP (NP (DT The) (JJ nicotinic) (NN acetylcholine) (NN receptor)) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (PP (IN on) (NP (NN chromosome) (CD 15q25)))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ major) (NN drug2)) (PP (IN in) (NP (NP (NP (DT the) (JJ general) (NN population)) (PP (IN with) (NP (NP (JJ additional) (VBN increased) (NN risk)) (PP (IN of) (NP (NN COPD)))))) (CONJP (RB as) (RB well) (IN as)) (NP (NN drug3))))))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (EX there)) (VP (VBD was) (NP (ADJP (RB only) (JJ moderate)) (NN linkage) (NN disequilibrium)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (DT the) (NN ApoE) (NN e4) (VBG defining) (NN SNP) (NN drug2))))))) (, ,) (NP (PRP we)) (VP (MD could) (RB not) (VP (VB find) (NP (NP (DT an) (JJ APOE-independent) (NN effect)) (PP (IN of) (NP (NN drug3))) (PP (PP (IN on) (NP (NN drug4))) (, ,) (CC either) (PP (IN in) (NP (ADJP (ADJP (JJ cross-sectional)) (CC or) (ADJP (FW in) (JJ longitudinal))) (NNS analyses))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (DT the) (JJ major) (NN locus)) (VP (VBG determining) (NP (JJ familial) (NN drug2)) (PP (IN up) (TO to) (NP (NP (JJ high) (NN age)) (SBAR (IN as) (S (VP (VBN detected) (PP (IN by) (NP (NN GWAS)))))))))) (VP (VBD was) (VP (VBN marked) (PP (IN by) (NP (NP (NN drug1)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (NNS tags) (NP (NP (DT the) (JJ deleterious) (NNS effects)) (PP (IN of) (NP (DT the) (NN ApoE) (NN e4) (NN allele))))))))))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (PP (IN After) (S (VP (VP (VBG correcting) (PP (IN for) (NP (NP (JJ multiple) (NN testing)) (PRN (-LRB- -LRB-) (NP (NN p<0.05)) (-RRB- -RRB-))))) (CC and) (VP (VBG accounting) (PP (IN for) (NP (NP (JJ significant) (NNS differences)) (PP (IN in) (NP (NP (DT the) (NN association) (NN effect) (NNS sizes)) (PP (IN between) (NP (NP (NNS subjects)) (PP (IN with) (CC and) (PP (IN without) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN p<0.05)) (-RRB- -RRB-))))))))))))))) (, ,) (NP (NP (NNS variants)) (PP (IN of) (NP (NP (NP (NN APOA5)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (CC and) (NP (NP (NN APOE)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))))) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NP (NN HDL-C)) (CC and) (NP (NP (NN LDL-C) (NNS responses)) (PP (IN in) (NP (NNS MetS) (NNS subjects))))))) (, ,) (SBAR (IN while) (S (NP (NN APOA4) (NN drug3)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NN TG) (NN response)) (PP (IN in) (NP (JJ non-MetS) (NNS subjects))))))))))) (. .))))
(S1 (S (S (NP (PRP$ Our) (NNS findings)) (VP (VBP confirm) (SBAR (IN that) (S (NP (DT the) (NN drug1) (NN gene)) (VP (VBZ represents) (NP (NP (DT an) (JJ important) (NN locus)) (PP (IN for) (S (VP (VBG predicting) (NP (NP (VBN inherited) (NN susceptibility)) (PP (TO to) (NP (NN drug2))))))))))))) (. .)))
(S1 (S (S (NP (NP (CD Five) (NNS polymorphisms)) (PRN (-LRB- -LRB-) (NP (CD -491) (NN drug1)) (, ,) (NP (NP (NN -427) (NN drug2)) (, ,) (NP (CD -219) (NN drug3)) (, ,) (CC and) (NP (NN e) (NN drug4))) (: -) (NP (NN drug5)) (-RRB- -RRB-))) (VP (VBD were) (VP (VBN studied) (PP (IN in) (NP (NP (NP (CD 1308) (NN drug6) (NNS patients)) (CC and) (NP (NN 1082) (JJ control) (NNS individuals))) (PP (IN from) (NP (DT the) (NNP Central-Northern) (NNP Italy)))))))) (. .)))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (NP (NP (NP (NP (NN Apolipoprotein) (NN E)) (PRN (-LRB- -LRB-) (NP (NN APOE)) (-RRB- -RRB-))) (NN genotype)) (PRN (-LRB- -LRB-) (NP (NP (NN e2/e3/e4)) (: :) (NP (NN drug1) (NN e4) (NN allele)) (: ;) (NP (NN drug2) (NN e2) (NN allele))) (-RRB- -RRB-))) (VP (VBZ is) (ADVP (RB strongly)) (VP (VBN associated) (PP (IN with) (NP (CC both) (NP (NN lipid) (NNS levels)) (CC and) (NP (NP (DT A) (NN drug3) (POS 's)) (NN disease))))))) (. .))))
(S1 (S (SBAR (IN As) (S (VP (VBN expected)))) (, ,) (NP (DT the) (ADJP (ADVP (RBS most) (RB strongly)) (VBN associated)) (NN SNP)) (VP (VBD was) (NP (NP (DT the) (JJ APOE) (NN e4) (NN drug1) (NN variant)) (PRN (-LRB- -LRB-) (NP (NNP HR=2.47) (CD -LSB-1.58) (, ,) (CD 3.87) (-RRB- -RSB-)) (, ,) (NP (CD p=7.52) (NN *) (CD 10) (-LRB- -LRB-) (CD -5) (-RRB- -RRB-)) (-RRB- -RRB-))) (, ,) (SBAR (IN although) (S (NP (NP (NNS variants)) (PP (IN within) (NP (NP (DT the) (ADJP (RBR more) (RB recently) (VBN implicated)) (NN SORL1)) (CC and) (NP (NN RUNX1) (NNS genes))))) (VP (VBD were) (ADVP (RB also)) (ADVP (RB strongly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN HR=0.54) (CD -LSB-0.37) (, ,) (CD 0.80) (-RRB- -RSB-) (, ,) (NP (NP (NN p=0.002)) (CC and) (NP (NN HR=1.61) (CD -LSB-1.15) (, ,) (CD 2.26) (-RRB- -RSB-))) (, ,) (NP (NN p=0.006)) (ADVP (RB respectively))) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (NP (NN Disease) (NN association) (NN analysis)) (VP (VBD revealed) (NP (NP (NP (DT a) (NN susceptibility) (NN haplotype) (NN CGTC)) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NP (NN order)) (PP (IN of) (NP (NN drug1))))) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (NNS carriers)) (PP (IN of) (NP (NP (DT this) (NN haplotype)) (VP (VBZ has) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (NP (QP (CD 3.53) (, ,) (CD 95)) (NN %)) (NP (NN CI) (CD 1.21-11.0))) (, ,) (NP (NN P=0.017))) (-RRB- -RRB-))) (CC and) (NP (NP (NN osteoporosis)) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (NN 3.61)) (, ,) (NP (CD 95) (NN %) (JJ CI) (CD 1.53-9.48)) (, ,) (NP (NN P=0.002))) (-RRB- -RRB-)))))) (PP (IN after) (S (VP (VBG adjusting) (NP (NP (DT the) (JJ confounding) (NN effect)) (PP (IN of) (NP (NP (NN age)) (, ,) (NP (NN BMI)) (CC and) (NP (NP (NNS years)) (PP (IN since) (NP (NN menopause)))))))))))))))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (PP (IN With) (NP (JJ multivariate) (JJ generalized) (NN linear) (NNS models))) (, ,) (NP (NP (DT the) (NN association)) (PP (IN of) (NP (NN TEF) (NN drug1))) (PP (IN with) (NP (NN drug2) (NNS symptoms)))) (VP (VBD was) (VP (VBN confirmed)))) (. .))))
(S1 (S (S (NP (NP (JJ Several) (NNS markers)) (PP (IN in) (NP (NP (NP (JJ strong) (NN LD)) (PRN (-LRB- -LRB-) (NP (NN r) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (QP (RB >) (CD 0.7))) (-RRB- -RRB-))) (PP (IN with) (NP (NN drug1)))))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2) (NN risk)) (PP (IN in) (NP (NP (JJ recent) (NN genome-wide) (NN association) (NNS studies)) (PP (IN with) (NP (JJ similar) (NN effect) (NNS sizes))))))) (, ,) (S (VP (VBG providing) (NP (NP (JJ independent) (NN support)) (PP (IN of) (NP (DT the) (JJ current) (NNS findings))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN frequency)) (PP (IN of) (NP (DT the) (NN G) (NN genotype))) (PP (IN in) (NP (NN COMT) (NN drug1)))) (VP (VBD was) (ADJP (RB statistically) (JJ different) (PP (PP (IN between) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NN drug2)))) (CC and) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NN P) (JJ =) (CD .04)) (-RRB- -RRB-))))) (, ,) (CC and) (PP (IN between) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NN drug3)))) (CC and) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NN P) (JJ =) (NN .02)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN frequency)) (PP (IN of) (NP (DT the) (NN A) (NN genotype))) (PP (IN in) (NP (NN PLCH1) (NN drug1)))) (VP (VBD occurred) (ADVP (RBR more) (RB frequently)) (PP (IN in) (NP (NN drug2))) (PP (IN than) (PP (IN in) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NN P) (JJ =) (NN .02)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN G/G) (JJ homozygous) (NN genotype)) (PP (IN in) (NP (NP (NN COMT) (NN drug1)) (CC and) (NP (NN A/A)) (NP (JJ homozygous) (NN genotype)))) (PP (IN in) (NP (NN PLCH1) (NN drug2)))) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)) (, ,) (ADVP (RB respectively)))) (PRN (-LRB- -LRB-) (NP (NP (NNS odds) (NN ratio)) (ADJP (JJ -LSB-OR))) (-RRB- -RSB-) (NP (NP (CD 0.61)) (CC and) (NP (CC OR) (NP (CD 2.01)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP (DT the) (NN COMT) (NN drug1) (NN SNP)) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (VBN reduced) (NN risk)) (PP (IN of) (NP (NN drug2)))) (, ,) (ADVP (RB especially)) (NP (NN drug3))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ suggests) (SBAR (IN that) (S (NP (DT this) (NN SNP)) (VP (MD may) (VP (VB have) (NP (DT a) (JJ protective) (NN effect)))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (DT the) (NN PLCH1) (NN drug1) (NN SNP)) (VP (VBD was) (ADVP (RB strongly)) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN drug2)))))))) (. ,)))
(S1 (S (NP (NP (NN OBJECTIVE)) (: :) (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN athero-thrombosis)))) (SBAR (WHADVP (WRB however)) (S (NP (NP (DT the) (NN association)) (PP (IN with) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN AAA)) (-RRB- -RRB-))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB previously)) (VP (VBN examined)))))))))) (. .))))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (PRP We)) (VP (VBD found) (NP (NP (DT no) (JJ consistent) (NN association)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (. .))))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (SBAR (IN As) (S (ADVP (RB previously)) (VP (VBN reported) (PP (IN in) (NP (NN Spain)))))) (, ,) (NP (NN drug1) (NN allele)) (VP (VBD was) (ADVP (RB strongly)) (VP (VBN associated) (PP (IN with) (NP (NN drug2))) (PP (IN in) (NP (PRP$ our) (NN series))) (PRN (-LRB- -LRB-) (NP (NP (CD OR=2.88) (CD -LSB-95) (NN %)) (NP (NNP C.I.) (CD 2.16-) (CD 3.84) (-RRB- -RSB-))) (, ,) (NP (CD p=7.38E-11)) (-RRB- -RRB-))))) (. .))))
(S1 (S (S (NP (PRP$ Our) (NNS results)) (VP (VBP strengthen) (NP (DT the) (NN evidence) (SBAR (IN that) (S (NP (NP (QP (CD one) (CC or) (JJR more)) (NNS variants)) (PP (IN in) (NP (NN drug1)))) (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ combined) (NN effect)) (PP (IN of) (NP (NN drug1) (NNS polymorphisms))) (PP (IN on) (NP (NN drug2) (NNS phenotypes)))) (VP (VBD was) (VP (VBN observed)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB n't) (VP (VB affect) (NP (NN drug2))) (, ,) (S (VP (VBG suggesting) (NP (NP (PRP$ its) (ADJP (ADJP (JJ potential)) (ADJP (JJ modality-specific))) (NNS effects)) (PP (IN on) (NP (JJ human) (NN pain)))))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VP (VBD compared) (NP (NP (NN genotype) (NNS frequencies)) (PP (IN in) (NP (NP (NNS subjects)) (PP (IN with) (NP (NN drug2)))))) (PP (IN with) (NP (NP (DT those)) (PP (IN with) (NP (NN NGT)))))) (CC and) (VP (VBD found) (NP (JJ marginal) (NN association)) (PP (IN for) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJ =) (NP (CD 0.05)))) (: ;) (NP (NNS odds) (NP (NP (NN ratio)) (NP (JJ -LSB-OR) (-RRB- -RSB-) (NN 1.51)))) (-RRB- -RRB-)))))) (: ;)))
(S1 (S (NP (NP (NN comparison)) (PP (IN between) (NP (NP (JJ NGT) (NN control) (NNS subjects)) (CC and) (NP (DT the) (JJ combined) (NN drug5) (NN /IGT) (NN case) (NN group))))) (VP (VBD showed) (NP (NP (NP (JJ strong) (NN association)) (PP (IN with) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJ =) (NP (CD 0.008-0.01)))) (: ;) (NP (CC OR) (CD 1.53-1.57)) (-RRB- -RRB-))))) (CC and) (NP (NP (JJ marginal) (NN association)) (PP (IN with) (NP (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NN P)) (ADJP (JJ =) (NP (CD 0.07)))) (CC and) (NP (NN P))) (ADJP (JJ =) (NP (CD 0.04)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VP (VBD genotyped) (NP (DT these) (NNS SNPs)) (PP (IN in) (NP (NP (NP (ADJP (ADJP (JJ nondiabetic)) (, ,) (ADJP (JJ non-Amish))) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 48)) (-RRB- -RRB-))) (, ,) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (JJ intravenous) (NN glucose) (NN tolerance) (NNS tests)) (VP (VBD were) (VP (VBN performed))))) (, ,)))) (CC and) (VP (VBD found) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (NP (NP (NN drug1)) (CC and) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN P) (JJ =) (CD 0.003)) (CC and) (NP (NP (NN P)) (VP (VBG =) (NP (CD 0.005))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN P) (JJ =) (CD 0.04)) (CC and) (NP (NP (NN P)) (VP (VBG =) (NP (CD 0.007))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (DT the) (NN drug1) (NN polymorphism)) (VP (VP (VBZ is) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (DT the) (NN Caucasian) (NN population))))))) (CC but) (VP (VBZ acts) (PP (IN as) (NP (NP (DT a) (NN modifier)) (PP (IN of) (NP (NP (DT the) (NN AAO)) (PP (IN in) (NP (NN drug3))) (PP (IN with) (NP (DT a) (JJ sexual) (NN dimorphism)))))))))) (: :) (S (NP (DT the) (NN Val) (NN allele)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJR younger) (NN AAO)) (PP (IN in) (NP (NP (NNS men)) (PP (IN with) (NP (JJ idiopathic) (NN PD)))))))))) (. .)))
(S1 (S (NP (DT The) (NN drug1) (NN at-risk) (NN allele)) (VP (VBZ associates) (PP (IN with) (NP (NP (VBN decreased) (NN drug2)) (CC and) (NP (NP (JJR earlier) (NN age)) (PP (IN at) (NP (NN diagnosis)))))) (PP (IN in) (NP (NP (NP (DT the) (CD drug3) (NNS subjects)) (PRN (-LRB- -LRB-) (S (S (NP (NN P)) (VP (JJ =) (NP (CD 8.0) (NN x) (CD 10) (-LRB- -LRB-) (CD -3) (-RRB- -RRB-)))) (CC and) (S (NP (NN P)) (VP (JJ =) (NP (CD 3.8) (NN x) (CD 10) (-LRB- -LRB-) (CD -4) (-RRB- -RRB-)) (, ,) (ADVP (RB respectively))))) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN supported) (PP (IN by) (NP (JJ quantitative) (JJ family-based) (NN association) (NNS tests)))))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN seen) (S (VP (TO to) (VP (VB show) (NP (NP (DT a) (VBN decreased) (NN risk)) (PP (IN for) (NP (NN drug2))) (PP (IN in) (NP (JJ Asian) (NN population)))))))))))))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (NNS polymorphisms)) (VP (VBD demonstrated) (NP (NP (DT an) (ADJP (ADJP (VBN increased)) (CC and) (ADJP (VBN decreased))) (NN risk)) (PP (IN for) (NP (NN drug3)))) (, ,) (ADVP (RB respectively)))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (PRP We)) (VP (VP (VBD found) (NP (NP (DT no) (NN association)) (PP (IN between) (NP (NP (NN drug2) (NN status)) (CC and) (NP (NN SNP) (NN drug1) (NN genotype)))))) (CC nor) (VP (VBD did) (NP (PRP we)) (VP (VB find) (NP (NP (DT a) (JJ significant) (NN association)) (PP (TO to) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NNS drug3)))))))))))))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (SBAR (IN Although) (S (NP (NP (JJ prefrontal) (JJ cortical)) (CC and) (NP (JJ ventral) (JJ striatal) (NN activity))) (VP (VP (VBP are) (ADJP (RB highly) (JJ relevant) (PP (IN for) (NP (NN drug3))))) (, ,) (CC and) (PP (IN under) (NP (NP (JJ partial) (NN control)) (PP (IN of) (NP (NN drug1) (NN genotype)))))))) (, ,) (NP (NP (DT no) (NN association)) (PP (IN between) (NP (NP (NN drug2)) (CC and) (NP (NN drug4) (NN behavior))))) (VP (VBD was) (VP (VBN observed)))))))
(S1 (S (S (NP (PRP$ Our) (NNS data)) (ADVP (RB strongly)) (VP (VBP confirm) (SBAR (IN that) (S (NP (NN drug1) (NN gene)) (VP (VBP contribute) (PP (TO to) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug2)))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (PRP$ our) (NNS findings)) (VP (VP (VBP provide) (NP (NN evidence) (SBAR (IN that) (S (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (JJ other) (NNS genes))))) (, ,) (NP (NN drug1)) (ADVP (RB also)) (VP (VBZ has) (NP (DT a) (JJ significant) (NN role)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN drug2)))))))))) (, ,) (CC and) (VP (VBP demonstrate) (SBAR (IN that) (S (S (VP (VBG analysing) (NP (NP (DT the) (JJ complex) (NN phenotype) (NNS associations)) (PP (IN of) (NP (NNS genes)))) (PP (IN by) (NP (NN haplotype) (NN tagging))))) (VP (VBZ is) (NP (DT a) (JJ powerful) (NN method))))))) (. .)))
(S1 (S (PP (IN In) (NN contrast) (TO to) (NP (JJ previous) (NNS findings))) (, ,) (NP (NP (NN analysis)) (PP (IN by) (NP (JJ logistic) (NN regression)))) (VP (VBD failed) (S (VP (TO to) (VP (VB find) (NP (NP (DT any) (NNS associations)) (PP (IN between) (NP (ADJP (ADJP (JJ drug1)) (CC and) (ADJP (JJ drug2))) (NNS symptoms)))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (JJ prefrontal) (JJ cortical)) (CC and) (NP (JJ ventral) (JJ striatal) (NN activity))) (VP (VP (VBP are) (ADVP (RB highly)) (ADJP (JJ relevant) (PP (IN for) (NP (NN drug3))))) (, ,) (CC and) (PP (IN under) (NP (NP (JJ partial) (NN control)) (PP (IN of) (NP (NN drug1) (NN genotype)))))))) (, ,) (NP (NP (DT no) (NN association)) (PP (IN between) (NP (NP (NN drug2)) (CC and) (NP (NN drug4))))) (VP (VBD was) (VP (VBN observed)))) (. .)))
(S1 (S (S (NP (DT A) (JJ significant) (NN association)) (VP (VBD was) (VP (VBN observed) (PP (IN between) (NP (, ,) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (CC OR) (NP (ADJP (JJ =) (NP (CD 1.95))) (, ,) (NP (NNP C.I.) (CD 1.13-3.36))) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (CC OR) (NP (ADJP (JJ =) (NP (CD 2.39))) (, ,) (NP (NNP C.I.) (CD 1.24-4.24))) (-RRB- -RRB-)))) (NNS polymorphisms))) (PP (IN with) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (PRP We) (VBN observed) (DT a) (JJ strong) (NN association) (NN drug4) (IN with) (DT all) (DT the) (NNS polymorphisms) (, ,) (VBG including) (NN drug1) (-LRB- -LRB-) (NNS odds) (NN ratio) (JJ -LSB-OR) (-RRB- -RSB-) (CD 1.50) (CD -LSB-95) (NN %) (CD CI) (JJ =) (CD 1.24-1.82) (-RRB- -RSB-) (, ,) (NN p) (JJ =) (CD 4.0) (NN x) (CD 10) (-LRB- -LRB-) (CD -5) (-RRB- -RRB-) (-RRB- -RRB-) (, ,) (NN drug2) (-LRB- -LRB-) (CC OR) (CD 1.48) (CD -LSB-95) (NN %) (CD CI) (JJ =) (CD 1.24-1.77) (-RRB- -RSB-) (, ,) (NN p) (JJ =) (CD 2.0) (NN x) (CD 10) (-LRB- -LRB-) (CD -5) (-RRB- -RRB-) (-RRB- -RRB-) (CC and) (NN drug3) (-LRB- -LRB-) (CC OR) (CD 1.46) (CD -LSB-95) (NN %) (CD CI) (JJ =) (CD 1.22-1.75) (-RRB- -RSB-) (, ,) (NN p) (JJ =) (CD 3.0) (NN x) (CD 10) (-LRB- -LRB-) (CD -5) (-RRB- -RRB-) (-RRB- -RRB-) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD found) (NP (NP (DT no) (NN association)) (PP (IN of) (NP (DT the) (NN TCF7L2) (NNS genotypes))) (PP (IN with) (NP (NN age)))) (PP (IN at) (NP (NP (NN diagnosis)) (, ,) (NP (NN BMI)) (CC or) (NP (NN WHR)))))) (, ,) (CC but) (S (NP (NP (DT the) (NN risk) (NN genotype)) (PP (IN at) (NP (NN drug1)))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD 0.001)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (NN 0.0002)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug4) (NN model) (NN assessment)) (PP (IN of) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN HOMA-R) (: ;) (NN p) (JJ =) (NN 0.012)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ non-diabetic) (NNS subjects))))))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (NP (PRP we)) (VP (VBD found) (NP (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (NP (NN drug1) (NN genotype)) (PRN (-LRB- -LRB-) (NP (JJ Val/Val)) (-RRB- -RRB-))) (CC and) (NP (DT A) (NN drug2) (NN carrier) (NN status))))) (CC and) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))))) (. .)))
(S1 (S (S (S (ADVP (RB However)) (, ,) (NP (NN drug1) (NNS polymorphisms)) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (ADVP (RB significantly)) (VP (VB affect) (NP (NN drug3) (NN risk)))))))) (, ,) (CC and) (S (NP (DT the) (NN drug2) (NN polymorphism)) (VP (VBD helped) (VP (VB determine) (NP (NN drug4)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN association)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (DT the) (NP (NN drug2)) (CC and) (NP (NN drug3)) (NP (NN combination))))) (VP (MD could) (VP (VB help) (S (VP (TO to) (VP (VB explain) (NP (NP (DT the) (JJ contradictory) (NNS results)) (PP (IN of) (NP (JJ previous) (NNS studies)))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD were) (NP (NP (DT no) (JJ significant) (NNS associations)) (PP (IN between) (NP (NP (NN drug1) (NNS genotypes)) (CC and) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN drug1) (NN allele)) (PP (IN of) (NP (DT the) (NN COMT) (NN gene)))) (VP (VBZ confers) (NP (NP (DT a) (ADJP (RB significantly) (VBN increased)) (NN risk)) (PP (IN for) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (PP (IN in) (NP (NN drug4)))))) (. .)))
(S1 (S (S (NP (DT The) (NNS data)) (VP (VP (VBP show) (NP (DT a) (JJ statistical) (NN association))) (CC and) (VP (VBP suggest) (NP (JJ biological) (NN plausibility) (SBAR (IN that) (S (NP (DT the) (NN drug1) (NN T>C) (NN polymorphism)) (VP (VBD contributed) (PP (TO to) (NP (NP (NP (VBN increased) (NNS risks)) (CC and) (NP (JJ poor) (NN prognosis))) (PP (IN of) (NP (CC both) (NP (NN drug2)) (CC and) (NP (NN drug3))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (VBN increased) (NNS volumes)) (PP (IN in) (NP (NP (DT the) (NP (NP (NN genu)) (, ,) (NP (NN splenium)) (CC and) (NP (JJ total) (NN CC)))) (PP (IN in) (NP (DT the) (NN drug3) (NN group)))))) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NP (NNS polymorphisms)) (PP (IN within) (NP (NP (DT the) (NN candidate) (NNS genes)) (: :) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NP (NN UFD1L)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN OPRM1) (NN drug1) (NN genotype)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NP (NP (NNS patients) (POS ') (NP (NN drug2) (NNS ratings)) (PP (IN at) (NP (CD 15) (NN min))) (PP (IN in) (NP (NP (DT the) (NN postanesthesia) (NN care) (NN unit)) (PRN (-LRB- -LRB-) (NP (NN PACU)) (-RRB- -RRB-))))) (PRN (-LRB- -LRB-) (NP (ADJP (NN p) (JJ =)) (CD .01)) (-RRB- -RRB-))) (CC and) (NP (NNS patients) (POS '))) (NN drug3)) (PP (IN at) (NP (CD 15) (NN min))) (PP (IN in) (NP (NP (DT the) (NNS PACU)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (NN .02)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NN COMT) (NN genotype) (NN drug1)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (NP (DT the) (JJ first) (CD 45) (NN min)) (PP (IN in) (NP (NP (DT the) (NNS PACU)) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (ADJP (JJ =) (NP (CD .04)))) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NN haplotype) (NN trend) (NN analysis)) (VP (VBD identified) (NP (NP (DT a) (NN drug1)) (VP (ADVP (RB significantly)) (VBN associated) (PP (IN with) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD .0013)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD .0024)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (NN .017)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NN Allele) (NN G) (NN fromCOMT) (NNS SNPs) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (VP (MD may) (VP (VB represent) (NP (NP (JJ reliable) (JJ state-dependent) (NNS predictors)) (PP (IN of) (NP (JJ global) (NN drug3)))) (PP (IN during) (NP (NP (ADJP (ADJP (JJ manic)) (CC and) (ADJP (JJ mixed))) (NNS episodes)) (PP (IN in) (NP (NN drug4)))))))) (. .)))
(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (NN T) (NN allele)) (PP (IN at) (NP (NN drug1)))) (VP (VBD was) (ADVP (RB inversely)) (VP (VBN associated) (PP (IN with) (NP (NP (ADJP (ADJP (JJ log-transformed)) (, ,) (ADJP (JJ HOMA-))) (NN %) (NN B)) (PRN (-LRB- -LRB-) (NP (NP (CD beta=-0.07)) (, ,) (NP (CD p=0.005))) (-RRB- -RRB-)))) (PP (IN as) (NP (NP (DT a) (NN measure)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3)))))) (PRN (-LRB- -LRB-) (NP (CD beta=-0.06)) (, ,) (NP (CD p=0.02)) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NP (NP (DT The) (JJ nicotinic) (NN acetylcholine) (NN receptor)) (NN polymorphism) (NN drug1)) (PP (IN on) (NP (NN chromosome) (CD 15q25)))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ major) (NN drug2)) (PP (IN in) (NP (NP (DT the) (JJ general) (NN population)) (PP (IN with) (NP (NP (JJ additional) (VBN increased) (NN risk)) (PP (IN of) (NP (NP (NN drug3)) (CONJP (RB as) (RB well) (IN as)) (NP (NN drug4))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Variant) (NNS alleles)) (PP (IN of) (NP (NP (NNS polymorphisms)) (PP (IN of) (NP (NP (NN TLR2) (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))))))) (VP (VBD demonstrated) (NP (NP (DT a) (JJ consistent) (NN association)) (PP (IN with) (NP (NN drug4)))) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (JJ =) (NP (NP (CD 0.008)) (, ,) (NP (NP (NN p)) (ADJP (JJ =) (NP (CD 0.006)))) (CC and) (NP (NP (NN p)) (ADJP (JJ =) (NP (NP (CD 0.029)) (ADVP (RB respectively)))))))) (-RRB- -RRB-)))) (. .)))
(S1 (S (NP (NP (JJ Variant) (NNS alleles)) (PP (IN of) (NP (NP (NNS polymorphisms)) (PP (IN of) (NP (NP (NN TLR2) (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))))))) (VP (VBD demonstrated) (NP (NP (DT a) (JJ consistent) (NN association)) (PP (IN with) (NP (NN drug4) (NN severity)))) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (JJ =) (NP (NP (CD 0.008)) (, ,) (NP (NP (NN p)) (ADJP (JJ =) (NP (CD 0.006)))) (CC and) (NP (NP (NN p)) (ADJP (JJ =) (NP (NP (CD 0.029)) (ADVP (RB respectively)))))))) (-RRB- -RRB-)))))
(S1 (S (NP (NP (NNS Patients)) (S (NP (NP (JJ homozygous) (NNS AA)) (PP (IN for) (NP (CD TLR1) (NN polymorphism) (NN drug1)))) (VP (VBP are) (ADVP (RBR more) (RB frequently)) (VP (VBN associated) (PP (IN with) (NP (NP (JJR faster) (NN decline)) (PP (IN of) (NP (NN drug2))) (PP (VBN compared) (PP (TO to) (NP (JJ heterozygous) (NN genotype)))))) (PRN (-LRB- -LRB-) (NP (NP (NNP OR:7.33)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 95) (NN %)) (CD CI:1.63-33.11)) (-RRB- -RRB-))))))))))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (EX There)) (VP (VBZ is) (NP (NP (NP (DT a) (JJ close) (NN relationship)) (PP (IN between) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN TLR3) (NN drug1) (NN /CT)))))) (CC and) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NP (NN pneumonia)) (PP (IN in) (NP (NP (NNS children)) (VP (VBN infected) (PP (IN by) (NP (DT the) (JJ pandemic) (NN A/) (NN drug2) (NN /2009) (NN drug3) (NN virus)))))))))))) (. .))))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (ADVP (RB Overall)) (, ,) (NP (NP (CD 150) (NNS patients)) (PP (IN with) (NP (NP (NN drug6)) (CC and) (NP (NN ascites))))) (VP (VBD were) (VP (VBN genotyped) (PP (IN for) (NP (NP (NN TLR2) (NN gene) (NNS variants)) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))) (, ,) (NP (NP (NN Pro631His)) (PRN (-LRB- -LRB-) (NP (NN drug5)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (NN TLR2GT) (NN microsatellite) (NN polymorphism)) (PP (IN in) (NP (NN intron) (CD 2)))))))))) (. .))))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (DT The) (NN study)) (VP (VP (VBZ extends) (PP (IN on) (NP (NP (DT the) (NN observation)) (PP (IN of) (NP (NP (DT a) (JJ strong) (JJ multiethnic) (NN association)) (PP (IN of) (NP (NP (NNS polymorphisms)) (PP (IN in) (NP (NP (DT the) (NP (NN drug1)) (CC and) (NP (NN drug2))) (PP (IN with) (NP (NN drug4)))))))))))) (, ,) (CC but) (VP (VBZ does) (RB not) (VP (VB confirm) (NP (NP (DT the) (NN association)) (PP (IN of) (NP (NP (NN CPT1B/CHKB)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT the) (JJ Chinese) (NN population)))))))) (. .))))
(S1 (S (S (S (NP (NP (JJ Common) (NN variation)) (PP (IN at) (NP (NN drug1)))) (VP (VP (VBZ is) (ADVP (RB robustly)) (VP (VBN associated) (PP (IN with) (NP (NN smoking) (NN quantity))))) (CC and) (VP (VBD was) (ADVP (RB recently)) (VP (VBN shown) (S (VP (TO to) (VP (VB influence) (NP (NN drug2)) (PP (IN during) (NP (NN pregnancy)))))))))) (, ,) (CC but) (S (NP (NP (PRP$ its) (NN influence)) (PP (IN on) (NP (NN birth) (NN weight)))) (VP (VBZ is) (RB not) (ADJP (JJ clear))))) (. .)))
(S1 (S (S (NP (JJ Stepwise) (JJ multiple) (NN regression) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (S (NP (NP (NP (DT the) (NN risk) (NN allele)) (PRN (-LRB- -LRB-) (NP (NN C)) (-RRB- -RRB-))) (PP (IN for) (NP (NN SNP) (NN drug1)))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (VBN decreased) (NN CPT1B) (NN mRNA) (NN expression))) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJ =) (NP (CD 1.0) (NN *) (CD 10) (-LRB- -LRB-) (CD -9) (-RRB- -RRB-)))) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (DT the) (NN CPT1B) (NN expression)) (VP (VBD was) (ADJP (ADJP (JJR higher)) (PP (IN in) (NP (DT the) (NN drug2) (NNS patients))) (PP (IN than) (PP (IN in) (NP (NP (DT the) (NNS controls)) (PRN (-LRB- -LRB-) (NP (NN P) (JJ =) (CD 0.005)) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (NN drug2)) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NN SNP) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NN P)) (PRN (-LRB- -LRB-) (NP (NN allele)) (-RRB- -RRB-))) (VP (VP (VBG =) (NP (CD 3.6x10) (-LRB- -LRB-) (CD -3) (-RRB- -RRB-) (: ;))) (CC OR) (VP (VBG =) (NP (CD 1.56))))) (: ;) (NP (ADJP (CD 95) (NN %)) (NN c.i.) (: :) (CD 1.12-2.15))) (-RRB- -RRB-))) (CC and) (NP (NN HLA-DRB1) (NN *) (NN 1501-DQB1) (NN *)) (NP (NN 0602) (NN haplotype)))) (PRN (-LRB- -LRB-) (ADJP (NN P) (-LRB- -LRB-) (NN positivity) (-RRB- -RRB-) (JJ =) (NP (NP (CD 9.2x10) (PRN (-LRB- -LRB-) (NP (NN -11)) (-RRB- -RRB-)) (: ;)) (CC OR) (NP (ADJP (JJ =) (NP (QP (CD 3.97) (: ;) (CD 95)) (NN %))) (NN c.i.) (: :) (CD 2.55-6.19)))) (-RRB- -RRB-))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NP (DT a) (NN SNP)) (ADJP (JJ located) (PP (IN between) (NP (NP (NN CPT1B)) (CC and) (NP (NN CHKB)))))) (, ,)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug3)) (PP (IN in) (NP (NP (NP (NN Japanese)) (PRN (-LRB- -LRB-) (NP (NN drug2) (NN -LSB-C)) (-RRB- -RSB-) (, ,) (NP (NP (NP (NNS odds) (NN ratio)) (PRN (-LRB- -LRB-) (NP (NN OR)) (-RRB- -RRB-))) (ADJP (JJ =) (NP (CD 1.79)))) (, ,) (NP (NP (JJ combined) (NN P)) (ADJP (JJ =) (NP (NP (CD 4.4) (CC x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD -7)) (-RRB- -RRB-))))) (-RRB- -RRB-))) (CC and) (NP (JJ other) (JJ ancestry) (NNS groups)))))) (PRN (-LRB- -LRB-) (CC OR) (NP (JJ =) (NN 1.40) (, ,) (NN P) (JJ =) (CD 0.02)) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NP (DT a) (NN SNP)) (ADJP (JJ located) (PP (IN between) (NP (NP (NN CPT1B)) (CC and) (NP (NN CHKB)))))) (, ,)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug3)) (PP (IN in) (NP (NP (NP (NN Japanese)) (PRN (-LRB- -LRB-) (NP (NN drug2) (NN -LSB-C)) (-RRB- -RSB-) (, ,) (NP (NP (NP (NNS odds) (NN ratio)) (PRN (-LRB- -LRB-) (NP (NN OR)) (-RRB- -RRB-))) (ADJP (JJ =) (NP (CD 1.79)))) (, ,) (NP (NP (JJ combined) (NN P)) (ADJP (JJ =) (NP (NP (CD 4.4) (CC x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD -7)) (-RRB- -RRB-))))) (-RRB- -RRB-))) (CC and) (NP (JJ other) (JJ ancestry) (NNS groups)))))) (PRN (-LRB- -LRB-) (CC OR) (NP (JJ =) (NN 1.40) (, ,) (NN P) (JJ =) (CD 0.02)) (-RRB- -RRB-))))) (. .)))
(S1 (S (NP (JJ Case-control) (NNS comparisons)) (VP (VP (VBD revealed) (NP (NP (JJR higher) (NN prevalence)) (PP (IN of) (NP (NP (JJ short) (NN CAG) (NNS alleles)) (CONJP (RB as) (RB well) (IN as)) (PP (IN of) (NP (NP (DT the) (NN A) (NN allele)) (PP (IN of) (NP (DT the) (NN drug1) (NN SNP))) (PP (IN in) (NP (JJ female) (NN drug3) (NNS cases)))))))) (PP (IN than) (PP (IN in) (NP (NNS controls))))) (, ,) (CC but) (VP (VBD revealed) (NP (DT no) (JJ significant) (NNS differences)) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (DT the) (NN drug2))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD identified) (NP (NN drug1)) (SBAR (IN as) (S (ADVP (RB strongly)) (VP (VBN associated) (PP (IN with) (NP (NN drug3)))))))) (, ,) (S (PP (IN In) (NP (JJ particular))) (, ,) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (NN drug2)) (ADJP (JJ located) (NP (NP (CD 8) (NN kb)) (PP (IN from) (NP (DT the) (NN EDA2R) (NN gene)))))) (VP (VBD showed) (NP (NP (DT the) (JJS best) (NN result)) (PRN (-LRB- -LRB-) (NP (NN P=7.77e) (-LRB- -LRB-) (CD -7) (-RRB- -RRB-)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ conditional) (JJ logistic) (NN regression))) (, ,) (NP (EX there)) (VP (VBD was) (NP (NP (NP (DT no) (NN association)) (PP (IN between) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NNS alleles))))) (PP (IN with) (NP (NP (NN drug1) (NN >or=21)) (PRN (-LRB- -LRB-) (CC or) (NP (CD >or=22)) (-RRB- -RRB-))))) (CC and) (NP (NP (NN risk)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC or) (NP (NN drug4)))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN 2001))) (, ,) (NP (PRP we)) (VP (VBN published) (NP (NP (DT the) (JJ first) (JJ significant) (NN evidence)) (PP (IN of) (NP (NP (DT a) (JJ genetic) (NN association)) (PP (IN between) (NP (NP (NN drug2)) (CC and) (NP (NP (NP (DT a) (JJ synonymous) (NN coding) (NN SNP) (NN drug1)) (PP (IN in) (NP (DT the) (NN androgen) (NN receptor) (NN gene)))) (, ,) (NP (NN AR))))))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VP (VBN utilised) (NP (NP (JJ statistical) (NNS methods)) (ADJP (JJ appropriate) (PP (IN for) (NP (NP (DT the) (JJ categorical) (NN nature)) (PP (IN of) (NP (NP (DT the) (NP (NN phenotype)) (CC and) (NP (JJ familial) (NN structure))) (PP (IN of) (NP (DT the) (NN cohort)))))))))) (, ,) (CC and) (VP (VBD determined) (SBAR (IN that) (S (SBAR (IN whilst) (S (NP (NN SNP) (NN drug1)) (VP (VBD was) (ADVP (RB strongly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN P) (NN <) (CD 0.0001)) (-RRB- -RRB-)))))))) (, ,) (NP (DT the) (JJ GGN) (NN triplet) (NN repeat)) (VP (VBD was) (RB not) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.13)))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD genotyped) (NP (NP (DT the) (NN CAG) (NN microsatellite)) (CC and) (NP (NP (NP (CD six) (JJ haplotype-tagging) (JJ single) (NN nucleotide) (NNS polymorphisms)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6))) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (NN androgen) (NN receptor) (NN gene))))) (PP (IN in) (NP (NP (NP (CD 987) (NN drug7) (NNS cases)) (CC and) (NP (CD 1,034) (NNS controls))) (PP (IN from) (NP (NP (DT a) (NN study)) (VP (VBN conducted) (PP (IN in) (NP (NP (NP (JJ New) (NN Hampshire)) (CC and) (NP (JJ eastern) (NN Massachusetts))) (PP (IN between) (NP (NN May) (CD 1992) (CC and) (NNP July) (CD 2003)))))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD observed) (SBAR (IN that) (S (NP (NP (NN carriage)) (PP (IN of) (NP (NP (CD two) (NNS alleles)) (PP (IN with) (NP (NP (NN >)) (CC or) (NP (JJ =) (CD 22) (NN drug1))))))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN drug2))))) (PP (VBN compared) (PP (IN with) (NP (NP (NN carriage)) (PP (IN of) (NP (NP (CD two) (NNS alleles)) (PP (IN with) (NP (NN <22) (NN CAG) (NNS repeats)))))))) (PRN (-LRB- -LRB-) (NP (NP (JJ covariate-adjusted) (NNS odds)) (NP (NNS ratios)) (, ,) (NP (ADJP (QP (CD 1.31) (: ;) (CD 95)) (NN %)) (NN confidence) (NNS intervals)) (, ,) (NP (CD 1.01-1.69))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN possession)) (PP (IN of) (NP (CD two) (JJ long) (NN AR) (NNS alleles) (NP (NN drug1))))) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (NN drug2))))) (PP (VBN compared) (PP (IN with) (NP (NP (NNS women)) (PP (IN with) (NP (NP (CD two) (JJ short) (NN AR) (NNS alleles)) (PRN (-LRB- -LRB-) (NP (CD <22) (NN CAG) (NNS repeats)) (-RRB- -RRB-)))))))))))))) (. .)))
(S1 (S (ADVP (RB Recently)) (, ,) (NP (NP (NN TCF7L2) (NNS variants)) (, ,) (PP (VBG including) (NP (NP (DT the) (NN microsatellite) (NN marker) (NN drug1)) (CC and) (NP (DT the) (ADJP (ADVP (RB nearly) (RB perfectly)) (VBN linked)) (NN SNP) (NN drug2)))) (, ,)) (VP (VBD were) (VP (VBN identified) (S (VP (TO to) (VP (VB associate) (PP (IN with) (NP (NN drug3))))))))))
(S1 (S (S (S (NP (NP (DT The) (NN T) (NN allele)) (PP (IN of) (NP (NN drug1)))) (VP (VBD showed) (NP (NP (DT an) (NN association)) (PP (IN with) (NP (NN borderline) (NN significance)))) (PRN (-LRB- -LRB-) (S (CC OR) (JJ =) (CD 1.19) (, ,) (CD 95) (NN %) (NN C.I.) (JJ =) (CD 1.01-1.42) (, ,) (NN P) (JJ =) (CD 0.04)) (-RRB- -RRB-)))) (, ,) (CC and) (S (NP (NP (DT the) (JJ Cochran-Armitage) (NN test)) (PP (IN for) (NP (NN trend)))) (VP (VBD revealed) (NP (NP (DT an) (ADJP (NN allele) (JJ dose-dependent)) (NN association)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN Ptrend) (JJ =) (CD 0.04)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (NP (NP (DT a) (JJ possible) (NN influence)) (PP (IN of) (NP (NN TCF7L2) (NN drug1))) (PP (IN on) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (ADVP (RB Further)) (, ,) (NP (NP (NNS effects)) (PP (IN of) (NP (NP (DT a) (JJR stronger) (JJ beneficial) (NN association)) (PP (IN between) (NP (NP (NN n-3) (NN drug4)) (PP (IN in) (NP (NP (NP (NNS RBCs)) (CC and) (NP (NN plasma) (NN lipid) (NN parameters-))) (VP (VBG including) (NP (NP (NP (NP (NP (JJR lower) (NN totalcholesterol)) (PRN (-LRB- -LRB-) (NP (NN TC)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN LDL-C)) (-RRB- -RRB-))) (CC or) (NP (JJR higher) (NN high-density) (NN lipoprotein) (NN cholesterol))) (PRN (-LRB- -LRB-) (NP (NN HDL-C)) (-RRB- -RRB-))) (NN concentrations-)))))))))) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NP (NN AGT) (NN M235T) (-LRB- -LRB-) (NN drug1) (-RRB- -RRB-) (NN TT) (NN genotype)) (, ,) (NP (NN CETP) (NN G-971A) (-LRB- -LRB-) (NN drug2) (-RRB- -RRB-) (NN AG) (NN genotype)) (, ,) (NP (NP (NN T) (NN allele) (NNS carriers)) (PP (IN of) (NP (NP (NN CETP) (NN C-4502T)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NN T) (NN allele) (NNS carriers)) (NP (NP (NN ofCETP) (NN Ile405Val)) (PRN (-LRB- -LRB-) (NP (CD rs5882)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (PP (VBN Based) (PP (IN on) (NP (NP (CD 12) (NNS studies)) (PP (IN with) (NP (NP (NP (CD 5,573) (NNS MetS) (NNS cases)) (CC and) (NP (CD 8,290) (NNS controls))) (PP (IN from) (NP (NP (CD 5) (JJ East) (NN Asian) (NNS studies)) (, ,) (NP (CD 5) (NN European) (NNS studies)) (CC and) (NP (NP (CD 2) (NNS studies)) (PP (IN of) (NP (JJ other) (JJ ethnic) (NNS groups))))))))))) (, ,) (NP (DT the) (NN drug1)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (NN drug2))))) (PP (IN with) (NP (NP (NP (DT an) (NN OR)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (NN CI)) (-RRB- -RRB-))) (VP (VBG =) (NP (NP (NP (NP (CD 1.33)) (PRN (-LRB- -LRB-) (NP (CD 1.16)) (, ,) (NP (CD 1.53)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (JJ overall) (NN population)))) (, ,) (NP (NP (NP (CD 1.43)) (PRN (-LRB- -LRB-) (NP (CD 1.29)) (, ,) (NP (CD 1.58)) (-RRB- -RRB-))) (PP (IN in) (NP (JJ East) (NP (NNP Asian))))) (CC and) (NP (NP (NP (CD 1.30)) (PRN (-LRB- -LRB-) (NP (CD 0.94)) (, ,) (NP (CD 1.78)) (-RRB- -RRB-))) (PP (IN in) (NP (NN European) (NNS populations)))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (DT the) (NN drug1)) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NP (JJ elevated) (NNS levels)) (PP (IN of) (NP (JJ fasting) (NN TG)))) (, ,) (NP (NP (NN TC)) (, ,) (NP (NN LDL-C)) (CC and) (NP (VBN decreased) (NN HDL-C))) (, ,)) (CC and) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (NN drug2))) (, ,) (ADVP (RB especially)) (PP (IN in) (NP (JJ East) (NNS Asians))))))))) (. .)))
(S1 (S (NP (NP (NN Conclusion)) (: :) (S (NP (DT This) (NN study)) (VP (VBZ highlights) (NP (NP (DT the) (ADJP (ADJP (JJ gender-specific)) (CC and) (ADJP (JJ weight-sensitive))) (NNS effects)) (PP (IN of) (NP (NN APOA5) (NN drug1))) (PP (IN on) (NP (NP (JJ central) (NN drug2)) (PP (IN in) (NP (NN Taiwanese) (NNS individuals)))))) (, ,) (UCP (CC and) (SBAR (IN that) (S (NP (DT these) (NNS effects)) (VP (VBP are) (ADJP (ADJP (JJ dyslipidemia-independent)) (CC and) (ADJP (JJ weight-loss)) (ADJP (JJ responsive))))))))) (. .))))
(S1 (S (SBAR (IN Though) (S (NP (NN drug1) (NN /C3/A4/A5) (JJ genetic) (NNS polymorphisms)) (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (NN drug2))))))) (, ,) (S (NP (NP (PRP$ their) (NN effect)) (PP (IN on) (NP (JJ central) (NN drug3)))) (VP (VBZ is) (ADVP (RBR less)) (VP (VBN known))))))
(S1 (S (S (NP (DT The) (JJ present) (NN study)) (VP (VBD demonstrated) (SBAR (IN that) (S (S (VP (VBG carrying) (NP (NP (JJ rare) (NNS alleles)) (PP (IN of) (NP (NN drug1)))))) (, ,) (NP (NP (NN -1131T>C)) (CC and) (NP (NN G185C))) (ADVP (RB alone)) (VP (VBP do) (RB not) (VP (VB constitute) (NP (NP (DT a) (NN risk)) (PP (IN for) (NP (NP (JJ ischemic) (NN drug2)) (PP (IN in) (NP (DT the) (VBN studied) (JJ Turkish) (NNS subjects)))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Multivariable) (JJ logistic) (NN regression) (NN analysis)) (PP (IN of) (NP (NP (JJ combined) (NNS genotypes)) (PP (IN with) (NP (NP (NN adjustment)) (PP (IN for) (NP (NP (NN age)) (, ,) (NP (NN gender)) (CC and) (NP (NN drug3) (NN mellitus))))))))) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (ADVP (ADVP (RB significantly)) (CC and) (ADVP (RB synergistically))) (VP (VBD affected) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NP (JJ Genetic) (NNS variants)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD may) (ADVP (RB synergistically)) (VP (VB affect) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NN drug3))) (PP (PP (IN in) (NP (JJ East) (NN Asian) (NNS populations))) (CC and) (PP (IN of) (NP (NP (NN drug4)) (PP (IN in) (NP (JJ Japanese) (NNS individuals)))))))))) (. .)))
(S1 (S (NP (PRP$ Our) (JJ cross-sectional) (NN study)) (VP (VP (VBD confirmed) (NP (NP (DT the) (JJ essential) (NNS roles)) (PP (IN of) (NP (NP (NP (DT the) (NNS polymorphisms)) (PP (IN of) (NP (DT the) (NN drug1)))) (, ,) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (PP (IN in) (NP (DT the) (NN lipid) (CC or) (NN drug4) (NNS disorders))))) (, ,) (CC and) (VP (VBD suggested) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (JJ fat) (JJ intake) (NN control))) (PP (IN in) (NP (NP (DT the) (JJ individualized) (NN prevention)) (PP (IN of) (NP (NN drug5)))))))) (. .)))
(S1 (S (NP (DT This) (NN study)) (VP (VBD examined) (NP (NP (DT the) (NNS associations)) (PP (IN of) (NP (NP (NP (DT the) (NN APOA5) (NN T-1131C)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (, ,) (NP (NP (NN G553T)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (, ,) (NP (NP (NN GCK) (NN G-30A)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN GCKR) (NN A/G)) (PP (IN at) (NP (NN intron16)))) (PRN (-LRB- -LRB-) (NP (NN drug5)) (-RRB- -RRB-))) (CC and) (NP (NNP T1403C) (-LRB- -LRB-) (NNP Leu446Pro) (, ,) (NN drug6) (-RRB- -RRB-) (NNS polymorphisms)))) (PP (IN with) (NP (NP (NN drug7)) (CC and) (NP (NN drug8))))) (PP (IN in) (NP (NN Japanese))) (, ,) (S (VP (VBG considering) (NP (JJ lifestyle) (NNS factors)))))))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT a) (ADJP (ADJP (JJ significant)) (ADJP (JJ positive))) (NN interaction)) (PP (IN between) (NP (NP (NP (NN drug1) (NN G/T+T/T) (NNS genotypes)) (CC and) (NP (JJ fat) (NN intake))) (VP (VBG >) (NP (NP (CD 25) (NN %)) (PP (IN of) (NP (JJ total) (NN energy)))) (PP (IN for) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug2))))))))) (VP (VBD was) (VP (VBN observed)))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (NNS polymorphisms)) (VP (MD may) (VP (VB serve) (PP (IN as) (NP (NP (NNS biomarkers)) (PP (IN in) (NP (DT the) (NNP South) (NNP Indian) (NN population))))) (S (VP (TO to) (VP (VB identify) (NP (NP (NN drug3) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (PP (IN at) (NP (NP (NN risk)) (PP (IN of) (NP (VBG developing) (NNS drug4))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (CD Two) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (-RRB- -RRB-))) (PP (IN in) (NP (NN IREB2)))) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN P=0.045)) (CC and) (NP (NN 0.032))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (PP (IN in) (NP (NN non-smoker)))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (PRP$ Our) (NNS findings)) (VP (VP (VBP extend)) (CC and) (VP (VBP add) (NP (JJ new) (NN information)) (PP (TO to) (NP (NP (DT the) (JJ existing) (NNS data)) (VP (VBG regarding) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN TG)) (NP (NN regulation))))) (PP (IN during) (NP (JJ long-term) (JJ atypical) (NN drug2) (NN treatment))))))))) (. .))))
(S1 (S (S (NP (NP (JJ significant) (NNS differences)) (PP (IN in) (NP (DT the) (NN association) (NN effect) (NNS sizes))) (PP (IN between) (NP (NP (NNS subjects)) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (NP (NP (NNS MetS)) (PRN (-LRB- -LRB-) (NP (NN p<0.05)) (-RRB- -RRB-))) (, ,) (NP (NP (NNS variants)) (PP (IN of) (NP (NN APOA5))) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (CC and) (NP (NP (NN APOE)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))))))) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug4)) (PP (IN in) (NP (NN drug5) (NNS subjects)))))) (, ,) (SBAR (IN while) (S (NP (NP (NN APOA4)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug6)) (PP (IN in) (NP (JJ non-MetS) (NNS subjects))))))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NP (DT The) (NN drug1) (NN allele)) (, ,) (VP (VBN associated) (PP (IN with) (NP (JJR higher) (NN fasting) (NN triglyceride) (NNS levels)))) (, ,)) (ADVP (RB strongly)) (VP (VBZ affects) (NP (NP (DT the) (NN risk)) (PP (IN for) (NP (JJ early-onset) (NN drug2)))) (, ,) (PP (ADVP (RB even)) (IN after) (S (VP (VBG adjusting) (PP (IN for) (NP (NNS triglycerides)))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN association)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (DT the) (JJ drug2) (NNS components)))))) (VP (VP (VBD was) (ADJP (JJ significant) (ADVP (RB regardless) (PP (IN of) (NP (NP (NN age)) (, ,) (NP (NN sex)) (, ,) (NP (NN obesity)) (CC and) (NP (NN alcohol) (NN drinking))))))) (, ,) (CC but) (ADVP (RB almost)) (VP (VBD disappeared) (PP (IN after) (S (ADVP (RB further)) (VP (VBG adjusting) (PP (IN for) (NP (NN plasma) (NNS triglycerides))))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (SBAR (IN While) (S (NP (NP (JJ previous) (NNS studies)) (PP (IN in) (NP (NNS adults)))) (VP (VBD demonstrated) (, ,) (SBAR (IN that) (S (NP (DT the) (NN drug1) (NN -1131C) (JJ minor) (NN allele)) (VP (VBZ confers) (NP (NP (NN risk)) (PP (IN for) (NP (NN drug2)))))))))) (, ,) (ADVP (RB here)) (NP (PRP we)) (VP (VBP show) (, ,) (SBAR (IN that) (S (NP (NP (DT the) (NN susceptibility) (NN nature)) (PP (IN of) (NP (NP (DT this) (NN SNP)) (ADJP (JJ restricted) (PP (TO to) (NP (NP (DT the) (NP (NN APOA5) (NN *) (CD 2)) (NN haplotype)) (PP (IN in) (NP (JJ pediatric) (JJ obese) (NNS subjects))))))))))))) (. .))))
(S1 (S (NP (NP (NN OBJECTIVE)) (: :) (S (S (NP (NP (NP (NN Apolipoprotein) (NN A5)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (NN gene) (NNS variants)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (JJ elevated) (NN TG) (NNS levels))))))))))) (: ;) (S (NP (DT the) (NN T-1131C) (-LRB- -LRB-) (NN drug2) (-RRB- -RRB-) (NN variant)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB confer) (NP (NP (NN risk)) (PP (IN for) (NP (NP (DT the) (NN drug3)) (PP (IN in) (NP (JJ adult) (NNS populations)))))))))))))) (. .))))
(S1 (S (S (NP (NP (NP (JJ Single) (NN nucleotide) (NNS polymorphisms)) (PRN (-LRB- -LRB-) (NP (NNS SNPs)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NN apolipoprotein) (NN A5) (-LRB- -LRB-) (NN drug1) (-RRB- -RRB-) (NN gene)))) (VP (VBP have) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NN drug2))))))) (. .)))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (S (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN HTG)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (JJ well-established) (JJ independent) (NN risk) (NN factor)) (PP (IN for) (NP (NN drug5) (NN disease)))))) (CC and) (S (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP (JJ several) (NN geneti) (NN c) (NNS variants)) (PP (IN in) (NP (NP (NNS genes)) (ADJP (JJ related) (PP (IN with) (NP (NP (NP (NN triglyceride)) (PRN (-LRB- -LRB-) (NP (NN TG)) (-RRB- -RRB-))) (NN metabolism))))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN described) (, ,) (PP (VBG including) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))))))))) (. .))))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (PRP$ Our) (NNS results)) (VP (VBD showed) (NP (NP (NP (DT a) (JJ significant) (JJ independent) (JJ additive) (NN effect)) (PP (IN on) (NP (NP (NN drug5)) (PP (IN of) (NP (DT the) (NN LPL) (NNS polymorphisms) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4)))))))) (: ;) (NP (NP (DT the) (NP (NN S19W)) (CC and) (NP (NN -1131T/C) (NNS variants))) (PP (IN of) (NP (NN APOA5)))) (, ,) (CC and) (NP (NP (DT the) (NN epsilon4) (NN allele)) (PP (IN of) (NP (NN APOE))) (PP (IN in) (NP (PRP$ our) (NN study) (NN population))))))) (. .))))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ different) (NNS SNPs)) (PP (IN in) (NP (NN drug1) (NNS polymorphisms)))) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NN triglyceride) (NN concentration)) (CC and) (NP (NN drug2))) (PP (IN in) (NP (NP (DT each)) (PP (IN of) (NP (DT these) (JJ ethnic) (NNS origins)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Homozygosity)) (PP (IN for) (NP (NP (NP (DT the) (JJ minor) (NN allele)) (PRN (-LRB- -LRB-) (NP (NN TT)) (-RRB- -RRB-))) (PP (IN of) (NP (NN SNP) (NN drug1)))))) (VP (VP (VBD occurred) (PP (IN in) (NP (NP (CD 9) (NN %)) (PP (IN of) (NP (NNS individuals)))))) (CC and) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (ADJP (CD 31) (NN %)) (NN reduction)) (PP (IN in) (NP (NN drug2))) (PP (IN in) (NP (DT a) (JJ recessive) (NN model))))))))) (. .)))
(S1 (S (S (NP (IN whereas) (NN drug1) (NN genotype)) (VP (VBD was) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (NNS measures)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (NN le)) (PP (IN of) (NP (NN drug1)))) (ADVP (RB as)) (ADVP (RB also)) (VP (VBN associated) (PP (IN with) (NP (NP (VBN increased) (NN prevalence)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NNS Genotypes)) (PP (IN at) (NP (NN drug1)))) (VP (VBD were) (RB not) (VP (VBN associated) (PP (IN with) (NP (DT any) (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (JJ Singlenucleotide) (NNS polymorphisms)) (PRN (-LRB- -LRB-) (NP (NNS SNPs)) (-RRB- -RRB-))) (CC and) (NP (NNS haplotypes))) (PP (IN in) (NP (DT the) (NN drug1) (NN /C3/A4/A5) (NN gene) (NN cluster)))) (VP (VBP are) (VP (VBN associated) (PP (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (NN Caucasians))))) (CC and) (PP (IN with) (NP (NP (NP (NNS elevatedtriglycerides)) (PRN (-LRB- -LRB-) (NP (NN TG)) (-RRB- -RRB-))) (PP (IN in) (NP (JJ various) (JJ ethnic) (NNS groups))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (NP (UCP (: :) (S (S (NP (NP (-LRB- -LRB-) (NN i) (-RRB- -RRB-) (NNS genotypes)) (, ,) (PP (VBG including) (NP (NP (DT those)) (PP (IN of) (NP (NP (NN drug1) (NN S19W)) (, ,) (NP (NN APOA5) (NN -1131T) (NN >) (NN C)) (, ,) (NP (NN APOE)) (, ,) (NP (NN GCKR)) (, ,) (NP (NN drug2)) (CC and) (NP (NN TBL2/MLXIPL)))))) (, ,)) (VP (VBD were) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (JJ severe) (NN drug3)))))) (: ;) (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)))) (NNS odds)) (NNS ratios)) (PP (IN for) (NP (DT these) (JJ genetic) (NNS variables)))) (VP (VBD were) (ADJP (JJ significant)) (PP (IN in) (NP (ADJP (CC both) (ADJP (JJ univariate)) (CC and) (ADJP (JJ multivariate))) (NNS regressionanalyses))) (, ,) (ADVP (RB irrespective) (PP (IN of) (NP (NP (NP (DT the) (NN presence)) (CC or) (NP (NN absence))) (PP (IN of) (NP (NP (NN drug4)) (CC or) (NP (NN drug5)))))))))))) (: ;) (S (LST (-LRB- -LRB-) (LS iii) (-RRB- -RRB-)) (NP (DT a) (JJ significant) (JJ fraction-about) (NN one-quarter-of) (NP (NP (DT the) (VBN explained) (NN variation)) (PP (IN in) (NP (NN disease) (NN status))))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (DT these) (NNS genotypes)))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (NP (DT no) (NNS relationships)) (VP (VBD were) (VP (VBN found) (PP (IN between) (NP (NP (NN drug1) (NN genotype)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (NP (NP (CD 2) (NNS cohorts)) (PRN (-LRB- -LRB-) (NP (NP (NN n=1648)) (CC and) (NP (NN n=1039))) (-RRB- -RRB-))) (PP (IN of) (NP (NP (JJ healthy) (JJ middle-aged) (NNS carriers)) (PP (IN of) (NP (DT the) (NN APOE) (NN e3/e3) (NN genotype))))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (JJ functional) (NN polymorphism)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (DT the) (NN drug2))))))))) (. .))))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (NP (NP (NP (NP (JJ Single) (NN nucleotide) (NNS polymorphisms)) (PRN (-LRB- -LRB-) (NP (NNS SNPs)) (-RRB- -RRB-))) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN e4)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN e2)) (-RRB- -RRB-))))) (, ,) (CC both) (NP (NP (VBG invoking) (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ amino-acid) (NN sequence)) (PP (IN of) (NP (DT the) (NN apolipoprotein) (NN E) (-LRB- -LRB-) (NN APOE) (-RRB- -RRB-) (NN gene)))))) (, ,)) (VP (VBP have) (ADVP (RB previously)) (VP (VBN been) (VP (VBN tested) (PP (IN for) (NP (NP (NN association)) (PP (IN with) (NP (NN drug3) (NN risk))))))))) (. .))))
(S1 (S (PP (IN Despite) (NP (NP (JJ sufficient) (NN power)) (S (VP (TO to) (VP (VB detect) (NP (NNS associations)) (PP (IN at) (NP (NN genome-wide) (NN significance) (NNS thresholds))) (PP (IN across) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NNS ORs)))))))))) (, ,) (NP (PRP$ our) (NNS analyses)) (VP (VBD did) (RB not) (VP (VB support) (NP (NP (DT a) (NN role)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)))) (PP (IN on) (NP (NN drug3)))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NNS studies)) (PP (IN of) (NP (NP (NP (NP (NN APOE) (NN drug1)) (, ,) (NP (NN drug2)) (, ,)) (PRN (-LRB- -LRB-) (NP (VBG defining) (NN e2/e3/e4) (NNS alleles)) (: ;) (NP (CD 12) (NNS studies)) (-RRB- -RRB-))) (CC and) (NP (NP (NN APOB) (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD eight) (NNS studies)) (-RRB- -RRB-)))))) (VP (VBD were) (VP (VBN included) (PP (IN in) (NP (NNS meta-analyses)))))) (, ,) (S (NP (NP (NP (DT the) (JJ observational) (NN hazard) (NN ratio)) (PRN (-LRB- -LRB-) (NP (NN HR)) (-RRB- -RRB-))) (PP (IN for) (NP (JJ symptomatic) (NN drug4))) (PP (IN for) (NP (NP (DT the) (ADJP (ADJP (JJ fifth)) (CC versus) (ADJP (JJ first))) (NN quintile)) (PP (IN of) (NP (NN LDL-C)))))) (VP (VBD was) (NP (NP (CD 0.94)) (PRN (-LRB- -LRB-) (NP (NP (CD 95) (NN %)) (ADJP (RB confidence) (JJ interval))) (: :) (NP (CD 0.76-1.17)) (-RRB- -RRB-))) (, ,) (PP (IN despite) (NP (NP (DT a) (JJ corresponding) (ADJP (CD 134) (NN %)) (NN increase)) (PP (IN in) (NP (NN LDL-C))))))) (. .)))
(S1 (S (NP (EX There)) (VP (VBD were) (NP (NP (DT no) (NNS associations)) (PP (IN between) (NP (NP (NN drug1) (NNS polymorphisms)) (CC and) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4)))))))))
(S1 (S (S (PP (IN In) (NP (NN drug2) (NNS patients))) (, ,) (NP (NP (JJ genetic) (NN heterogeneity)) (PP (IN in) (NP (DT the) (NN drug1) (JJ genomic) (NN region)))) (VP (VBZ is) (VP (ADVP (RB significantly)) (VBN associated) (PP (PP (IN with) (NP (NP (NN variation)) (PP (IN in) (NP (NN serum) (NN ApoE) (CC and) (NN ApoB) (NNS levels))))) (, ,) (CC and) (PP (RB also) (IN with) (NP (NN fibrosis)))) (S (VP (VBG suggesting) (NP (NP (DT a) (JJ pleiotropic) (NN attribute)) (PP (IN of) (NP (DT this) (JJ genomic) (NN region))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NP (DT the) (NN intake)) (PP (IN of) (NP (NN drug2)))) (, ,) (CC and) (NP (NN drug3)))) (PP (IN in) (NP (JJ Lithuanian) (JJ adult) (NN population))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN SFA) (NN intake)) (, ,) (CC and) (NP (NN drug2))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug3)) (PP (IN in) (NP (JJ Lithuanian) (JJ adult) (NN population)))))))))))) (. .)))
(S1 (S (S (NP (JJ Multivariate) (NN analysis)) (VP (VBD showed) (NP (NP (NN association)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug3))))) (, ,) (ADVP (RB independently)) (PP (IN from) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (JJ Pooled) (NN DNA) (NNS GWAS)) (VP (VBD enabled) (NP (NP (DT the) (NN identification)) (PP (IN of) (NP (NP (NP (DT a) (JJ novel) (NN drug2) (NN candidate) (NN risk) (NN variant)) (, ,) (NP (NN drug1) (-LRB- -LRB-) (CD 9q21.33) (-RRB- -RRB-)) (, ,)) (VP (VBG tagging) (NP (NP (DT a) (JJ possible) (JJ genomic) (NN enhancer)) (VP (VBG affecting) (NP (NP (JJ proximal) (VBN transcribed) (NNS elements)) (PP (VBG including) (NP (NN DAPK1) (NN gene)))))))))))) (. .)))
(S1 (S (NP (NP (DT the) (JJ minor) (NNS alleles)) (PP (IN of) (NP (NP (NN cholesteryl) (NN ester) (NN transfer) (NN protein) (-LRB- -LRB-) (NN CETP) (-RRB- -RRB-) (NN gene) (NNS SNPs)) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NN drug12)) (CC and) (NP (NN drug3))) (PP (IN with) (NP (NP (NN drug13)) (: ;) (NP (NP (NP (NN CETP) (NNS SNPs)) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6)) (CC and) (NP (NN apolipoprotein) (NN B) (-LRB- -LRB-) (NN APOB) (-RRB- -RRB-) (NN gene) (NN SNP) (NN drug7)))) (PP (IN with) (NP (NN drug14)))) (: ;) (NP (NP (NP (JJ APOE) (NN SNP) (NN drug8)) (, ,) (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor) (NN gamma) (-LRB- -LRB-) (NN PPARG) (-RRB- -RRB-) (NN gene) (NN SNP) (NN drug9)) (PP (IN with) (NP (NN drug15)))) (, ,) (CC and) (NP (NN CETP) (NN SNP) (NN drug10))) (PP (IN with) (NP (NN drug16)))) (: ;) (CC and) (NP (NP (NN APOE/C1/C4/C2) (NN cluster) (NN SNP) (NN drug11)) (PP (IN with) (NP (JJR lower) (NN serum) (NN TG)))))))))) (. .)))
(S1 (S (S (S (PP (IN For) (NP (NN example))) (, ,) (NP (NP (DT the) (NN association)) (PP (IN of) (NP (NNS polymorphisms) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (PP (IN with) (NP (NN drug3)))) (VP (VBD was) (ADJP (JJ heterogeneous)) (PP (IN between) (NP (NP (NP (NN Caucasians)) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (ADJP (JJ =) (NP (QP (CD 1.32) (CC and) (CD 1.22) (: ;) (CD 95)) (NN %))) (NN CI)) (: :) (NP (CD 1.25-1.44) (CC and) (CD 1.05-1.42)) (: ;) (NP (CD P<0.0005) (CC and) (CD 0.008)) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (CC and) (NP (NP (JJ East) (NNS Asians)) (PRN (-LRB- -LRB-) (NP (CC OR) (NP (ADJP (JJ =) (NP (NP (CD 1.51) (CC and) (CD 1.03)) (: ;) (NP (CD 95) (NN %) (CD CI) (: :) (CD 0.76-3))))) (CC and) (NP (NN 0.47-2.27))) (: ;) (S (NP (NN P)) (VP (JJ =) (NP (NP (CD 0.237)) (CC and) (NP (NN 0.934))) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))) (PP (IN under) (NP (JJ theallelic) (NN model))))) (, ,) (CC and) (S (NP (DT this) (NN association)) (VP (VBD was) (ADVP (RB relatively)) (VP (VBN strengthened) (PP (IN under) (NP (DT the) (JJ dominant) (NN model))))))) (. .)))
(S1 (S (S (VP (VBG Inside) (NP (NP (DT this) (NN region)) (PP (IN of) (NP (CD 26.9) (NN kb)))))) (, ,) (S (NP (NP (NP (NN LD)) (PRN (-LRB- -LRB-) (NP (NN r2) (NN >) (CD 0.50)) (-RRB- -RRB-))) (PP (IN between) (NP (NP (NP (NN TOMM40)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (CC and) (NP (NP (NN APOE)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))))) (VP (VBD was) (VP (VBN observed) (PP (PP (IN in) (NP (NN drug3))) (CC and) (PP (IN in) (NP (NNS controls))) (, ,) (CC but) (PP (RB not) (IN in) (NP (NN drug4)))))))))
(S1 (S (S (NP (DT The) (NN SIRT2) (NN drug1) (NN T) (NN allele)) (VP (VBZ deserves) (NP (JJ further) (NN investigation)) (PP (IN as) (NP (NP (DT a) (JJ novel) (JJ minor) (JJ genetic) (NN risk) (NN factor)) (PP (IN for) (NP (NN drug2))) (PP (IN in) (NP (DT the) (NN APOE) (JJ e4-negative) (NN Caucasian) (NN population))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (JJ moderate) (NN consistency)) (PP (IN between) (NP (DT the) (ADJP (ADJP (JJ cross-sectional)) (CC and) (ADJP (JJ longitudinal))) (NNS findings))) (, ,) (PP (IN with) (NP (NP (CD eight) (NN SNP) (: :) (NN drug8) (NNS associations)) (VP (ADVP (RB consistently)) (VBN identified) (PP (IN across) (NP (DT both) (NN study) (NNS designs)))))))) (: :) (S (CD -LSB-APOE.2) (CC and) (CD APOE.4) (-LRB- -LRB-) (NN drug1) (CC and) (NN drug2) (-RRB- -RRB-) (-RRB- -RSB-) (: :) (NP (NP (NN TC)) (PRN (: ;) (NP (NP (NP (NN HL/LIPC)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (: :) (NP (NN HDL)) (: ;) (NP (NP (NN -LSB-APOB)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))) (, ,) (NP (NP (CD APOE.2) (CC and) (CD APOE.4)) (PRN (-LRB- -LRB-) (NP (NP (NN drug5)) (CC and) (NP (NN drug6))) (-RRB- -RRB-) (-RRB- -RSB-))) (: :) (NP (NN LDL)) (: ;) (NP (NP (NP (NN -LSB-APOA5)) (PRN (-LRB- -LRB-) (NP (NN drug7)) (-RRB- -RRB-))) (CC and) (NP (NP (NN APOC) (CD III)) (PRN (-LRB- -LRB-) (NP (NN drug9)) (-RRB- -RRB-))))) (-RRB- -RSB-))) (: :) (NP (NN TG))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NP (DT The) (NN frequency)) (PP (IN of) (NP (NN drug1) (NNS polymorphisms)))) (VP (VBD did) (RB not) (VP (VB differ) (PP (IN between) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNS drug2)) (CC and) (NP (NNS controls))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (ADJP (RB predominantly) (JJ middle-aged)) (NNS persons))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS results)) (VP (VBD indicated) (SBAR (IN that) (S (NP (NP (JJ homozygous) (NN drug1) (NNS carriers)) (ADJP (JJ aged) (NP (NP (CD 35) (NNS years)) (CC or) (NP (JJR older))))) (VP (VBD had) (NP (JJR worse) (NN drug2)) (PP (IN than) (NP (NP (JJ heterozygous) (NNS carriers)) (CC and) (NP (NNS noncarriers))))))))) (. .)))
(S1 (S (S (ADVP (RB Collectively)) (, ,) (NP (DT these) (NNS results)) (ADVP (RB also)) (VP (VBP suggest) (NP (NP (CC and) (NN claim)) (PP (IN for) (NP (NP (JJ further) (NNS investigations)) (PP (IN on) (NP (NN drug1) (NN /HP) (NN interaction))))) (PP (IN in) (NP (NP (JJ other) (JJ age-related) (NNS diseases)) (PP (JJ such) (IN as) (NP (NP (NN drug2) (POS 's) (NN disease)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4) (POS 's) (NN disease))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN Apolipoprotein) (NN E)) (PRN (-LRB- -LRB-) (NP (NN APOE)) (-RRB- -RRB-))) (JJ functional) (NNS haplotypes)) (VP (VBN determined) (PP (IN by) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (NP (NNS SNPs)))))) (VP (VBP have) (VP (VBN been) (ADVP (RB extensively)) (VP (VP (VBN studied)) (CC and) (VP (VBN found) (S (VP (TO to) (VP (VB be) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (JJ consistent)) (NN association)) (PP (IN in) (NP (JJ human) (NN drug3) (NNS studies)))))))))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NN drug1) (NNS haplotypes)) (VP (VBP are) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (PRP$ our) (NN population)))))))) (. .))))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (SBAR (IN Although) (S (NP (NP (DT the) (JJ physiological) (NN role)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))) (VP (VBZ needs) (NP (JJ further) (NNS investigations))))) (, ,) (NP (PRP$ our) (NNS results)) (VP (VBP suggest) (NP (NP (DT an) (NN involvement)) (PP (IN of) (NP (DT the) (NN drug2) (NN gene) (NN locus))) (PP (IN in) (NP (NP (DT the) (NNS genetics)) (PP (IN of) (NP (NP (NN drug5)) (CC and) (NP (NN drug6))))))))) (. .))))
(S1 (S (S (NP (NNS Individuals)) (VP (VBD were) (VP (VBN genotyped) (PP (IN for) (NP (NP (NP (NN PCSK9) (NN R46L)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (, ,) (NP (NP (NN ABCG8) (NN D19H)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN APOE) (NNP R112C) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-)) (CC and) (NN R158C) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-)) (NNS polymorphisms)))))) (, ,) (SBAR (WHNP (NP (DT all)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (ADVP (RB lifelong)) (NN drug5)))))))) (. .)))
(S1 (S (S (NP (DT This) (NN paper)) (VP (VBZ addresses) (NP (NP (DT a) (NN tenet)) (PP (IN of) (NP (NP (DT the) (NN literature)) (PP (IN on) (NP (NN drug1)))))) (, ,) (PP (FW i.e.)) (, ,) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT the) (NN e4)))) (, ,) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ established) (JJ genetic) (NN risk) (NN factor)) (PP (IN for) (NP (NN drug2)))))) (, ,) (CC and) (NP (PRP$ its) (NN expression) (NNS levels)))) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NN APOE) (NN promoter) (NNS polymorphisms))))))))) (. .)))
(S1 (S (S (NP (NP (CD Three) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (PP (IN in) (NP (NP (NN IREB2)) (, ,) (NP (NP (NN drug2)) (PP (IN in) (NP (NN LOC123688)))) (, ,) (CC and) (NP (NP (NN drug3)) (PP (IN in) (NP (NN CHRNA3))))))) (-RRB- -RRB-))) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug4)) (PP (IN of) (NP (VBN predicted))) (PP (IN in) (NP (DT the) (NN AAT) (NP (JJ Genetic) (NNS Modifiers)) (NN Study)))))))) (. .)))
(S1 (S (S (NP (NP (CD Two) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (-RRB- -RRB-))) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN drug3)) (PP (IN of) (NP (NP (VBN predicted)) (CC and) (NP (NNS drug4))))))))) (: ;) (S (NP (JJ SNP-by-gender) (NNS interactions)) (VP (VBD were) (VP (VBN observed)))) (. .)))
(S1 (S (S (S (PP (IN In) (NP (DT the) (NP (NNP UK) (NNP National) (NNP Registry)) (NN dataset))) (, ,) (NP (NN drug1)) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (DT the) (JJ male) (NN subgroup)))))))) (: ;) (S (NP (JJ significant) (JJ SNP-by-smoking) (NNS interactions)) (VP (VBD were) (VP (VBN observed))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (JJ thecausal) (NN relationship)) (PP (IN between) (NP (NP (NP (NNS drug2)) (CC and) (NP (NNS symptoms))) (PP (IN of) (NP (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (PP (IN in) (NP (DT the) (NN Norwegian) (NN HUNT) (NN study)))))))) (S (VP (VBG using) (NP (NP (DT the) (NN drug1) (JJ single) (NN nucleotidepolymorphism) (-LRB- -LRB-) (NN SNP) (-RRB- -RRB-) (NN variant)) (ADJP (JJ located) (PP (IN in) (NP (NP (NP (DT the) (NN nicotine) (NN acetylcholine) (NN receptor)) (NN gene) (NN cluster)) (PP (IN on) (NP (NN chromosome) (CD 15))))))) (PP (IN as) (NP (NP (DT an) (JJ instrumental) (NN variable)) (PP (IN for) (NP (NNS smokingphenotypes))))))))))
(S1 (S (S (NP (PRP$ Our) (NNS data)) (VP (VBP are) (ADJP (JJ compatible) (PP (IN with) (NP (NP (DT the) (NN hypothesis)) (PP (IN of) (NP (NP (DT a) (JJ complex) (NN role)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (DT the) (NN drug2) (NN pathogenesis))))))) (, ,) (PP (IN with) (NP (NP (ADJP (ADJP (JJ positive)) (CC and) (ADJP (JJ negative))) (NNS effects)) (VP (VBG occurring) (ADVP (RB concomitantly)) (PP (VBG according) (PP (TO to) (NP (NP (PRP$ its) (NN expression) (NNS levels)) (CC and) (NP (NP (PRP$ its) (JJ protein-protein) (NNS interactions)) (VP (ADVP (RB largely)) (VBN unclarified)))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN VKORC1) (NN 3673) (NN AA) (CC or) (NN GA) (NN genotype)) (PRN (-LRB- -LRB-) (NP (NN P<0.0001)) (-RRB- -RRB-))) (, ,) (NP (NP (QP (CD one) (CC or) (CD two)) (JJ variant) (NNS alleles)) (PP (IN of) (NP (NP (NN CYP2C9) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN P=0.0004)) (-RRB- -RRB-))))) (, ,) (NP (NP (NN drug1) (NN e2) (NN haplotype)) (PRN (-LRB- -LRB-) (NP (NN P=0.01)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (VBG increasing) (NN age)) (PRN (-LRB- -LRB-) (NP (NN P<0.0001)) (-RRB- -RRB-)))) (VP (VBD were) (ADVP (RB all)) (VP (VBN associated) (PP (IN with) (NP (JJR lower) (NN warfarin) (NN dose)))) (, ,) (SBAR (IN whereas) (S (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN P=0.025)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN P=0.0059)) (-RRB- -RRB-)))) (VP (VBD showed) (NP (NP (NN association)) (PP (IN with) (NP (JJR higher) (NN warfarin) (NNS doses)))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (DT The) (NN study)) (VP (VBZ shows) (SBAR (IN that) (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2) (NNS polymorphisms)) (, ,) (NP (NN APOE) (NN e2) (NN variant)) (, ,) (CC and) (NP (JJ several) (JJ clinical/demographic) (NNS variables))) (VP (VBP are) (NP (NP (JJ important) (NNS determinants)) (PP (IN of) (NP (NN drug3) (NN dose) (NNS requirements))) (PP (IN in) (NP (NN Egyptian) (NNS patients))))))))) (. .))))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (SBAR (IN Although) (S (NP (NN drug1) (NN genotype)) (VP (VBZ does) (VP (VB have) (NP (NP (JJ strong) (NNS associations)) (PP (IN with) (NP (NN lipid) (NNS levels)))) (PP (IN in) (NP (NN childhood))))))) (, ,) (NP (EX there)) (VP (VBZ does) (RB not) (VP (VB seem) (S (VP (TO to) (VP (VB be) (NP (NP (JJ meaningful) (NNS effects)) (PP (IN on) (NP (NNS drug2)))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (DT any) (JJ detrimental) (NNS effects)) (PP (IN of) (NP (DT the) (NN e4) (NN allele))) (PP (IN on) (NP (JJ cognitive) (NN function)))) (VP (VBP are) (RB not) (ADJP (JJ important) (PP (IN until) (NP (JJ later) (NN life))))))))))) (. .))))
(S1 (S (NP (NN drug1)) (ADVP (RB alone)) (VP (VBZ is) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN association)) (PP (IN of) (NP (NN APOE))) (PP (IN with) (NP (NN drug2))))))) (: ;)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (DT The) (JJ present) (NN study)) (VP (VBD exposed) (NP (DT a) (NN susceptibility) (NN haplotype) (NN drug1)) (, ,) (PP (IN within) (NP (NP (NN drug2) (NN gene)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NN drug3)) (CC and) (NP (NN risk))) (PP (IN of) (NP (NP (NP (NN drug4)) (CC and) (NP (NN drug5))) (PP (IN in) (NP (NP (JJ postmenopausal) (NNS females)) (PP (IN of) (NP (NN India))))))))))))))))))))) (. .))))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (NP (NP (DT The) (NN association)) (PP (IN of) (NP (NN drug1) (-LRB- -LRB-) (NN APOE) (-RRB- -RRB-) (NNS genotypes))) (PP (IN with) (NP (NP (NP (NN bone) (JJ mineral) (NN density)) (PRN (-LRB- -LRB-) (NP (NN BMD)) (-RRB- -RRB-))) (CC and) (NP (NP (NN risk)) (PP (IN of) (NP (NN drug2))))))) (VP (VBP have) (VP (VBN remained) (ADJP (JJ unclear))))) (. .))))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (S (NP (NP (NN Hypertriglyceridemia)) (PRN (-LRB- -LRB-) (NP (NN HTG)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (JJ well-established) (JJ independent) (NN risk) (NN factor)) (PP (IN for) (NP (JJ drug4) (NN disease)))))) (CC and) (S (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP (JJ several) (JJ genetic) (NNS variants)) (PP (IN in) (NP (NP (NNS genes)) (ADJP (JJ related) (PP (IN with) (NP (NP (NP (NN triglyceride)) (PRN (-LRB- -LRB-) (NP (NN TG)) (-RRB- -RRB-))) (NN metabolism))))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN described) (, ,) (PP (VBG including) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))))))))) (. .))))
(S1 (S (S (PP (IN Among) (NP (NP (NNS SNPs)) (VP (VBN tested) (PP (IN with) (NP (NP (DT an) (NN allele) (NN frequency)) (PP (IN of) (NP (QP (IN at) (JJS least) (CD 5)) (NN %)))))))) (, ,) (NP (NP (JJ only) (NNS SNPs)) (PP (IN in) (NP (NN drug1)))) (VP (VBP are) (VP (VBN found) (S (VP (TO to) (VP (VB influence) (NP (NN drug2)) (ADVP (RB significantly)))))))) (. .)))
(S1 (S (S (PP (IN Of) (NP (NP (DT the) (CD 3) (NNS SNPs)) (VP (ADVP (RBS most) (RB significantly)) (VBN associated) (PP (IN with) (NP (NN MI)))))) (, ,) (NP (NP (NN drug1)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ defines) (NP (DT the) (NN Apo) (NN E2) (NN isoform))))) (, ,)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (CC both) (NP (NP (DT a) (JJR lower) (NN Apo) (NN B/A1) (NN ratio)) (PRN (-LRB- -LRB-) (NP (NN P=1.0x10) (-LRB- -LRB-) (CD -7) (-RRB- -RRB-)) (-RRB- -RRB-))) (CC and) (NP (JJR lower) (NN drug2) (NN risk)))) (PRN (-LRB- -LRB-) (NP (NN P=0.0004)) (-RRB- -RRB-))))) (. .)))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (PRP We)) (VP (VBN reviewed) (NP (NP (DT the) (NN literature)) (VP (VBG relating) (PP (TO to) (NP (NP (NN SNPs) (NN drug1)) (CC and) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))))) (, ,) (CC and) (NP (NP (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ preclinical))) (NNS studies)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VB shed) (NP (NN light)) (PP (IN on) (NP (NP (DT the) (NNS mechanisms)) (VP (VBG underlying) (NP (DT these) (NNS associations))))))))))))
(S1 (S (NP (NP (NP (CD Two) (NNS polymorphisms)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2))) (-RRB- -RRB-))) (SBAR (WHNP (WDT that)) (S (VP (VBP define) (NP (NP (DT the) (NP (NP (NN epsilon2)) (, ,) (NP (NN epsilon3)) (, ,) (CC and) (NP (NN epsilon4))) (NNS isoforms)) (PP (IN of) (NP (NN apolipoprotein) (NN E)))))))) (VP (VP (VBD were) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ percent) (NN reduction)) (PP (IN in) (NP (NN drug3))))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN epsilon2) (NNS carriers) (CD 53.8) (NN %)) (, ,) (NP (NN epsilon3/epsilon3) (CD 48.1) (NN %)) (, ,) (CC and) (NP (NN epsilon4) (NNS carriers)) (NP (CD 46.4) (NN %))) (, ,) (ADVP (RB respectively))) (, ,) (NP (CD P=0.00039)) (-RRB- -RRB-)))) (CC and) (VP (VBD replicated) (PP (IN in) (NP (DT the) (NN drug4))) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NN epsilon2) (NNS carriers)) (CD 22.1) (NN %)) (, ,) (NP (NN epsilon3/epsilon3) (CD 21.8) (NN %)) (, ,) (CC and) (NP (NN epsilon4) (NNS carriers)) (NP (CD 16.6) (NN %))) (, ,) (ADVP (RB respectively))) (, ,) (NP (CD P=0.00038)) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NNS results)) (VP (VBP support) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBP influence) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (ADVP (RB possibly)) (NP (NN overweight)))) (PP (IN in) (NP (NN drug3) (NNS patients)))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS associations)) (VP (VBP warrant) (NP (NP (JJ prospective) (NN study)) (S (VP (TO to) (VP (VB assess) (NP (NP (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NP (DT the) (NN propensity)) (PP (IN of) (NP (NN antipsychotics))) (S (VP (TO to) (VP (VB induce) (NP (NN drug2))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJR Lower) (NN lipid) (NN profile) (NNS values)) (PP (IN among) (NP (NP (NNS patients)) (, ,) (ADVP (RB even)) (NP (NP (DT those)) (PP (IN on) (NP (NP (JJ lipid-rich) (NNS diets)) (VP (VBN associated) (PP (IN with) (NP (DT the) (NN drug1) (NN allele))))))) (, ,)))) (VP (VBP suggest) (NP (NP (NNS alterations)) (PP (IN in) (NP (NP (DT the) (NP (NN lipid) (NN synthesis)) (CC and) (NP (NN metabolism) (NNS pathways))) (PP (IN in) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NN GAB2) (NN drug1) (NN marker)) (VP (VBZ does) (RB not) (VP (VB modify) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (NP (NN Spanish) (NN APOE) (NN epsilon) (CD 4)) (NNS carriers))))))) (. .)))
(S1 (S (NP (NP (NN OBJECTIVE)) (: :) (S (SBAR (IN Although) (S (NP (JJ several) (NNS studies)) (VP (VBP have) (VP (VBN reported) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN OSA)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (JJ chromosomal) (NN region)) (VP (VBG containing) (NP (DT the) (NP (NP (NN Apolipoprotein) (NN E)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (NN gene))))))))))) (, ,) (NP (NP (NNS findings)) (PP (IN about) (NP (NP (DT the) (JJ exact) (NN location)) (PP (IN in) (NP (DT the) (NN ApoE) (NN gene)))))) (VP (VBP have) (VP (VBN been) (ADJP (JJ inconsistent))))) (. .))))
(S1 (S (S (NP (DT The) (JJ sliding) (NN window) (NN haplotype) (NN trend) (NN regression) (NN test)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NN SNP) (NN drug1)) (VP (VBD was) (VP (VBN included) (PP (IN in) (NP (NP (DT all) (NNS haplotypes)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (JJ drug2) (NN status))))))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (DT a) (JJ clinical) (NN setting))) (, ,) (S (S (NP (NN drug1)) (VP (MD could) (VP (VB offer) (NP (NP (JJ additional) (JJ biological) (NN evidence)) (PP (IN of) (SBAR (IN whether) (S (NP (DT a) (NN subject)) (VP (MD may) (VP (VB develop) (NP (NN drug2))))))))))) (, ,) (CC but) (S (NP (PRP it)) (VP (VBZ is) (RB not) (ADJP (JJ robust) (RB enough) (S (VP (TO to) (VP (VB serve) (PP (IN as) (NP (NP (DT an) (JJ independent) (NN screening) (CC or) (JJ predictive) (NN test)) (PP (IN in) (NP (NP (NN thediagnosis)) (PP (IN of) (NP (NN drug3))))))))))))))))
(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (NNS variants)) (PP (IN in) (NP (NP (CD three) (JJ key) (NN pigmentation) (NN genes-) (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))))) (VP (VBD --were) (VP (VBN involved) (PP (IN in) (NP (NN drug4) (NN predisposition))))))))))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (NP (NNS variants))) (VP (VBD had) (NP (JJ additive) (NNS effects)) (PP (IN on) (NP (NN drug3) (NN risk))))) (, ,) (CC and) (S (PP (IN after) (S (VP (VBG adjusting) (PP (IN for) (NP (NN pigmentation) (NNS characteristics)))))) (, ,) (NP (DT the) (NN risk)) (VP (VBD was) (ADJP (JJ persistent)) (, ,) (SBAR (RB even) (IN though) (S (NP (DT both) (NNS genes)) (VP (VBD had) (NP (DT a) (JJ strong) (NN impact)) (PP (IN on) (NP (NN pigmentation))))))))))
(S1 (S (NP (PRP We) (VP (VBN conducted) (NP (JJ additional) (NN genotyping)) (S (VP (TO to) (VP (VB clarify) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (DT the) (NN drug1) (NN locus))) (PP (IN in) (NP (NP (DT the) (NN inheritance)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (JJ other) (JJ pigmentary) (NNS traits)))) (VP (VBN associated) (PP (IN with) (NP (NN drug3) (NN risk) (NN inwhite) (NNS populations))))))))))))))
(S1 (S (S (NP (NP (DT The) (JJ minor) (NNS alleles)) (PP (IN of) (NP (NP (NP (NN drug1) (NN T=) (NN TF)) (PRN (-LRB- -LRB-) (NP (NN TCF7L2)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug2) (NN T=TF)) (PRN (-LRB- -LRB-) (NP (NN TCF7L2)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN -30G/A)) (, ,) (NP (NN GCK)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN E23K)) (, ,) (NP (NN KCNJ11)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN CDKAL1)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (NP (NN IGF2BP2)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (NP (NN MTNR1B)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug8)) (PRN (-LRB- -LRB-) (NP (NN MTNR1B)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug9)) (PRN (-LRB- -LRB-) (NP (NNP Gly972Arg) (, ,) (NNP IRS1)) (-RRB- -RRB-)))))) (VP (VBD were) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJR higher) (NN risk)) (PP (IN of) (NP (NN drug10)))))))) (. .)))
(S1 (S (PP (IN Among) (NP (PRP them))) (, ,) (NP (NP (JJ genetic) (NNS variants)) (PP (IN in) (NP (NN drug1)))) (VP (VBD showed) (NP (NP (DT the) (JJS strongest) (NN association)) (PP (IN with) (NP (NN drug4) (NN risk)))) (, ,) (PP (IN with) (NP (NP (NP (NNS ORs)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (NN CIs)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NP (NP (CD 1.44)) (PRN (-LRB- -LRB-) (NP (NN 1.29-1.60)) (, ,) (NP (NN P) (JJ <) (CD 0.001)) (-RRB- -RRB-))) (PP (IN per) (NP (NP (NN T) (NN allele)) (PP (IN of) (NP (NN drug2)))))) (CC and) (NP (NP (NP (CD 1.46)) (PRN (-LRB- -LRB-) (NP (CD 1.15-1.84)) (, ,) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.002)))) (-RRB- -RRB-))) (PP (IN per) (NP (NP (NN T) (NN allele)) (PP (IN of) (NP (NN drug3)))))))))))))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (NP (NP (CD Two) (JJ single-nucleotide) (NNS polymorphisms)) (, ,) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (, ,) (ADJP (JJ located) (PP (IN within) (NP (NP (NP (DT the) (JJ nicotinic) (NN acetylcholine) (NN receptor)) (NN gene) (NN cluster)) (PP (IN on) (NP (NN chromosome) (CD 15q25) (NN locus)))))) (, ,)) (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NN heaviness)) (PP (IN of) (NP (NN drug3)))) (, ,) (NP (NP (NN risk)) (PP (IN for) (NP (NN drug4)))) (, ,) (CC and) (NP (JJ other) (JJ smoking-related) (NN health) (NNS outcomes))))))) (. .))))
(S1 (S (NP (NP (NN OBJECTIVE)) (: :) (S (NP (PRP We)) (VP (VBD aimed) (S (VP (TO to) (VP (VB replicate) (NP (NP (DT the) (NN association)) (PP (IN of) (NP (NP (NP (DT the) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN IVS3C/T)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN IVS3C/T)) (-RRB- -RRB-))) (NP (NNS polymorphisms)))) (PP (IN of) (NP (NP (NP (NN transcription) (NN factor) (JJ 7-like) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN TCF7L2)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (JJ Han) (NN Chinese) (NN people)) (PP (IN in) (NP (NNP Henan) (NNP province) (, ,) (NNP China)))))))))) (. .))))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NP (NP (NP (NP (DT The) (NN CC) (NN genotype)) (CC and) (NP (NP (DT the) (JJ recessive) (NN model)) (PP (IN of) (NP (DT the) (JJ variant) (NN drug1))))) (PRN (-LRB- -LRB-) (NP (NN IVS3C/T)) (-RRB- -RRB-))) (CC and) (NP (JJ CC) (NN haplotype))) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN IVS3C/T)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN IVS3C/T)) (-RRB- -RRB-))))) (PP (IN in) (NP (NN TCF7L2may)))) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug4)) (PP (IN in) (NP (NP (NN Han) (NN Chinese) (NN people)) (PP (IN in) (NP (NNP Henan) (NNP province) (, ,) (NNP China) (. .)))))))))) (. .))))
(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP report) (NP (NP (NN replication)) (PP (IN of) (NP (NP (NN association)) (PP (IN between) (NP (NP (NP (CD drug6) (CC and) (CD three) (NNS SNPs)) (PP (IN in) (NP (NP (DT the) (JJ case-control)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN P=0.003))) (: ;) (NP (NN drug2)) (, ,) (NP (NN P=0.00002)) (: ;) (NP (NN and.) (NN drug3)) (, ,) (NP (NN P=0.000004)) (-RRB- -RRB-))))) (CC and) (NP (NP (CD two) (NNS SNPs)) (PP (IN in) (NP (NP (DT the) (ADJP (ADJP (JJ family-based)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN drug4)) (, ,) (NP (NN P=0.01)) (CC and) (NP (NN drug5))) (, ,) (NP (NN P=0.04))) (-RRB- -RRB-))) (NNS samples)) (PP (IN from) (NP (NN northern) (NN Sweden)))))))))))) (. .)))
(S1 (S (NP (DT This) (NN 263) (NN indel) (-LRB- -LRB-) (NN drug1) (-RRB- -RRB-)) (VP (VBZ is) (ADJP (JJ </ModMar>reported</ModMar>) (S (VP (TO to) (VP (VB be) (PP (IN in) (NP (NP (NP (JJ strong) (NN linkage) (NN disequilibrium)) (PRN (-LRB- -LRB-) (NP (NN LD)) (-RRB- -RRB-))) (PP (IN with) (NP (NP (NP (NP (DT a) (JJ single) (NN nucleotide) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NN SNP)) (-RRB- -RRB-))) (CD 35) (NNS kilobases)) (ADVP (JJ upstream) (PP (IN of) (NP (NP (NP (NN HLA-C)) (PRN (-LRB- -LRB-) (NP (NN -35T/C) (: ;) (CD rs9264942)) (-RRB- -RRB-))) (PP (IN in) (NP (NN Caucasian) (NNS individuals)))))))))))))) (, ,) (S (VP (VBG making) (NP (DT this) (NN SNP)) (NP (NP (DT a) (JJ potential) (NN marker)) (PP (IN for) (NP (CC both) (NP (NN HLA-C) (NN expression)) (CC and) (NP (NN drug2) (NN disease) (NN progression))))))))))
(S1 (S (S (NP (NP (CD Two) (NNS polymorphisms)) (VP (VBG affecting) (NP (NP (NN HLA-Csurface) (NN expression)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (-RRB- -RRB-))))) (VP (VBP have) (ADVP (RB recently)) (VP (VBN been) (VP (VP (VBN identified)) (, ,) (CC and) (VP (VBN shown) (S (VP (TO to) (VP (VB influence) (NP (NP (NN progression)) (PP (IN of) (NP (NN drug3) (NN infection)))))))))))) (. .)))
(S1 (S (NP (NP (NN OBJECTIVE)) (: :) (S (NP (NP (NN Heterozygosity)) (PP (IN for) (NP (NP (DT a) (ADJP (CD 32) (NN base) (NN pair)) (NN deletion)) (PP (IN in) (NP (NP (NP (DT the) (NN CCR5) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN CCR5wt/d32)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (JJ minor) (NNS alleles)) (PP (IN of) (NP (DT a) (JJ single-nucleotide) (NN polymorphism))) (PP (PP (IN in) (NP (NP (DT the) (NN HCP5) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (NP (DT the) (JJ HLA-C) (NN gene) (NN region)) (PRN (-LRB- -LRB-) (NP (NP (NN -35HLA-C)) (: ;) (NP (NN drug2))) (-RRB- -RRB-))))))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (DT a) (NN drug3))))))))))
(S1 (S (S (NP (NP (NP (NP (DT A) (JJ single) (NN nucleotide) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NN SNP)) (-RRB- -RRB-))) (CD 35) (NN kb)) (ADVP (RB upstream) (PP (IN of) (NP (NN HLA-C))) (PRN (-LRB- -LRB-) (NP (NN drug1)) (: ;) (QP (VBN termed) (CD -35)) (-RRB- -RRB-)))) (VP (VBZ associates) (PP (PP (IN with) (NP (NP (NN control)) (PP (IN of) (NP (NN drug2))))) (, ,) (CC and) (PP (IN with) (NP (NP (NNS levels)) (PP (IN of) (NP (NP (JJ HLA-C) (NN messenger) (NN RNA) (NNS transcripts)) (CC and) (NP (JJ cell-surface) (NN expression))))))))) (, ,) (CC but) (S (NP (NP (DT the) (NN mechanism)) (VP (VBG underlying) (NP (PRP$ its) (JJ varied) (NN expression)))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (NP (JJ Significant) (NNS associations)) (PP (IN between) (NP (NP (NP (DT the) (JJ minor) (NN allele) (NNS variants)) (PP (IN of) (NP (NNS SNPs) (NP (NP (NN HLA-C) (NN drug1)) (CC and) (NP (NN HCP5) (NN drug2)))))) (CC and) (NP (NP (DT a) (JJR lower) (JJ viral) (NN load)) (PP (IN at) (NP (NN set) (NN point))))))) (VP (MD could) (VP (VB be) (VP (VBN replicated) (PP (IN in) (NP (DT the) (NN drug3))))))) (. .))))
(S1 (S (PP (IN In) (NP (ADJP (ADJP (JJ adiposity-matched)) (, ,) (ADJP (JJ normal-weight))) (NNS humans))) (, ,) (NP (PRP we)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NNS subjects)) (ADJP (JJ homozygous) (PP (IN for) (NP (DT the) (NN FTO) (NN drug2) (NN drug1) (NN A) (NN allele))))) (VP (VBP have) (VP (VP (VBN dysregulated) (NP (NP (JJ circulating) (NNS levels)) (PP (IN of) (NP (DT the) (JJ orexigenic) (NN hormone) (NN acyl-ghrelin))))) (CC and) (VP (VBN attenuated) (NP (NN drug3)))))))) (. .)))
(S1 (S (PP (IN Through) (NP (NP (NP (DT an) (JJ exhaustive) (NN search)) (PP (IN of) (NP (JJ pair-wise) (NNS interactions)))) (CC and) (NP (NP (DT a) (VBN selected) (NN search)) (PP (IN of) (NP (CD three-))) (PP (TO to) (NP (NP (JJ five-way) (NNS interactions)) (VP (VBN conditioned) (PP (IN on) (NP (JJ significant) (JJ pair-wise) (NNS results))))))))) (, ,) (NP (PRP we)) (VP (VBD identified) (NP (NP (CD 24) (NN core) (NNS SNPs)) (PP (IN in) (NP (NP (NP (CD six) (NNS genes)) (PRN (-LRB- -LRB-) (NP (NNP FTO)) (: :) (NP (NN drug1)) (, ,) (NP (NP (NN drug2) (, ,) (NN drug3) (, ,) (NN drug4) (, ,) (NN drug5) (, ,) (NP (NP (NN drug6)) (: ;) (NP (NN TSPAN8)) (: :) (NP (NN drug7)) (: ;) (NP (NN TCF7L2)) (: :) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (CD drug10)) (, ,)) (NN drug11)) (, ,) (NP (CD drug12)) (, ,) (NP (NN drug13)) (, ,) (NP (NN drug14)) (, ,) (NP (CD drug15)) (: ;) (NP (NN L3MBTL3)) (: :) (NP (CD drug16)) (, ,) (NP (CD drug17)) (: ;) (NP (NN CELF4)) (: :) (NP (CD drug18)) (, ,) (NP (CD drug19)) (: ;) (NP (NN RUNX1)) (: :) (NP (CD drug20)) (, ,) (NP (NN drug21)) (, ,) (NP (NN drug22)) (, ,) (NP (NN drug23)) (, ,) (NP (CD drug24))) (-RRB- -RRB-))) (SBAR (WHNP (WDT that)) (S (VP (VBP appear) (S (VP (TO to) (VP (VB be) (ADJP (JJ important) (PP (IN for) (NP (NN drug25)))))))))))))) (. .)))
(S1 (S (NP (NP (DT The) (NN increase)) (PP (IN in) (NP (NN cotinine) (NNS levels)))) (VP (VBD indicated) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (NP (DT each) (JJ additional) (NN copy)) (PP (IN of) (NP (DT the) (NN drug1) (: -) (NN drug2) (NN risk) (NN allele)))))))))
(S1 (S (NP (NP (NN OBJECTIVE)) (: :) (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN if) (S (NP (DT the) (NN FTO) (NN drug1)) (VP (VBZ associates) (PP (IN with) (NP (NP (JJ food) (NNS preferences)) (PP (IN in) (NP (NP (JJ healthy) (NNS adults)) (PP (IN with) (NP (NP (NN no) (NN drug2)) (, ,) (NP (NN drug3) (NN disease)) (, ,) (CC or) (NP (NN drug4))))))))))))) (. .))))
(S1 (S (NP (NP (NNS Conclusions)) (: :) (S (NP (DT The) (JJ present) (NN study)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NN FTO) (ADJP (ADJP (JJ drug1)) (CC and) (ADJP (JJ combined))) (NNS SNPs)) (VP (VBD were) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN risk)) (PP (IN of) (NP (NN drug2))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ seems) (S (VP (TO to) (VP (VB be) (ADJP (JJ dependent) (PP (IN on) (NP (NN BMI)))))))))))))))))) (. .))))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (DT The) (JJ present) (NN study)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NN FTO) (ADJP (ADJP (JJ drug1)) (CC and) (ADJP (JJ combined))) (NNS SNPs)) (VP (VBD were) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN risk)) (PP (IN of) (NP (NN drug2))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ seems) (S (VP (TO to) (VP (VB be) (ADJP (JJ dependent) (PP (IN on) (NP (NN BMI)))))))))))))))))) (. .))))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (DT All) (JJ drug2) (NNS patients)) (VP (VBD were) (NP (JJ genotypedfor) (NP (NP (DT the) (JJ FTO) (JJ single) (NN nucleotide) (NN polimorphysm)) (PRN (-LRB- -LRB-) (NP (NN SNP)) (-RRB- -RRB-))) (NN drug1)))) (. .))))
(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (NP (NP (DT the) (NN drug1) (JJ single) (NN nucleotide) (NN polymorphism)) (PP (IN in) (NP (DT the) (NN nicotine) (NN acetylcholine) (NN receptor) (NN gene) (NN cluster)))) (PRN (-LRB- -LRB-) (NP (NN CHRNA5-CHRNA3-CHRNB4)) (-RRB- -RRB-))) (, ,) (VP (VBN associated) (PP (IN with) (NP (NN smoking) (NNS phenotypes)))) (, ,)) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD continued) (PP (TO to) (NP (NN smoke))))))) (VP (VBD were) (ADVP (RB also)) (ADJP (RBR more) (JJ likely)) (S (VP (TO to) (VP (VBP report) (NP (NP (DT a) (NN drug2)) (PP (IN during) (NP (NN pregnancy)))))))))))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBD found) (S (PP (IN among) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD smoked) (NP (NN pre-pregnancy))))))) (, ,) (NP (NP (DT those)) (PP (IN with) (NP (DT the) (NN drug1) (NN T) (NN allele)))) (VP (VP (VBD smoked) (ADVP (RBR more))) (CC and) (VP (VBD were) (ADVP (RBR less) (RB likely)) (VP (TO to) (VP (VB quit) (VP (VBN drug2) (PP (IN during) (NP (NN pregnancy)))))) (, ,) (CC but) (VP (VBD were) (ADVP (RB also)) (ADJP (RBR less) (JJ likely) (S (VP (TO to) (VP (VBP report) (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NN drug3)))) (PP (IN at) (NP (NP (CD 18) (NNS weeks)) (PP (IN of) (NP (NP (NN pregnancy)) (PRN (-LRB- -LRB-) (PP (IN per) (NP (NP (NN allele)) (CC OR) (NP (ADJP (JJ =) (NP (CD 0.84) (, ,) (CD 95) (NN %) (CD CI))) (NP (CD 0.72) (TO to) (CD 0.99))))) (, ,) (NP (NN p) (JJ =) (NN 0.034)) (-RRB- -RRB-))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ drug1) (JJ genetic) (NN variant)) (PP (IN within) (NP (DT the) (NN CHRNA5-A3-B4) (NN gene) (NN cluster)))) (VP (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NN drug2))))) (CC and) (VP (VBZ has) (ADVP (RB recently)) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (NN likelihood)) (PP (IN of) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (JJ potential) (NN association)) (PP (IN of) (NP (NN drug1) (NN gLLLenotype))) (PP (IN with) (NP (NP (VBN reduced) (NN likelihood)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (NP (CD 2) (NNS cohorts)) (PP (IN of) (NP (NP (JJ treatment-seeking) (NNS smokers)) (PP (IN in) (NP (NP (JJ primary) (NN care)) (PP (IN in) (NP (DT the) (JJ United) (NN Kingdom))))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NN association)) (PP (IN of) (NP (NN drug1) (NN genotype))) (PP (IN with) (NP (NN drug2)))))) (PP (IN in) (NP (NP (PRP$ our) (JJ open-label) (NN trial) (NN sample)) (CONJP (CC but) (RB not)) (NP (NP (PRP$ our) (JJ placebo-controlled) (NN trial)) (NN sample)))))) (. .)))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (DT the) (NN drug1) (NN variant)) (VP (MD may) (RB not) (ADVP (RB merely)) (VP (VB operate) (PP (IN as) (NP (NP (DT a) (NN marker)) (PP (IN for) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (RB Nominally) (JJ significant)) (NNS associations)) (PP (IN with) (NP (NP (NNS candidateSNPs)) (PP (IN within) (NP (NP (JJ cholinergic) (NNS receptors)) (, ,) (NP (JJ nicotinic) (, ,) (NP (NP (NP (NN alpha) (CD 3/5)) (PRN (-LRB- -LRB-) (NP (NN CHRNA3/CHRNA5)) (: ;) (NP (NN eg)) (, ,) (NP (NP (NN p=0.00011)) (PP (IN for) (NP (NN SNP) (NN drug1)))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NP (NN cytochrome) (NN P450)) (, ,) (NP (NN family) (CD 2)) (, ,) (NP (NN subfamily) (NN A)) (, ,) (NP (NN polypeptide) (CD 6))) (PRN (-LRB- -LRB-) (NP (NN CYP2A6)) (: ;) (NP (NN eg)) (, ,) (NP (NP (NP (NN p=2.78) (NN *) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD -5)) (-RRB- -RRB-))) (PP (IN for) (NP (DT a) (JJ non-synonymous) (NN SNP) (NN drug2)))) (-RRB- -RRB-))) (NNS regions))))))))) (VP (VBD were) (VP (VBN observed) (PP (IN for) (NP (NN drug3)))))) (, ,) (RB however) (S (ADVP (RB only)) (NP (NN CYP2A6)) (VP (VBD showed) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (JJ significant) (NN association)) (PP (IN with) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN candidate) (NN SNP) (NN drug1)) (PP (IN in) (NP (NN drug2)))) (VP (VBD was) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NN p=0.015)) (-RRB- -RRB-)) (VP (VBN associated) (PP (IN with) (NP (NN drug3)))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBD examined) (NP (NP (DT the) (NNS associations)) (PP (IN between) (NP (NP (NP (DT the) (JJ nicotinic) (NN acetylcholine) (NN receptor)) (NN polymorphism) (NN drug1)) (PP (IN on) (NP (NP (NN chromosome) (CD 15q25)) (VP (VBG marking) (NP (NP (NN thegene) (NN cluster) (NN CHRNA3-CHRNB4-CHRNA5)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))) (PP (IN in) (NP (DT the) (JJ general) (NN population)))))))))) (. .)))
(S1 (S (NP (CC Both) (NP (NP (DT the) (NN T-allele)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (DT the) (NN T-allele)) (PP (IN of) (NP (NN drug2))))) (ADVP (RB significantly)) (VP (VBP increase) (NP (NN drug3) (NN risk)) (PP (IN with) (NP (NP (DT an) (JJ allelic) (NNS odds) (NP (NP (NN ratio)) (-LRB- -LRB-) (CC OR) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NP (NP (NP (CD 1.69)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (NN CI) (CD 1.55-1.83)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJ =) (NP (NP (CD 6.0) (CC x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD -35)) (-RRB- -RRB-))))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (CD 1.60)) (PRN (-LRB- -LRB-) (NP (NN 1.47-1.74)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 7.6) (NN x) (CD 10) (-LRB- -LRB-) (CD -28) (-RRB- -RRB-)))) (-RRB- -RRB-)))) (, ,) (ADVP (RB respectively))))))) (. .)))
(S1 (S (NP (DT The) (NN drug1) (NN T) (NN at-risk) (NN allele)) (VP (VBZ associates) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NP (JJR earlier) (NN age)) (PP (IN at) (NP (NN diagnosis)))))) (PP (IN in) (NP (NP (NP (DT the) (NN drug3) (NNS subjects)) (PRN (-LRB- -LRB-) (S (S (NP (NN P)) (VP (JJ =) (NP (CD 8.0) (NN x) (CD 10) (-LRB- -LRB-) (CD -3) (-RRB- -RRB-)))) (CC and) (S (NP (NN P)) (VP (JJ =) (NP (CD 3.8) (NN x) (CD 10) (-LRB- -LRB-) (CD -4) (-RRB- -RRB-)) (, ,) (ADVP (RB respectively))))) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (NP (JJ supportedby) (JJ quantitative) (JJ family-based) (NN association) (NNS tests)))))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBD genotyped) (NP (NP (NP (CD four)) (PP (IN of) (NP (DT the) (NNS SNPs)))) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN Amish) (NNS subjects)) (PP (IN with) (NP (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (NN 137)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (NP (NN IGT)) (: ;) (S (NP (NN n)) (VP (JJ =) (NP (CD 139)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (NP (NN NGT)) (: ;) (S (NP (NN n)) (VP (JJ =) (NP (CD 342)))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NP (NN A-allele)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN drug2))))) (ADVP (RB regardless) (PP (IN of) (NP (NN smoking) (NN exposure))) (PRN (-LRB- -LRB-) (NP (JJ pooled) (CC OR) (JJ =) (NP (NP (QP (CD 1.26) (, ,) (CD 95)) (NN %)) (NP (NN CI) (CD 1.18-1.34)))) (, ,) (NP (NP (NN p)) (ADJP (RB <) (JJ 10))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN drug1)) (PP (IN in) (NP (NN CHRNA)))) (VP (VBZ is) (NP (NP (DT a) (NN susceptibility) (NN variant)) (PP (IN for) (NP (NN drug2)))) (, ,) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (CC both) (NP (NN airway) (NN obstruction)) (CC and) (NP (NN parenchyma) (NN destruction))))))))))) (. .)))
(S1 (S (ADVP (RB Recently)) (, ,) (NP (NP (DT a) (NN microsatellite) (NN marker)) (PP (IN in) (NP (NP (NN intron) (CD 3) (NN drug1)) (CC and) (NP (NP (CD five) (JJ correlated) (JJ single) (NN nucleotide) (NNS polymorphisms)) (PRN (-LRB- -LRB-) (NP (NNS SNPs)) (-RRB- -RRB-)))))) (VP (VBD were) (VP (VBN identified) (PP (IN in) (NP (NP (JJ Icelandic) (NNS individuals)) (SBAR (WHNP (WDT that)) (S (VP (VBD showed) (NP (NP (JJ strong) (NN association)) (PP (IN with) (NP (NP (NN drug2)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (VP (VBN replicated) (PP (IN in) (NP (ADJP (ADJP (JJ Danish)) (CC and) (ADJP (JJ European-American))) (NNS cohorts))))))))))))))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBD genotyped) (NP (NP (NP (CD four)) (PP (IN of) (NP (DT the) (NNS SNPs)))) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN Amish) (NNS subjects)) (PP (IN with) (NP (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (NN 137)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (NP (NN IGT)) (: ;) (S (NP (NN n)) (VP (JJ =) (NP (CD 139)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (NP (NN NGT)) (: ;) (S (NP (NN n)) (VP (JJ =) (NP (CD 342)))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VP (VBD compared) (NP (NP (NN genotype) (NNS frequencies)) (PP (IN in) (NP (NP (NNS subjects)) (PP (IN with) (NP (NN drug2)))))) (PP (IN with) (NP (NP (DT those)) (PP (IN with) (NP (NN NGT)))))) (CC and) (VP (VBD found) (NP (JJ marginal) (NN association)) (PP (IN for) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJ =) (NP (CD 0.05)))) (: ;) (NP (NNS odds) (NP (NP (NN ratio)) (NP (JJ -LSB-OR) (-RRB- -RSB-) (NN 1.51)))) (-RRB- -RRB-)))))) (: ;)))
(S1 (S (NP (NP (NN comparison)) (PP (IN between) (NP (NP (JJ NGT) (NN control) (NNS subjects)) (CC and) (NP (DT the) (JJ combined) (NN drug5) (NN case) (NN group))))) (VP (VBD showed) (NP (NP (NP (JJ strong) (NN association)) (PP (IN with) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJ =) (NP (CD 0.008-0.01)))) (: ;) (NP (CC OR) (CD 1.53-1.57)) (-RRB- -RRB-))))) (CC and) (NP (NP (JJ marginal) (NN association)) (PP (IN with) (NP (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NN P)) (ADJP (JJ =) (NP (CD 0.07)))) (CC and) (NP (NN P))) (ADJP (JJ =) (NP (CD 0.04)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VP (VBD genotyped) (NP (DT these) (NNS SNPs)) (PP (IN in) (NP (NP (NP (ADJP (ADJP (JJ nondiabetic)) (, ,) (ADJP (JJ non-Amish))) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 48)) (-RRB- -RRB-))) (, ,) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (JJ intravenous) (NN drug3) (NNS tests)) (VP (VBD were) (VP (VBN performed))))) (, ,)))) (CC and) (VP (VBD found) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (NP (NP (NN drug1)) (CC and) (NP (NP (NN drug2)) (CC and) (NP (NN drug4)))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN P) (JJ =) (CD 0.003)) (CC and) (NP (NP (NN P)) (VP (VBG =) (NP (CD 0.005))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN P) (JJ =) (CD 0.04)) (CC and) (NP (NP (NN P)) (VP (VBG =) (NP (CD 0.007))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NN association)) (PP (IN of) (NP (NP (NP (DT a) (JJ common) (NN variant)) (PP (IN of) (NP (DT the) (NN TCF7L2) (NN gene)))) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (NN drug2) (NN risk)) (PP (IN among) (NP (NNS Caucasians))))))) (. .)))
(S1 (S (PP (IN Over) (NP (NP (DT an) (JJ average) (NN period)) (PP (IN of) (NP (CD three) (NNS years))))) (, ,) (NP (NP (NNS participants)) (PP (IN with) (NP (NP (DT the) (JJ risk-conferring) (NN TT) (NN genotype)) (PP (IN at) (NP (NN drug1)))))) (VP (VBD were) (ADJP (RBR more) (JJ likely)) (S (VP (TO to) (VP (VB have) (NP (NP (NN progression)) (PP (IN from) (NP (NN drug2))) (PP (TO to) (NP (NN drug3)))) (SBAR (IN than) (SINV (VBD were) (NP (NP (JJ CC) (NNS homozygotes)) (PRN (-LRB- -LRB-) (NP (NN hazard) (NN ratio)) (, ,) (NP (CD 1.55)) (: ;) (NP (NP (CD 95) (NN percent)) (ADJP (RB confidence) (JJ interval))) (, ,) (NP (CD 1.20) (TO to) (CD 2.01)) (: ;) (NP (NN P<0.001)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Common) (NNS variants)) (PP (IN in) (NP (NN drug1)))) (VP (VBP seem) (S (VP (TO to) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN drug2))) (PP (IN among) (NP (NP (NNS persons)) (PP (IN with) (NP (NN drug3))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN SNP) (NN drug1)) (VP (VBD was) (ADVP (RB nominally)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (DT the) (JJ initial) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (ADJP (JJ =) (NP (CD 0.08)))) (-RRB- -RRB-)) (CC and) (CD two) (NN replication) (NN sample) (NNS sets))))) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (JJ =) (NP (NP (CD 0.05)) (CC and) (NP (CD 0.06))))) (-RRB- -RRB-))))) (. .)))
(S1 (S (PP (IN For) (NP (NP (DT the) (JJ combined) (NN sample) (NN set)) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (PRP we)) (ADVP (RB successfully)) (VP (VBD genotyped) (NP (NP (NP (NN 1,174) (NN type) (CD 2) (NN diabetes)) (NNS patients)) (CC and) (NP (CD 823) (JJ control) (NNS subjects)))))))) (, ,) (NP (NN drug1)) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN association)) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NNS odds) (NN ratio)) (ADJP (JJ =) (NP (CD 1.69) (CD -LSB-95) (NN %) (QP (RB CI) (CD 1.21-2.36))))) (-RRB- -RSB-) (, ,) (NP (NN p) (JJ =) (CD 0.002)) (-RRB- -RRB-)))) (PP (IN with) (NP (DT the) (JJ same) (NN direction)))) (PP (IN as) (NP (NP (DT the) (JJ previous) (NNS reports)) (PP (IN in) (NP (NP (NNS samples)) (PP (IN from) (NP (NP (NNP European)) (CC and) (NP (NNP European-origin)) (NP (NNS populations))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN rest)) (PP (IN of) (NP (NP (DT the) (CD five) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))) (-RRB- -RRB-))))) (VP (VBD did) (RB not) (VP (VB show) (NP (NP (DT any) (JJ significant) (NNS associations)) (PP (IN with) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ consistent) (NN association)) (PP (IN between) (NP (NN drug1))) (PP (IN in) (NP (NP (NP (NN TCF7L2)) (CC and) (NP (NN drug2))) (PP (IN in) (NP (NP (JJ different) (JJ ethnic) (NNS groups)) (, ,) (PP (VBG including) (NP (DT the) (JJ Japanese) (NN population))) (, ,)))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN TCF7L2)) (VP (VBZ is) (NP (NP (DT a) (JJ common) (NN susceptibility) (NN gene)) (PP (IN for) (NP (NN type) (CD 2) (NNS diabetes))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ minor) (NNS alleles)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN TCF7L2)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN TCF7L2)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN -30G/A)) (, ,) (NP (NN GCK)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN E23K)) (, ,) (NP (NN KCNJ11)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN CDKAL1)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (NP (NN IGF2BP2)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (NP (NN MTNR1B)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug8)) (PRN (-LRB- -LRB-) (NP (NN MTNR1B)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug9)) (PRN (-LRB- -LRB-) (NP (NNP Gly972Arg) (, ,) (NNP IRS1)) (-RRB- -RRB-)))))) (VP (VBD were) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJR higher) (NN risk)) (PP (IN of) (NP (NN drug10)))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN summary))) (, ,) (PP (IN by) (S (VP (VBG pooling) (NP (NP (DT all) (JJ available) (VBN qualified) (NNS data)) (PP (IN from) (NP (NP (JJ genetic) (NNS studies)) (PP (IN on) (NP (NP (NN drug1)) (CC and) (NP (NN drug3)))))))))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN confirmed) (SBAR (IN that) (S (NP (NN drug2)) (VP (VBZ is) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN susceptibility)) (PP (TO to) (NP (NN drug4))) (PP (IN in) (NP (DT the) (JJ global) (NN population))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ recent) (NNS years))) (, ,) (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (ADVP (RB widely)) (VP (VBN accepted) (SBAR (IN that) (S (NP (NP (NN transcription) (NN factor) (JJ 7-like) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN TCF7L2)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NN type) (CD 2) (NN diabetes) (NN mellitus)) (NN drug3)) (PP (IN in) (NP (NP (JJ multiple) (JJ ethnic) (NNS groups)) (, ,) (ADVP (RB especially)) (NP (NP (PRP$ its) (JJ single) (NN nucleotide) (NNS polymorphisms)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN rs290487T/C))))))))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (DT this) (NN study)) (VP (VBD indicated) (SBAR (IN that) (S (NP (NP (DT the) (NN drug1) (NN polymorphism)) (PP (IN of) (NP (DT the) (NN TCF7L2) (NN gene)))) (VP (VBD had) (NP (DT a) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (NN drug4) (NN risk)) (PP (IN in) (NP (JJ Chinese) (JJ Han) (NN population))))) (, ,) (PP (IN with) (NP (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (NNS polymorphisms)) (VP (VBG showing) (NP (DT no) (JJ significant) (NN effect))))))))) (. .)))
(S1 (S (S (NP (NNS Subgroups) (NNS analyses)) (VP (VBP show) (SBAR (IN that) (S (NP (JJ significant) (NNS associations)) (VP (VBP are) (RB not) (VP (VBN found) (PP (IN between) (NP (NP (NP (DT the) (CD six) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6))) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (NNS drug7)) (PP (IN in) (NP (DT some) (JJ ethnic) (NNS populations)))))))))))) (. .)))
(S1 (S (S (NP (DT The) (CD four) (VBN tested) (NN TCF7L2) (NNS variants)) (VP (VBD were) (PP (IN in) (NP (NN linkage) (NN disequilibrium))))) (, ,) (CC and) (S (NP (JJ 4-locus) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-)) (NN haplotype) (NN analysis)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NN haplotype) (NN 1111)) (VP (VBD was) (ADVP (RB negatively)) (VP (VBN associated) (PRN (-LRB- -LRB-) (NP (NN Pc<0.001)) (-RRB- -RRB-)) (, ,) (SBAR (IN while) (S (NP (NNS haplotypes) (NP (NP (NP (CD 2222)) (PRN (-LRB- -LRB-) (NP (CD Pc=0.008)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 2211)) (PRN (-LRB- -LRB-) (NP (NN Pc=0.020)) (-RRB- -RRB-))))) (VP (VBD were) (ADVP (RB positively)) (VP (VBN associated) (PP (IN with) (NP (NN drug5) (NN risk))) (, ,) (PP (IN after) (S (VP (VBG controlling) (PP (IN for) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NNS covariates)))))))))))))))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBD evaluated) (NP (NP (DT the) (VBN published) (NN evidence)) (PP (IN for) (NP (NP (NN association)) (PP (IN between) (NP (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN k)) (ADJP (JJ =) (NP (CD 27) (NNS samples)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN k)) (ADJP (JJ =) (NP (CD 44) (NNS samples)))) (-RRB- -RRB-)))) (NNS SNPs))) (PP (IN with) (NP (NN drug3)))))) (S (VP (VBG using) (NP (JJ meta-analytic) (NNS techniques))))) (. .)))
(S1 (S (NP (NN Meta-analysis)) (VP (VBD indicated) (NP (NP (JJ compelling) (NN evidence)) (PP (IN of) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (NP (DT the) (NP (NN drug1) (NNS variants)) (CC and) (NP (NNS drug2))) (PRN (-LRB- -LRB-) (NP (JJ fixed) (NNS effects)) (: :) (NP (NP (NN B)) (ADJP (JJ =) (NP (NP (ADJP (QP (CD 0.91) (, ,) (CD 95)) (NN %)) (NN CI)) (ADJP (JJ =) (NP (CD 0.77)))))) (, ,) (NP (CD 1.06)) (, ,) (NP (NN p) (JJ <) (CD .001)) (: ;) (NP (NP (JJ random) (NNS effects)) (: :) (NP (NP (NN B)) (ADJP (JJ =) (NP (NP (CD 1.01) (, ,) (CD 95) (NN %) (NN CI)) (ADJP (JJ =) (NP (CD 0.81))))))) (, ,) (NP (CD 1.22)) (, ,) (NP (NN p) (JJ <) (CD .001)) (-RRB- -RRB-))) (, ,) (ADJP (JJ equivalent) (PP (TO to) (NP (NP (DT a) (JJ per-allele) (NN effect)) (PP (IN of) (NP (QP (RB approximately) (CD 1)) (NN cigarette/day)))))))))))) (. .)))
(S1 (S (PP (IN Among) (NP (NP (NNS women)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NN drug2))))))) (, ,) (NP (NP (DT the) (NN TT) (NN genotype)) (PP (IN of) (NP (NN drug1)))) (VP (VBD increased) (NP (NN drug3) (NN risk)) (PRN (-LRB- -LRB-) (CC OR) (, ,) (NP (CD 2.46) (: ;) (CD 95) (NN %) (NN CI) (CD 1.28-4.73)) (-RRB- -RRB-)))))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NN Donor) (NN TCF7L2) (NN drug1) (NN polymorphism)) (VP (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN drug2))) (PP (IN after) (NP (NN LT))))))) (CC and) (VP (VBZ has) (NP (NP (DT a) (JJ potential) (JJ clinical) (NN value)) (PP (IN for) (NP (NP (DT the) (NN prediction)) (PP (IN of) (NP (NN NODM))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ minor) (NN T) (NN allele)) (PP (IN of) (NP (NN TCF7L2) (NN drug1)))) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (ADVP (RB significantly)) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug2)))) (, ,) (PP (IN with) (NP (NP (NP (DT an) (NP (JJ allelic) (NNS odds)) (NN ratio)) (PRN (-LRB- -LRB-) (NP (NN OR)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NN 1.458)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (NN CI) (CD 1.108-1.918)) (, ,) (S (NP (NN p)) (VP (JJ =) (NP (CD 0.007)))) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD found) (NP (NP (DT a) (JJ strong) (NN correlation)) (PP (IN between) (NP (NP (DT the) (NN drug1)) (CC and) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug2)))))) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.02)) (PP (IN with) (NP (DT a) (ADJP (ADJP (JJ high)) (CC OR) (ADJP (JJ =))) (NN 8.28))))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (S (NP (NN drug1) (NN GTCF7L2) (NN variant)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ peripheral) (NNS drug2)) (PP (IN in) (NP (NN drug3)))))))) (CC but) (S (NP (DT this) (NN effect)) (VP (VBZ is) (RB not) (VP (VBN seen) (PP (IN in) (NP (JJ control) (NNS women)))))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NN TCF7L2) (NN drug1) (NN polymorphism)) (VP (VBZ protects) (NP (NN Mexican) (NNS children)) (PP (IN from) (NP (NN drug2))))) (. .))))
(S1 (S (S (NP (NP (JJ THADA) (NN variant)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NN drug2))) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (CD 1.5) (: ;) (CD 95) (NN %) (NN CI) (CD 1.04)) (, ,) (NP (NN 2.22)) (: ;) (NP (NP (NN p)) (ADJP (JJ =) (NP (CD 0.03))))) (-RRB- -RRB-))))) (. .)))
(S1 (S (SBAR (IN If) (S (NP (NP (DT the) (NN application)) (PP (IN of) (NP (NN TCF7L2) (NN drug1) (NNS SNPs))) (PP (IN as) (NP (NP (DT a) (NN marker)) (PP (IN for) (NP (NNS drug2)))))) (VP (VBZ is) (VP (VBN confirmed) (PP (IN by) (NP (JJ further) (JJ independent) (NNS studies))))))) (, ,) (S (VP (VBG replacing) (NP (NN tacrolimus)) (PP (IN with) (NP (JJ other) (NNS immunosuppressants))))) (VP (MD could) (VP (VB be) (VP (VBN warranted) (PP (IN in) (NP (NP (NNS patients)) (PP (IN at) (NP (NP (JJ high) (NN risk)) (PP (IN of) (NP (NN drug3))))))) (, ,) (SBAR (IN as) (S (VP (VBN diagnosed) (PP (IN by) (NP (NN TCF7L2) (NN genotyping))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT an) (NN association)) (PP (IN of) (NP (NP (CD two) (NNS SNPs)) (PP (IN of) (NP (DT the) (NN TCF7L2) (NN gene))))) (PP (IN with) (NP (NN drug3)))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NP (DT both) (NNS cities)) (: :) (NP (NP (NP (NN drug1)) (PRN (, ,) (-LRB- -LRB-) (PP (PP (IN for) (NP (NP (NN Guerrero)) (CC OR) (NP (ADJP (JJ =) (NP (CD 1.98))) (CD CI95) (NN %) (CD 1.02-3.89)))) (CC and) (PP (IN for) (NP (NP (NNP Mexico)) (CC OR) (NP (JJ =) (CD 1.94))))) (NP (CD CI95) (NN %) (CD 1.31-2.88)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CC OR) (NP (ADJP (JJ =) (NP (CD 1.79) (CD CI95) (NN %) (CD 1.08-2.97)))) (, ,) (CC OR) (NP (ADJP (JJ =) (NP (NP (NP (CD 1.78)) (NP (CD CI95) (NN %) (CD 1.17-2.71))) (ADVP (RB respectively)))))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (DT No) (NN interaction)) (VP (VBD was) (VP (VBN observed) (PP (IN between) (NP (NP (NP (NN drug1)) (CC and) (NP (NN HLA-DQB1) (NN *) (NN 0602))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADVP (RB negatively)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (NP (NNS mothers)) (VP (VBN born) (PP (IN in) (NP (NP (NN Sweden)) (PRN (-LRB- -LRB-) (NP (NN P) (JJ =) (NN 0.010)) (-RRB- -RRB-)))))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ genetic) (NN variant)) (PP (IN within) (NP (NP (DT the) (JJ CHRNA5-CHRNA3-CHRNB4) (NN region)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-)))) (, ,) (VP (ADVP (RB previously)) (VBN associated) (PP (IN with) (NP (NN drug2) (NN quantity)))) (, ,)) (VP (VBD was) (ADVP (RB recently)) (VP (VBN shown) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NN drug3))) (PP (IN on) (NP (NN drug4) (NN predisposition))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN drug1) (NN variant)) (VP (VBD was) (RB not) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2) (NN status)) (CC or) (NP (NN snus) (NN use)))) (PRN (-LRB- -LRB-) (NP (NN P) (NN >) (CD 0.05)) (-RRB- -RRB-))))) (: ;) (S (NP (DT the) (NN T) (NN allele)) (VP (VBD was) (VP (VBN associated) (PP (PP (IN with) (NP (NP (JJR lower) (NN BMI)) (PP (IN in) (NP (NP (DT the) (JJ overall) (NN cohort)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (NN b) (JJ =)) (NN -0.10) (NN kg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (, ,) (NP (NP (NN SE)) (ADJP (JJ =) (NP (CD 0.05)))) (: ;) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.03)))) (-RRB- -RRB-)))))) (CC and) (PP (IN with) (NP (NP (NN drug3) (NN quantity)) (PP (IN in) (NP (NP (DT those)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (DT this)) (VP (VBD was) (VP (VBN measured)))))))))) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 5,304)))) (-RRB- -RRB-))))) (PRN (-LRB- -LRB-) (NP (NP (NN b)) (ADJP (JJ =) (NP (CD 0.08)))) (, ,) (NP (NP (NN SE)) (ADJP (JJ =) (NP (CD 0.01)))) (: ;) (NP (NN P) (JJ <) (CD 0.0001)) (-RRB- -RRB-))))
(S1 (S (S (S (NP (DT The) (NN drug1) (-LRB- -LRB-) (NN T) (-RRB- -RRB-) (NN allele) (NN genotype)) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NN drug3))) (PRN (-LRB- -LRB-) (NP (NN P) (JJ =) (CD 0.003)) (-RRB- -RRB-))))) (CC but) (S (NP (NN drug2) (-LRB- -LRB-) (NN T) (-RRB- -RRB-) (NN allele) (NN genotype)) (VP (VBD was) (RB not) (VP (VBN associated) (PP (IN with) (NP (DT the) (JJ clinico-pathologic) (NNS characteristics))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (DT the) (NN drug1) (CC and) (NN drug2) (NNS markers)) (VP (VBP are) (NP (NP (JJ independent) (JJ genetic) (NN drug3) (NN risk) (NNS factors)) (PP (IN in) (NP (DT a) (JJ Russian) (NN population)))))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (DT the) (NN drug1) (CC and) (NN drug2) (NNS markers)) (VP (VBP are) (NP (NP (JJ independent) (JJ genetic) (NN drug3) (NN risk) (NNS factors)) (PP (IN in) (NP (DT a) (JJ Russian) (NN population)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ non-synonymous) (NN drug1) (NN polymorphism)) (PP (IN of) (NP (DT the) (NN ADRB3) (NN gene)))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NNP drug2) (-LRB- -LRB-) (NNP Trpallele)))))) (, ,) (CC OR) (JJ =) (NN 0.62) (, ,) (NN p) (JJ =) (CD 0.001) (-RRB- -RRB-) (CC and) (NN drug3) (-LRB- -LRB-) (NN Trp) (NN allele) (, ,) (NN OR) (JJ =) (CD 0.74) (, ,) (NN p) (JJ =) (CD 0.018) (-RRB- -RRB-) (. .)))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (NP (NP (NP (NP (JJ Single) (NN nucleotide) (NNS polymiorphisms)) (PRN (-LRB- -LRB-) (NP (NNS SNPs)) (-RRB- -RRB-))) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (ADJP (JJ located) (PP (IN within) (NP (NN TCF7L2) (NN gene))))) (VP (VBP have) (VP (VBN been) (VP (VBN identified) (PP (IN as) (NP (NP (DT the) (JJS strongest) (JJ common) (JJ genetic) (NN risk) (NNS factors)) (PP (IN for) (NP (NP (NN development)) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN T2D)) (-RRB- -RRB-)))))))))))) (. .))))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (SBAR (IN Although) (S (NP (NP (NP (DT the) (NN biology)) (PP (IN of) (NP (DT the) (NN Wnt/beta-catenin) (NN signaling) (NN pathway)))) (CC and) (NP (NP (JJ prior) (NN association)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (JJ numerous) (NNS phenotypes)))))) (VP (VBN warranted) (NP (NP (NN examination)) (PP (IN of) (NP (DT this) (NN TCF7L2) (NN SNP))))))) (, ,) (NP (NP (DT no) (JJ compelling) (NN evidence)) (PP (IN for) (NP (NP (NN association)) (PP (IN with) (NP (NP (NN breast)) (CC or) (NP (NN drug2))))))) (VP (VBD was) (VP (VBN observed)))) (. .))))
(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN risk) (NN allele)) (PP (IN at) (NP (NN TCF7L2) (NN drug1)))) (VP (VP (VBD was) (ADJP (RBR more) (JJ frequent) (PP (IN in) (NP (JJ drug2) (NNS subjects)))) (PP (IN than) (PP (IN in) (NP (NNS controls)))) (SBAR (WHADVP (WRB when)) (S (NP (PRP we)) (VP (VBN restricted) (NP (DT the) (NN analysis)) (PP (TO to) (NP (NP (DT the) (NNS subjects)) (PP (IN with) (NP (NP (JJR lower) (NN weight-for-height)) (PP (IN than) (NP (NP (DT the) (NN median)) (PP (IN of) (NP (DT the) (NN PA) (NNS subjects))))))))))))) (-LRB- -LRB-))))
(S1 (S (VP (TO To) (VP (VP (VB investigate) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN drug2) (NN protein))) (PP (IN in) (NP (JJ normal) (NN breast) (NN tissue))))) (, ,) (CC and) (VP (VB examine) (NP (NP (DT the) (NN difference)) (PP (IN in) (NP (NP (NN ABCC11) (NN mRNA)) (CC and) (NP (NN proteinexpression)))) (PP (IN between) (NP (NP (JJ normal) (NN breast) (CC and) (NN drug3) (NNS tissues)) (VP (VBG taking) (PP (IN into) (NP (NP (NP (NN account) (NN ABCC11) (NN genotype)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (JJ functional) (NN SNP)) (, ,) (NP (NN drug1))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN estrogen) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN ER)) (-RRB- -RRB-))) (NN status)))))))))))))
(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (S (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (DT the) (NN SNP)) (VP (MD can) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (JJ diagnostic) (NN marker)) (PP (IN for) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN AO)) (-RRB- -RRB-))))))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (NP (NNS genotypes)) (PP (IN at) (NP (NN drug1))) (PP (IN in) (NP (CD 79) (JJ Japanese) (JJ AO) (NNS individuals))))))) (. .)))
(S1 (S (PP (IN In) (NP (NNP Europeans))) (, ,) (S (NP (NP (CD three) (NNS haplotypes)) (PP (IN in) (NP (DT the) (NN region)))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NN eye) (NN pigmentation))))))))))) (CC and) (S (NP (NP (DT a) (NN missense) (NN SNP)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NN drug2)))))))))
(S1 (S (S (NP (PRP$ Our) (NNS data)) (VP (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN haplotype)) (VP (VBN restricted) (PP (TO to) (NP (NN Europe))))) (VP (VBZ is) (NP (NP (DT the) (JJS strongest) (NN marker)) (PP (IN for) (NP (NN drug2)))) (ADVP (RB globally)))))) (CC and) (VP (VBP add) (NP (JJ further) (JJ inferential) (NN evidence) (SBAR (IN that) (S (NP (NP (DT the) (VBN derived) (NN allele)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (NP (DT an) (JJ East) (NN Asian) (NN drug3) (NN allele))))))))) (. .)))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (NN TT) (NN genotype)) (PP (IN of) (NP (NP (NP (DT the) (JJ nicotinic) (NN acetylcholine) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN nAChR)) (-RRB- -RRB-))) (NN a3-subunit) (-LRB- -LRB-) (NN CHRNA3) (-RRB- -RRB-) (NN drug1) (NN polymorphism)))) (VP (VBZ has) (ADVP (RB previously)) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (DT the) (JJ variant) (NN allele)) (PP (IN of) (NP (NP (NN OCA2) (NN R419Q)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))))) (VP (VBD was) (VP (VP (VBN associated) (PP (IN with) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (NN drug2)))))) (-LRB- -LRB-))))))))
(S1 (S (NP (PRP We)) (VP (VBD were) (ADVP (RB also)) (ADJP (JJ able) (S (VP (TO to) (VP (VB demonstrate) (NP (NP (DT the) (NN OCA2) (NN R419Q)) (, ,) (NP (NN drug1)) (, ,) (VP (VP (VBG coding) (S (NP (NN SNP)) (VP (VBZ acts) (PP (IN as) (NP (NP (DT a) (NN penetrance) (NN modifier)) (PP (IN of) (NP (DT this) (JJ new) (NN drug2) (NN SNP))) (PP (IN for) (NP (NN eye) (NN color)))))))) (, ,) (CC and) (ADVP (RB somewhat)) (ADVP (RB independently))) (, ,) (PP (IN of) (NP (NN drug3) (NN risk))))))))) (. .)))
(S1 (S (NP (NP (NNS Conclusions)) (: :) (S (NP (NP (JJ Genetic) (NN variation)) (PP (IN of) (NP (NP (NN DRD2)) (, ,) (NP (ADVP (RB specifically)) (NP (DT the) (NN drug1) (NN polymorphism))) (, ,)))) (VP (MD may) (VP (VB produce) (NP (NP (DT an) (JJR earlier) (JJ clinical) (NN presentation)) (PP (IN of) (NP (NP (NP (NN drug2) (NN disease) (JJ neuropsychiatric) (NNS symptoms)) (CC and) (NP (NNS signs))) (SBAR (WHNP (WDT that)) (S (VP (VBP occur) (PP (IN in) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (JJ dopaminergic) (NN system) (NN impairment))))) (PP (JJ due) (TO to) (NP (NP (NN copper) (NN accumulation)) (PP (IN in) (NP (DT the) (NN brain)))))))))))))) (. .))))
(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (JJ drug4) (NNS symptoms)) (CC and) (NP (NP (NP (NP (NN dopamine) (NN receptor) (CD 2)) (NN DRD2) (NN gene) (NN polymorphisms-141) (NN C) (NN I/D) (-LRB- -LRB-) (NN drug1) (-RRB- -RRB-) (NN exon) (CD 8) (NN G/A) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)) (CC and) (NN ANKK1) (PRN (-LRB- -LRB-) (NP (NP (NN Ankyrin) (NN Repeat)) (CC and) (NP (NN Kinase) (NN Domain) (NN Containing) (CD 1))) (-RRB- -RRB-)) (NN gene) (NN polymorphism)) (NN Taq1A)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-)))))))))
(S1 (S (S (NP (DT These) (NNS results)) (ADVP (RB strongly)) (VP (VBD suggested) (SBAR (IN that) (S (S (NP (NP (JJ A1+) (NNS variants)) (PP (IN of) (NP (DT the) (NN drug1) (NN allele)))) (VP (VBP do) (VP (VB confer) (NP (NP (DT an) (VBN associated) (NN risk)) (PP (IN for) (NP (NP (NN drug2) (NNS inpatients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (NNS SGAs))))))))))))) (, ,) (CC and) (S (NP (DT these) (NNS variants)) (VP (MD may) (VP (VB explain) (NP (NP (NNS inconsistencies)) (VP (VBN found) (PP (IN across) (NP (JJ prior) (NNS studies))))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBG comparing) (NP (NP (NNS FGAs)) (CC and) (NP (NNS SGAs))))))))))))) (. .)))
(S1 (S (NP (NP (NP (NP (CD Eleven) (NN tag) (JJ single) (NN nucleotide) (NNS polymorphisms)) (PRN (-LRB- -LRB-) (NP (NNS SNPs)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NN PRCP) (NN gene)))) (CC and) (NP (NP (NP (CD four) (NN tag) (NNS SNPs)) (CC and) (NP (NN G-1903A) (NN drug1) (NN polymorphism))) (PP (IN in) (NP (DT the) (NN CMA1) (NN gene))))) (VP (VBD were) (VP (VBN genotyped) (PP (IN in) (NP (NP (DT the) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN n=1020)) (-RRB- -RRB-)))) (S (VP (VBG using) (NP (NP (DT a) (NN polymerase) (NN chain) (NN reaction-restriction) (NN fragment) (NN length) (NN polymorphism)) (NN method))))))))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (DT The) (JJ present) (NNS results)) (VP (VBD indicated) (SBAR (IN PRCP) (S (NP (NN drug1)) (VP (MD can) (VP (VB be) (VP (VBN considered) (PP (IN as) (NP (NP (DT a) (NN marker)) (PP (IN for) (S (NP (NP (NP (NP (NN EH)) (CC and) (NP (NN Hap3) (NN GAGCACTAACA))) (PRN (-LRB- -LRB-) (NP (NN PRCP)) (-RRB- -RRB-))) (CC and) (NP (NP (NN Hap16) (NN TTTA)) (PRN (-LRB- -LRB-) (NP (NN CMA1)) (-RRB- -RRB-)))) (VP (MD might) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (JJ Chinese) (JJ Han) (NN population))))))))))))))))))) (. .))))
(S1 (S (S (NP (JJ Previous) (NNS studies)) (VP (VBP have) (VP (VBN indicated) (SBAR (IN that) (S (S (NP (NP (NN CMA1) (NN promoter) (NN polymorphism)) (NN drug1)) (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (S (VP (VBG regulating) (NP (NP (NP (NP (NN immunoglobulin) (NN E)) (PRN (-LRB- -LRB-) (NP (NN IgE)) (-RRB- -RRB-))) (NNS levels)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN drug2))))))))))))) (, ,) (CC and) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NN drug3))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Polymorphism) (NN drug1)) (PP (IN of) (NP (NN CMA1)))) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (PP (IN with) (NP (NP (NN serum) (NN IgE) (NN level)) (PP (IN in) (NP (NN drug2) (NNS subjects))))) (, ,) (CC but) (PP (RB not) (IN with) (NP (NP (NN chymase) (NN level)) (PP (IN in) (NP (DT both) (NNS groups)))))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (NN CMA) (NN drug1) (NN polymorphism)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NN drug2) (NN inKorean) (NNS patients))))))))))) (. .))))
(S1 (S (PP (IN In) (NP (DT the) (NN LEUVEN) (NN cohort))) (, ,) (NP (NP (NN drug1) (NNS AA-carriers)) (CC and) (NP (NN rs8034191) (NNS GG-carriers))) (VP (VBD had) (NP (NP (DT a) (RB two-fold) (VBN increased) (NN risk)) (S (VP (TO to) (VP (VB suffer) (PP (IN from) (NP (NN drug2) (NN GOLD) (CD IV))))))) (-LRB- -LRB-))))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NNS Results)) (VP (VP (VBP confirm) (NP (NP (JJ previous) (NNS observations)) (PP (PP (IN of) (NP (NP (DT a) (JJ significant) (NN association)) (PP (IN between) (NP (NP (DT the) (NN CMA1) (NN promoter) (NN polymorphism) (NN drug1)) (CC and) (NP (JJ atopic) (NN drug2)))))) (, ,) (CONJP (CC but) (RB not)) (PP (IN with) (NP (NN serum) (NN IgE) (NNS levels))) (, ,)))) (CC and) (VP (VBP support) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NN CMA1)) (VP (VBZ serves) (PP (IN as) (NP (NP (NN candidate) (NN gene)) (PP (IN for) (NP (JJ atopic) (NN eczema)))))))))))) (. .))))
(S1 (S (NP (NP (DT The) (VBN increased) (NN risk)) (PP (IN of) (NP (NN brain) (NN drug5)))) (VP (VBD was) (ADJP (JJ evident) (PP (IN for) (NP (NP (NP (NN CYP1A1) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN P) (JJ =) (NN 0.0028)) (: ;) (CC OR) (NP (ADJP (JJ =) (NP (CD 2.06) (: ;) (CD 95) (NN %))) (NN CI))) (, ,) (NP (CD 1.27-3.34)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ minor) (NNS haplotypes)) (NP (NP (NN drug2)) (CC -) (NP (NP (NP (NN drug3)) (CC -) (NP (NN drug4))) (PP (IN in) (NP (NP (NNS females)) (PRN (-LRB- -LRB-) (NP (JJ global) (NN haplotypeassociation) (NN P) (NN value)) (, ,) (NP (NN 0.0011)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (NP (QP (RB Only) (CD STK39)) (NN drug1)) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (NP (JJR higher) (NN DBP)) (PRN (-LRB- -LRB-) (NP (NN P) (JJ =) (CD 0.02)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (JJ drug2) (NNS subjects)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN association)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2) (NN susceptibility))))) (VP (VBZ has) (VP (VBN been) (ADVP (RB widely)) (VP (VBN studied))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NP (NN drug1) (NN polymorphism)) (PP (IN of) (NP (NN MTHFR) (NN gene)))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug2) (NN cancer))) (PP (IN in) (NP (DT the) (JJ complete) (JJ over-dominant) (NN model))))))) (. .))))
(S1 (S (S (NP (DT The) (NN ACTN3) (CD R577X) (-LRB- -LRB-) (NN drug1) (-RRB- -RRB-) (NN polymorphism)) (VP (VBZ determines) (NP (NP (DT the) (NP (NN presence)) (CC or) (NP (NN absence))) (PP (IN of) (NP (NP (JJ functional) (NN ACTN3)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB influence) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (JJ exercise-induced) (NNS drug2))))))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (NN HIF1A) (NN drug1) (NN polymorphism)) (PP (IN by) (NP (PRP itself)))) (VP (VBZ is) (RB not) (ADJP (JJ critical) (PP (IN in) (S (VP (VBG determining) (NP (NN drug2))))))))))) (. .)))
(S1 (S (PP (TO To) (NP (NP (JJS best)) (PP (IN of) (NP (PRP$ our) (NN knowledge))))) (, ,) (NP (PRP we)) (ADVP (RB first)) (VP (VBD screened) (NP (NP (DT these) (NNS variants)) (VP (VBN known) (S (VP (TO to) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug10) (NN disease)) (, ,) (NP (NP (NP (NN E46K)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (PP (IN in) (NP (NN SNCA)))) (, ,) (NP (NP (NN drug2)) (PP (IN in) (NP (NP (NN LRRK2)) (, ,) (NP (NN drug3) (NN n) (NN PARK2)) (, ,) (NP (NP (NN drug4)) (PP (IN in) (NP (NN SLC41A1)))) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NP (NNP G908R)) (PRN (-LRB- -LRB-) (NP (CD drug7)) (-RRB- -RRB-))) (, ,) (NP (NP (NN 1007fs)) (PRN (-LRB- -LRB-) (NP (NN drug8)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (NP (NP (NN NOD2)) (CC and) (NP (NN G2385R))) (PRN (-LRB- -LRB-) (NP (NN drug9)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN LRRK2)) (PP (IN from) (NP (NN southern) (NN China) (NN population))))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug5)) (VP (VBD were) (VP (VP (ADVP (RB positively)) (VBN associated) (PP (IN with) (NP (NP (DT the) (NN risk) (NNS alleles)) (PP (IN of) (NP (NP (NP (NN IL23R) (NN drug1)) (PRN (-LRB- -LRB-) (CC OR) (NP (ADJP (JJ =) (NP (CD 2.25))) (CD -LSB-1.13-4.51) (-RRB- -RSB-)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 6q21) (NN drug2)) (PRN (-LRB- -LRB-) (CC OR) (NP (ADJP (JJ =) (NP (CD 1.60))) (CD -LSB-1.10-2.34)) (-RRB- -RSB-)))))))) (CC and) (VP (ADVP (RB negatively)) (VBN associated) (PP (IN with) (NP (NP (DT the) (NN risk) (NNS alleles)) (PP (IN of) (NP (NP (NP (NN IRGM) (NN drug3)) (PRN (-LRB- -LRB-) (CC OR) (NP (ADJP (JJ =) (NP (CD 0.29))) (CD -LSB-0.11-0.74) (-RRB- -RSB-)) (-RRB- -RRB-))) (CC and) (NP (NP (NN DEFB1) (NN drug4)) (PRN (-LRB- -LRB-) (CC OR) (NP (ADJP (JJ =) (NP (CD 0.50))) (CD -LSB-0.30-0.80) (-RRB- -RSB-)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN genotype-association) (NN SNP) (NN analysis))) (, ,) (NP (NP (NP (DT all) (NN NOD2) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (NN IL23r) (NN SNP)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-)))) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN association)) (PP (TO to) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN p) (NN <) (CD 0.03)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (NP (CD Three) (NN NOD2/CARD15) (NNS variants)) (, ,) (ADVP (RB namely)) (NP (CD two) (NN missense) (NNS polymorphisms) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (, ,) (CC and) (NP (NP (DT a) (NN frame) (NN shift)) (NN polymorphism) (NN drug3)) (, ,)) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug4)) (PP (IN in) (NP (NN Caucasian) (NNS populations)))))))) (. .)))
(S1 (S (NP (PRP$ Our) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (NNS effects)) (PP (IN of) (NP (NP (NP (CD two) (JJ linked) (NNS variants)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NN AGPHD1/CHRNA3) (NN cluster))))) (PP (IN on) (NP (NN drug3) (NN development)))) (VP (VBP are) (ADVP (RB significantly)) (, ,) (ADVP (RB yet)) (RB not) (ADVP (RB entirely)) (, ,) (VP (VBN mediated) (PP (IN by) (NP (DT the) (JJ smoking-related) (NNS phenotypes))))))))))
(S1 (S (PP (IN In) (NP (NN association) (NN analysis))) (, ,) (NP (PRP we)) (VP (VBD found) (NP (NP (ADJP (RB statistically) (JJ significant)) (NN association)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN p) (NP (NN =0.001)) (, ,) (NP (NN OR=3.011)) (, ,) (NP (CD CI95) (NN %) (CD =1.494-6.071))) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD p=2.62) (NN *) (NN 10<formula>^) (NN -LCB-) (CD -4) (NN -RCB-) (CD </formula>) (, ,) (CD OR=14.117)) (, ,) (S (NP (CD CI95) (NN %)) (VP (JJ =) (NP (CD 1.884-105.799)))) (-RRB- -RRB-))) (NP (NNS polymorphisms)))) (PP (IN with) (NP (NN drug3) (NNS patients))))) (. .)))
(S1 (S (S (SBAR (IN Whereas) (S (NP (NP (DT the) (NN NOD2) (NN genotype)) (CC and) (NP (NN drug2))) (VP (VBP are) (ADVP (RB positively)) (VP (VBN associated) (PP (IN with) (NP (NN drug3))))))) (, ,) (NP (DT the) (NN drug1) (NN genotype)) (VP (VBZ is) (ADVP (RB positively)) (VP (VBN associated) (PP (IN with) (NP (NN drug4) (-LRB- -LRB-) (NN L2) (-RRB- -RRB-) (NN disease)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN association)) (PP (IN between) (NP (NP (NP (DT the) (NN Serine/threonine) (NN kinase) (CD 15) (-LRB- -LRB-) (NN STK15) (-RRB- -RRB-) (NN F31I) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (CC and) (NP (NN drug2) (NN susceptibility))))) (VP (VBZ remains) (ADJP (JJ controversial)))) (. .)))
(S1 (S (NP (NP (JJ Stratified) (NN analysis)) (PP (IN by) (NP (NN drug2) (NN type)))) (VP (VBD revealed) (SBAR (IN that) (S (NP (DT the) (NN STK) (NN drug1) (NN polymorphism)) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NP (CD drug3)) (PRN (-LRB- -LRB-) (NP (NP (NN AA)) (CC vs.) (NP (NN TT))) (: :) (NP (CD OR=1.21)) (, ,) (NP (CD 95) (NN %) (CD CI=1.01-1.44)) (, ,) (NP (CD Pheterogeneity=0.002)) (-RRB- -RRB-))) (, ,) (NP (NP (CD drug4)) (PRN (-LRB- -LRB-) (NP (NP (NN AA)) (CC vs.) (NP (ADJP (JJ UNASSIGNED)))) (: :) (NP (CD OR=1.24)) (, ,) (NP (CD 95) (NN %) (CD CI=1.05-1.47)) (, ,) (NP (CD Pheterogeneity=0.124)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (CD drug5)) (PRN (-LRB- -LRB-) (NP (NP (NN AA)) (CC vs.) (NP (ADJP (JJ UNASSIGNED)))) (: :) (NP (NP (NN OR=1.19)) (, ,) (NP (CD 95) (NN %) (CD CI=1.02-1.39))) (, ,) (NP (CD Pheterogeneity=0.148)) (-RRB- -RRB-))))))))))))))
(S1 (S (NP (DT The) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (CD four) (NNS SNPs)) (PP (IN in) (NP (NP (NP (NN AURKA)) (PRN (-LRB- -LRB-) (NP (NP (NNS data)) (PP (IN in) (NP (NP (JJ recessive) (NN model)) (, ,) (NP (NP (NN drug1)) (: :) (CC OR) (NP (JJ =) (NN 2.19)))))) (, ,) (NP (CD 95) (NN %) (NN CI) (JJ =) (CD 1.03-4.66)) (, ,) (NP (NP (NP (NN p) (JJ =) (CD 0.0422)) (: ;) (NP (NN drug2)) (: :) (CC OR) (NP (ADJP (JJ =) (NP (CD 0.38) (, ,) (CD 95) (NN %) (CD CI))) (JJ =) (NN 0.18-0.82)) (, ,) (NP (NN p) (JJ =) (CD 0.0141)) (: ;) (NP (NN drug3)) (: :) (CC OR) (NP (JJ =) (CD 1.54) (, ,) (CD 95) (NN %) (CD CI))) (ADJP (JJ =) (NP (NP (CD 1.18-2.00)) (, ,) (NP (NP (NN p) (JJ =) (CD 0.0014)) (: ;) (NP (NN drug4)) (: :) (CC OR) (NP (ADJP (JJ =) (NP (CD 0.68) (, ,) (CD 95) (NN %) (CD CI))) (JJ =) (NN 0.47-0.98)))))) (, ,) (NP (NN p) (JJ =) (CD 0.0380)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (CD one) (NN SNP)) (PP (IN in) (NP (NN BRCA1)))) (PRN (-LRB- -LRB-) (NP (NP (NN drug5)) (, ,) (NP (JJ dominant) (NN model)) (CC OR) (NP (ADJP (JJ =) (NP (QP (CD 1.35) (, ,) (CD 95)) (NN %))) (NN CI) (JJ =) (CD 1.11-1.64))) (, ,) (NP (NN p) (JJ =) (CD 0.0030)) (-RRB- -RRB-)))))) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NN drug6) (NN susceptibility)))))))) (. .)))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (NP (NP (CD Six) (JJ single) (NN nucleotide) (NNS polymorphisms)) (PRN (-LRB- -LRB-) (NP (NNS SNPs)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NP (DT the) (NN AURKA)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (, ,) (NP (NP (NN ERBB2)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (NP (NP (NN MDM2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (, ,) (NP (NP (NN CDH1)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))) (, ,) (NP (NP (NN CDKN2A)) (PRN (-LRB- -LRB-) (NP (NN drug5)) (-RRB- -RRB-))) (, ,) (CC and) (NP (CD TP73) (PRN (-LRB- -LRB-) (NP (NN drug6)) (-RRB- -RRB-)) (NNS genes))))) (VP (VBD were) (VP (VBN genotyped) (PP (IN in) (NP (NP (DT a) (JJ consecutive) (NN cohort)) (PP (IN of) (NP (CD 346) (NN drug7) (NNS patients))) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD had) (VP (VBD underwent) (NP (NP (JJ surgical) (NN resection)) (PP (IN with) (NP (JJ curative) (NN intent))))))))))))) (. .))))
(S1 (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (DT a) (JJ multivariate) (NN analysis))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNS drug2)) (VP (VBG carrying) (NP (DT the) (JJ heterozygous) (NN MDM2) (-LRB- -LRB-) (NN drug1) (-RRB- -RRB-) (NN T/G) (NN genotype)))))) (VP (VBD had) (ADVP (RB significantly)) (VP (VBD improved) (NP (NN DFS)) (PP (VBN compared) (PP (IN with) (NP (NP (NNS patients)) (VP (VBG carrying) (NP (NP (DT the) (JJ wild-type) (NN genotype)) (PRN (-LRB- -LRB-) (NP (NP (NP (VBN adjusted) (NN hazard) (NN ratio)) (PRN (-LRB- -LRB-) (NP (NN AHR)) (-RRB- -RRB-))) (, ,) (NP (CD 0.63)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)) (PRN (-LRB- -LRB-) (NP (NNP CI) (-RRB- -RRB-) (CD -LSB-0.45-0.88)) (-RRB- -RSB-)))) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (JJR higher) (NNS frequencies)) (PP (IN of) (NP (NP (NP (DT the) (NN MMP1) (NN drug1) (NN 2G) (NN allele)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN p)) (VP (VBG =) (NP (CD 0.017)))) (, ,) (CC OR) (NP (CD 1.49) (, ,) (CD 95) (NN %) (NN CI) (CD 1.06-2.08))) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (NN MMP1/MMP3) (NN drug2) (: /) (NN drug3) (NN 2G/G) (NN haplotype)) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (NN 1.45)) (, ,) (NP (CD 95) (NN %) (JJ CI) (CD 1.01-2.10))) (-RRB- -RRB-)))))) (VP (VBD were) (VP (VBN detected) (PP (IN in) (NP (NP (NN drug4) (NNS patients)) (PP (IN than) (PP (IN in) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 295)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN presence)) (PP (IN of) (NP (NP (DT the) (JJ variant) (NN allele) (NN TNFA) (NN c.-238A)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))))) (VP (VBD was) (VP (VBN associated) (PP (PP (IN with) (NP (NP (JJR lower) (NN serum) (NNS levels)) (PP (IN of) (NP (NN TNF-a))))) (, ,) (CC and) (PP (IN with) (NP (NP (ADJP (RB significantly) (VBN decreased)) (NN risk)) (PP (IN of) (NP (NP (NN drug2)) (PP (IN in) (NP (DT both) (NNS cohorts))))))))))) (. .)))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (NP (NN Evidence)) (VP (VBZ has) (VP (VBN suggested) (SBAR (IN that) (S (S (NP (NP (NP (NN tumour) (NN necrosis) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN TNF)) (-RRB- -RRB-))) (NN -a)) (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN aetiology)) (PP (IN of) (NP (NN psoriasis))))))))) (, ,) (CC but) (S (NP (NP (DT the) (JJ underlying) (NN association)) (PP (IN of) (NP (DT the) (NN TNF-a) (NNS polymorphisms) (NP (NP (NP (NN -238G/A)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (CC and) (NP (NP (NN -308G/A)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))))) (PP (IN with) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug3)))))) (VP (VBZ is) (ADVP (RB still)) (VP (VBN unconfirmed))))))))) (. .))))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (NP (NN Risk) (NNS alleles)) (VP (ADVP (RB previously)) (VBN associated) (PP (IN with) (NP (NN drug5))))) (VP (VBD were) (ADVP (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NN P<0.05)) (-RRB- -RRB-))) (VP (VBN associated) (PP (PP (IN with) (NP (NP (VBN reduced) (NN abstinence)) (PP (PP (IN in) (NP (NP (NP (DT the) (NN PLA) (NN pharmacotherapy) (NN group)) (PRN (-LRB- -LRB-) (NP (NN PG)) (-RRB- -RRB-))) (PP (IN at) (NP (NP (NN 6MO) (NN -LSB-for) (NN drug1)) (, ,) (NP (NP (NNS odds) (NN ratio)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (NN confidence) (NN interval)) (-RRB- -RRB-) (NP (CD 0.41) (-LRB- -LRB-) (CD 0.17-0.99) (-RRB- -RRB-)) (-RRB- -RSB-))) (, ,))))) (CC and) (PP (IN at) (NP (NP (NN end)) (PP (IN of) (NP (NN treatment)))))))) (CC and) (PP (IN at) (NP (NP (NN 6MO) (NN -LSB-for) (NN drug2)) (, ,) (NP (NP (CD 0.42) (-LRB- -LRB-) (CD 0.19-0.93) (-RRB- -RRB-)) (CC and) (NP (CD 0.31) (-LRB- -LRB-) (CD 0.12-0.80) (-RRB- -RRB-))))) (-RRB- -RSB-)) (PRN (, ,) (PP (CC and) (PP (IN with) (NP (NP (NP (VBN increased) (NN abstinence)) (PP (IN in) (NP (DT the) (NN NRT) (NN PG))) (PP (IN at) (NP (NN 6MO) (NN -LSB-for) (NN drug3)))) (, ,) (NP (NP (CD 2.07)) (PRN (-LRB- -LRB-) (NP (CD 1.11-3.87)) (-RRB- -RRB-))))) (CC and) (PP (IN for) (NP (NN drug4)))) (, ,) (NP (CD 2.54) (-LRB- -LRB-) (CD 1.29-4.99) (-RRB- -RRB-)) (-RRB- -RSB-))))))))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (DT This) (NN meta-analysis)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (DT the) (NP (NP (NN drug1)) (CC and) (NP (CD -308))) (NN promoter) (NNS polymorphisms)) (VP (MD may) (VP (VB play) (NP (JJ different) (NNS roles)) (PP (IN in) (S (VP (VBG conferring) (NP (NP (NN susceptibility)) (PP (TO to) (NP (NN drug2))))))))))))) (. .))))
(S1 (S (NP (PRP We)) (VP (VP (VBN genotyped)) (CC and) (VP (VBD analyzed) (NP (NP (NP (CD 4) (NNS SNPs)) (PP (IN in) (NP (CD 3) (NNS genes)))) (: :) (NP (NP (NP (NN PTPN22) (NN C1858T)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (, ,) (NP (NN TNFA) (NN G-308A)) (, ,) (NP (NP (NN G-238A)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (CC and) (NP (NP (NN MIF) (NN G-173C)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (CD 647) (NN drug5) (NNS cases)) (CC and) (NP (CD 751) (JJ healthy) (NNS controls)))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (PRP We)) (VP (VBP have) (VP (VBN confirmed) (NP (NP (NNS associations)) (PP (IN between) (NP (NP (NN drug3)) (CC and) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))) (. .))))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (DT The) (NN drug1)) (VP (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADJP (JJ predictive) (PP (IN of) (NP (JJ clinical) (NN response))))))))) (CC and) (VP (VBD was) (ADVP (RBR more) (RB likely)) (S (VP (TO to) (VP (VB predict) (NP (NP (JJ long-term) (NN survival)) (PP (IN in) (NP (NP (NN Japanese) (NN drug2) (NNS patients)) (VP (VBG receiving) (NP (JJ definitive) (JJ 5-FU/CDDP-based) (NN CRT)))))))))))) (. .))))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (NP (NN drug2)) (PP (VBN compared) (PP (TO to) (NP (JJ healthy) (NNS individuals))))) (VP (VBD demonstrated) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN increase)) (PP (IN in) (NP (NP (NN drug1) (NN allele)) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (VP (VBG =) (NP (CD 0.037)))) (, ,) (CC OR) (NP (ADJP (JJ =) (NP (QP (CD 2.12) (, ,) (CD 95)) (NN %))) (NN CI) (CD 1.29-3.4)) (-RRB- -RRB-))))))) (. .))))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (NP (JJ Genome-wide) (NN significance)) (PP (IN in) (NP (NP (ADJP (RB fully) (VBN adjusted)) (NNS models)) (PRN (-LRB- -LRB-) (NP (NP (NN sex)) (, ,) (NP (NN age)) (, ,) (NP (NN APOE) (NN genotype)) (, ,) (NP (NN population) (NN stratification))) (-RRB- -RRB-))))) (VP (VBD was) (VP (VBN observed) (PP (IN for) (NP (NP (DT a) (NN SNP)) (PP (IN in) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (, ,) (NP (NN allele) (JJ =) (NN G)) (: ;) (NP (NN frequency)) (, ,) (NP (NP (CD 0.09) (NNS cases)) (CC and) (NP (CD 0.06) (NNS controls))) (: ;) (NP (NP (NNS odds)) (ADJP (NN ratio) (JJ -LSB-OR))) (-RRB- -RSB-))) (PRN (, ,) (NP (CD 1.79) (CD -LSB-95) (NN %) (CD CI) (, ,) (CD 1.47-2.12) (-RRB- -RSB-)) (: ;) (S (NP (NN P)) (VP (JJ =) (NP (CD 2.2) (NN *) (CD 10) (-LRB- -LRB-) (CD -9) (-RRB- -RRB-)))) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (PP (IN in) (NP (NP (NN linkage) (NN disequilibrium)) (PP (IN with) (NP (NP (NNS SNPs)) (VP (ADVP (RB previously)) (VBN associated) (PP (IN with) (NP (NN drug3) (NN disease))) (ADVP (ADVP (FW in) (FW Europeans)) (PRN (-LRB- -LRB-) (NP (CD 0.8) (NN <) (NN D') (NN <) (CD 0.9)) (-RRB- -RRB-)))))))))))))))) (. .))))
(S1 (S (S (NP (NN Genotyping)) (VP (VBD was) (VP (VBN performed) (PP (IN for) (NP (NP (NP (CD five) (JJ single-nucleotide) (NNS polymorphisms)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NN drug6))))))))) (: :) (NP (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN CLSTN2))) (PRN (-LRB- -LRB-) (NP (NN drug5)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NP (CD Three) (JJ SNPs-LSB-) (NN drug1)) (PP (IN in) (NP (NN APOE)))) (PRN (: :) (NP (NP (NNS odds) (NN ratio)) (-LRB- -LRB-) (CC OR) (-RRB- -RRB-) (NP (CD =4.24) (, ,) (CD 95) (NN %) (NN confidence) (NN interval)) (-LRB- -LRB-) (CD CI) (-RRB- -RRB-) (CD =3.01-5.96)) (, ,) (NP (NNP P=1.23) (NNP *) (CD 10)) (: ;) (NP (NP (NP (NN drug2)) (PP (IN in) (NP (NN APOE)))) (: :) (NP (CD OR=3.57) (, ,) (CD 95) (NN %) (CD CI=2.51-5.06))) (, ,) (NP (NNP P=1.23) (NNP *) (CD 10) (: ;) (CC and) (NP (NP (NN drug3)) (PP (IN in) (NP (NN PICALM))))) (: :) (NP (NNP OR=0.63) (, ,) (CD 95) (NN %) (CD CI=0.49-0.81) (, ,) (CD P=0.00036)) (, ,) (NP (NN log) (JJ additive) (NN model)) (-RRB- -RSB-)) (VP (VBD were) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NN drug4) (NN susceptibility))) (PP (IN after) (NP (NP (NN correction)) (PP (IN for) (NP (JJ multiple) (NN testing)))))))) (. .)))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (NP (NP (NP (NP (JJ Single) (NN nucleotide) (NNS polymorphisms)) (PRN (-LRB- -LRB-) (NP (NNS SNPs)) (-RRB- -RRB-))) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN e4)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN e2)) (-RRB- -RRB-))))) (, ,) (CC both) (NP (NP (VBG invoking) (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ amino-acid) (NN sequence)) (PP (IN of) (NP (DT the) (NN apolipoprotein) (NN E) (-LRB- -LRB-) (NN APOE) (-RRB- -RRB-) (NN gene)))))) (, ,)) (VP (VBP have) (ADVP (RB previously)) (VP (VBN been) (VP (VBN tested) (PP (IN for) (NP (NP (NN association)) (PP (IN with) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN MS)) (-RRB- -RRB-))) (NN risk))))))))) (. .))))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (PP (IN Despite) (NP (NP (JJ sufficient) (NN power)) (VP (TO to) (VP (VB detect) (NP (NNS associations)) (PP (IN at) (NP (NN genome-wide) (NN significance) (NNS thresholds))) (PP (IN across) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NNS ORs))))))))) (, ,) (NP (PRP$ our) (NNS analyses)) (VP (VBD did) (RB not) (VP (VB support) (NP (NP (DT a) (NN role)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)))) (PP (IN on) (NP (NN drug3) (NN susceptibility))))))))))
(S1 (S (NP (NP (DT The) (NNS distributions)) (PP (IN of) (NP (NP (NNS SNPs)) (VP (VBG relating) (PP (PP (TO to) (NP (NP (DT the) (JJ amyloid) (NN cascade) (NN hypothesis)) (PRN (-LRB- -LRB-) (NP (NP (CD TOMM40) (NN drug1) (NN G)) (CC and) (NP (CD TOMM40) (NN drug2) (NN G))) (-RRB- -RRB-)))) (, ,) (PP (TO to) (NP (NP (DT the) (NN drug8)) (PRN (-LRB- -LRB-) (NP (NP (NN ApoE) (NN drug3) (NN C)) (, ,) (NP (NN LDLR) (NN drug4) (NN G)) (CC and) (NP (NN CH25H) (NN drug5) (NN T)) (CC and) (NP (NN PLAU) (NN drug6) (NN CT))) (-RRB- -RRB-)))) (CC and) (PP (TO to) (NP (NP (NP (DT the) (JJ tau) (NN hypothesis)) (PRN (-LRB- -LRB-) (NP (NN MAPT/STH) (NN drug7) (NN GG)) (-RRB- -RRB-))) (PP (IN in) (NP (NN aMCI)))))))))) (VP (VBD were) (ADJP (RB significantly) (JJ different) (PP (IN than) (NP (NP (DT those)) (PP (IN in) (NP (JJ normal) (NNS controls))))))) (. .)))
(S1 (S (NP (DT The) (NNS authors)) (ADVP (RB then)) (VP (VP (VBD performed) (NP (NP (DT a) (JJ large) (NN meta-analysis)) (PP (IN of) (NP (NP (CD 36) (NNS studies)) (VP (VBG examining) (NP (NP (DT the) (NN association)) (PP (IN of) (NP (NN drug5))) (PP (IN with) (NP (NP (NNS polymorphisms)) (PP (IN in) (NP (DT the) (NN TCF7L2) (NN gene)))))) (PP (IN in) (NP (JJ various) (NNS ethnicities)))))) (, ,) (VP (VBG containing) (NP (NP (NP (NN drug1) (JJ C-to-T)) (PRN (-LRB- -LRB-) (NP (NN IVS3C>T)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug2) (NN T-to-C)) (PRN (-LRB- -LRB-) (NP (NN IVS3T>C)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN drug3) (JJ G-to-T)) (PRN (-LRB- -LRB-) (NP (NN IVS4G>T)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN drug4) (NN G-to-C)) (PRN (-LRB- -LRB-) (NP (NN IVS4G>C)) (-RRB- -RRB-))) (NP (NNS polymorphisms)))))) (CC and) (VP (VBP toevaluate) (NP (NP (NP (DT the) (NN size)) (PP (IN of) (NP (NN gene) (NN effect)))) (CC and) (NP (NP (DT the) (JJ possible) (JJ genetic) (NN mode)) (PP (IN of) (NP (NN action)))))))))
(S1 (S (S (NP (NP (NN Carbohydrate) (NN quality)) (CC and) (NP (NN quantity))) (VP (VBD modified) (NP (NP (NN risk)) (PP (IN of) (NP (NN drug2))) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug1)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN risk)) (ADJP (JJ attributable) (PP (TO to) (NP (DT the) (NN TCF7L2) (NN variant))))))) (VP (VBP are) (VP (VBN magnified) (PP (IN under) (NP (NP (NNS conditions)) (PP (IN of) (NP (VBN increased) (NN insulin) (NN demand)))))))))))))))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBD genotyped) (NP (NP (NP (NP (DT the) (NN TCF7L2) (JJ single) (NN nucleotide) (NNS polymorphisms)) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (-LRB- -LRB-) (VP (ADVP (RB previously)) (VBN associated) (PP (IN with) (NP (NN drug5)))) (-RRB- -RRB-)) (CC and) (NP (NP (NN drug3) (NN nd) (NN drug4)) (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (NP (NN tag) (NN haplotype) (NN A) (NN -LSB-HapA)))) (-RRB- -RSB-) (, ,) (NP (NP (DT a) (NN haplotype)) (VP (VBN reported) (S (VP (TO to) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug6) (-RRB- -RRB-)) (PP (IN in) (NP (NN 2,512) (NN FHS) (NNS participants)))))))))))))) (. .)))
(S1 (S (S (SBAR (IN As) (S (VP (VBN expected)))) (, ,) (NP (NP (DT the) (NN T) (NN risk) (NN allele)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (JJR higher) (NN drug2))) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (JJ =) (NP (CD 0.01)))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT no) (NN association)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (NN 0.98)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD 0.89)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (ADJP (JJ =) (NP (CD 0.32)))) (-RRB- -RRB-))) (CC or) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (ADJP (JJ =) (NP (CD 0.92)))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD confirmed) (SBAR (IN that) (S (NP (NP (DT the) (NN risk) (NN allele)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN a)) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD did) (RB not) (VP (VB detect) (NP (NP (DT any) (NN association)) (PP (IN of) (NP (DT the) (NN drug1))) (PP (IN with) (NP (NN drug2))))))) (. ,)))
(S1 (S (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NP (NP (JJ single) (NN nucleotide) (NNS polymorphisms)) (PRN (-LRB- -LRB-) (NP (NN SNP)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (, ,)) (PP (IN within) (NP (DT the) (NN TCF7L2) (NN locus))))) (PP (IN on) (NP (NP (NP (NN drug3)) (CC and) (NP (JJ other) (NNS drug4))) (CC and) (NP (NP (PRP$ their) (NN modulation)) (PP (IN by) (NP (NN dietary) (NN fat))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN summary))) (, ,) (NP (NP (CD drug2)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (ADJP (JJ >)) (CC or) (ADJP (JJ =))) (CD 6.62) (NN %)) (PP (IN of) (NP (NN energy) (NN intake)))) (-RRB- -RRB-))) (VP (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug3)) (PP (IN in) (NP (NP (NNS carriers)) (PP (IN of) (NP (NP (DT the) (JJ minor) (NN T) (NN allele)) (PP (IN at) (NP (DT the) (NN TCF7L2) (NN drug1) (NN SNP))))))))))) (CC and) (VP (MD may) (VP (VB predispose) (NP (PRP them)) (PP (TO to) (NP (NP (NNS MetS)) (, ,) (NP (NNS diabetes)) (, ,) (CC and) (NP (JJ cardiovascular) (NN disease)))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (NNS SNPs) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4)))) (PP (IN in) (NP (DT the) (NN TCF7L2) (NN gene)))) (VP (VBD were) (ADVP (RB strongly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN p<0.004)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN drug1))) (, ,) (NP (NP (NN T2D) (NNS patients)) (VP (VBG carrying) (NP (NNS genotypes) (NP (NP (NN CT)) (CC or) (NP (NN TT)))))) (VP (VBD had) (NP (NP (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN FPG)) (-RRB- -RRB-))) (NNS levels)) (PRN (-LRB- -LRB-) (NP (NN p=0.042)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN p=0.015)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN p=0.015)) (-RRB- -RRB-)))) (PP (VBN compared) (PP (TO to) (NP (NP (DT the) (NNS patients)) (VP (VBG carrying) (NP (NN CC) (NN genotype))))))) (. .)))
(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (DT the) (NN risk) (NNS alleles)) (PP (IN from) (NP (NP (NN TCF7L2) (NN drug1) (NN polymorphism)) (PP (CC either) (PP (IN with) (NP (NP (NN drug2) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NP (NN p=0.0257)) (, ,) (NP (NN OR=1.398))) (-RRB- -RRB-)))) (CC or) (PP (IN with) (NP (NP (NN drug3) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NP (NN p=0.0024)) (, ,) (NP (NN OR=1.514))) (-RRB- -RRB-)))))))) (VP (VBD were) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NN drug4))))) (. .)))
(S1 (S (NP (NP (DT The) (NN allele) (CC and) (NN genotype) (NNS frequencies)) (PP (IN of) (NP (NP (CD two) (NN SNP) (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD showed) (SBAR (IN that) (S (NP (DT these)) (VP (VBP are) (VP (VBN associated) (PRN (-LRB- -LRB-) (NP (NNS odds) (NP (NN ratio) (QP (RB up) (TO to) (CD 4)))) (-RRB- -RRB-)) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN drug3))) (PP (PP (IN in) (NP (DT the) (JJ autoantibody-negative) (JJ diabetic) (NN cohort))) (, ,) (CC but) (PP (RB not) (IN in) (NP (DT the) (JJ autoantibody-positive) (JJ diabetic) (NN cohort))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (PRP$ our) (JJ case-control) (NNS subjects))) (, ,) (NP (NP (NN susceptibility)) (PP (TO to) (NP (NN drug9)))) (VP (VBD was) (VP (VBN replicated) (PP (IN in) (NP (NP (NN TCF7L2) (NN drug1)) (, ,) (NP (NN CDKAL1) (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NP (NN HHEX)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))) (, ,) (NP (NP (NN IGF2BP2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug5)) (CC and) (NP (NN drug6))) (-RRB- -RRB-))) (, ,) (NP (NP (NN CDKN2A/B)) (PRN (-LRB- -LRB-) (NP (NN drug7)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN SLC30A8)) (PRN (-LRB- -LRB-) (NP (NN drug8)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (DT these) (NNS polymorphisms))))) (, ,) (NP (NN meta-analysis)) (VP (VBD confirmed) (NP (NP (DT the) (NN association)) (PP (IN of) (NP (NN drug4) (NN susceptibility))) (PP (IN with) (NP (NP (NN KCNJ11) (NN drug1)) (, ,) (NP (NN TCF7L2) (NN drug2)) (, ,) (CC and) (NP (NN HHEX) (NN drug3))))))) (. .)))
(S1 (S (NP (DT The) (NN TCF7L2) (NN drug1) (NN polymorphism)) (VP (VBD showed) (NP (NP (NP (DT the) (JJS highest) (NNS odds) (NN ratio)) (PRN (-LRB- -LRB-) (NP (NN OR)) (-RRB- -RRB-))) (PP (IN for) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (CC OR) (NP (NN 1.714) (CD -LSB-1.298-2.263)) (-RRB- -RSB-) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (S (NP (NP (NNS Odds) (NN ratio)) (PP (IN of) (NP (JJ other) (NNS polymorphisms)))) (VP (VBD ranged) (PP (IN from) (NP (CD 1.13) (TO to) (CD 1.41.))))) (S (NP (NP (DT The) (NN risk) (NN allele)) (PP (IN of) (NP (NN CDKAL1) (NN drug1)))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2) (NNS patients)) (PP (IN after) (NP (NP (NN adjustment)) (PP (IN for) (NP (JJ other) (VBG confounding) (NNS factors))))))))))) (. .)))
(S1 (S (PP (VBN Compared) (PP (IN with) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NP (NP (NNS men)) (CC and) (NP (NNS women))) (VP (VBN combined))) (-RRB- -RRB-))))) (, ,) (NP (NN drug10)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NP (NN drug1)) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (CD 1.55) (, ,) (CD 95) (NN %) (NN CI) (CD 1.34-1.79)) (, ,) (NP (NP (NN p)) (ADJP (JJ =) (NP (NP (CD 4.17) (CC x) (CD 10)) (PRN (-LRB- -LRB-) (NP (NN -9)) (-RRB- -RRB-)))))) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NP (NP (NN CDKAL1)) (: ;) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (NN 1.49)) (, ,) (NP (CD 95) (NN %) (NN CI) (CD 1.29-1.72)) (, ,) (NP (NP (NN p)) (ADJP (JJ =) (NP (NP (CD 1.05) (CC x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD -7)) (-RRB- -RRB-)))))) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NN CDKN2A-CDKN2B) (NN region)))) (: ;) (NP (NN drug4))) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (CD 1.27) (, ,) (CD 95) (NN %) (NN CI) (CD 1.09-1.49)) (, ,) (NP (NN p) (JJ =) (CD 0.003))) (-RRB- -RRB-))) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6)))) (PP (IN in) (NP (NN HHEX)))) (: ;) (NP (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (CD 1.18) (, ,) (CD 95) (NN %) (NN CI) (CD 1.01-1.38)) (, ,) (NP (NN p) (JJ =) (CD 0.03))) (-RRB- -RRB-))) (PP (IN in) (NP (NN IGF2BP2)))) (: ;) (NP (NP (NP (NN drug8)) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (CD 1.24) (, ,) (CD 95) (NN %) (NN CI) (CD 1.07-1.43)) (, ,) (NP (NN p) (JJ =) (CD 0.005))) (-RRB- -RRB-))) (PP (IN in) (NP (NN SLC30A8)))) (: ;) (CC and) (NP (NP (NP (NN drug9)) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (CD 1.58) (, ,) (CD 95) (NN %) (NN CI) (CD 1.03-2.43)) (, ,) (NP (NN p) (JJ =) (CD 0.038))) (-RRB- -RRB-))) (PP (IN in) (NP (NN TCF7L2)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN risk) (NNS alleles)) (PP (IN of) (NP (NP (DT the) (NNS SNPs) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (NP (NN CDKAL1)) (: ;) (NP (NP (NN drug3)) (PP (IN in) (NP (DT the) (NN CDKN2A-CDKN2B) (NN region)))) (: ;) (CC and) (NP (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC and) (NP (NN drug6))) (PP (IN in) (NP (NN HHEX))))))))) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug7) (NN AUC)) (PP (IN during) (NP (NP (DT a) (CD 100) (NN g) (NN OGTT)) (VP (VBN performed) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NP (NN diagnosis)) (PP (IN of) (NP (NN drug8))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN risk) (NNS alleles)) (PP (IN of) (NP (NP (DT the) (NN TCF7L2) (NN gene)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (-RRB- -RRB-))))) (VP (VBD were) (ADVP (RB strongly)) (VP (VBN associated) (PP (IN with) (NP (NN drug3))) (, ,) (PP (ADVP (RB even)) (IN after) (S (VP (VBG controlling) (PP (IN for) (NP (NP (JJ traditional) (NN risk) (NNS factors)) (PP (IN in) (NP (CC both) (DT a) (ADJP (ADJP (JJ cross-sectional)) (CC and) (ADJP (JJ prospective))) (NN setting))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ minor) (NN allele) (NN frequency)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBD was) (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (NN drug4) (NNS patients))) (PP (VBN compared) (PP (IN with) (NP (NP (DT that)) (PP (IN in) (NP (JJ non-diabetic) (NNS individuals)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN T) (-LRB- -LRB-) (JJ minor) (-RRB- -RRB-) (NN allele)) (PP (IN of) (NP (DT the) (JJ variant) (NN drug1)))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJR greater) (NN OR)) (PP (IN for) (NP (NN drug2))) (VP (VBN adjusted) (PP (IN for) (NP (NP (NN age)) (, ,) (NP (NN sex)) (CC and) (NP (NN BMI)))) (PP (IN in) (NP (JJ logistic) (NN regression) (NN analysis))))))))) (: :)))
(S1 (S (S (NP (NP (DT No) (ADJP (RB statistically) (JJ significant)) (NN association)) (PP (IN of) (NP (DT the) (NNS SNPs)))) (VP (VBD was) (VP (VBN observed) (PP (PP (IN with) (NP (NP (NN drug3)) (CC or) (NP (NN drug4)))) (CC or) (PP (IN between) (NP (NP (NP (NNS carriers)) (CC and) (NP (NNS non-carriers))) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2) (NNS mutations)))))))))) (. .)))
(S1 (S (S (ADVP (IN while)) (, ,) (NP (NN drug1)) (VP (VBD showed) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN association)) (PP (IN between) (NP (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (NNS patients)) (VP (VBG carrying) (NP (NP (DT the) (NN 26V) (NN allele)) (PRN (-LRB- -LRB-) (CC OR) (NP (JJ =) (CD 1.69) (, ,) (CD 95) (NN %) (NN CI) (JJ =) (CD 1.11-2.56)) (, ,) (NP (NN P) (JJ =) (NN 0.013)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (NNS variants)) (PP (IN of) (NP (NN TCF7L2)))) (VP (VBP have) (VP (VBN been) (ADVP (RB strongly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug3) (NN risk)) (PP (IN in) (NP (NP (JJS most) (NNS populations)) (VP (VBN studied) (PP (TO to) (NP (NN date)))))))))))) (. .)))
(S1 (S (NP (NP (NN Comparison)) (PP (IN between) (NP (NP (NN allele)) (CC and) (NP (NN genotype)) (NP (NNS frequencies)))) (PP (IN of) (NP (NP (DT these) (NNS SNPs)) (PP (IN in) (NP (NP (NNS patients)) (CC and) (NP (NNS controls))))))) (VP (VBD showed) (NP (NP (JJ marginal) (NN association)) (PP (IN for) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN with) (NP (NN drug3)))) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (ADJP (JJ =) (NP (NP (NP (CD 0.063)) (, ,) (CC OR) (NP (CD 1.982))) (, ,) (NP (CD 95) (NN %) (QP (RB CI) (CD 1.128-3.485)))))) (: ;) (S (S (NP (NN p)) (VP (JJ =) (NP (CD 0.071)))) (, ,) (CC OR) (S (NP (CD 1.237) (, ,) (CD 95) (NN %)) (VP (JJ CI) (NP (CD 0.983-1.557)) (, ,) (ADVP (RB respectively))))) (-RRB- -RRB-))) (. .)))
(S1 (S (S (NP (DT No) (NN association)) (VP (VBD was) (VP (VBN found) (PP (IN for) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN c.1,637C>A)) (CC and) (NP (NN drug3)))) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (JJ =) (NP (CD 0.278-1.000)))) (-RRB- -RRB-))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBD evaluated) (NP (NP (DT the) (NN association)) (PP (IN of) (NP (NP (DT a) (NN polymorphism)) (PP (IN in) (NP (NP (NN TCF7L2) (NN drug1)) (PP (IN in) (NP (DT the) (NN WNT) (NN signaling) (NN pathway))) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB previously)) (VP (VBZ has) (VP (VBN been) (ADVP (RB strongly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN risk)) (PP (IN of) (NP (NN drug2))))) (, ,) (PP (IN with) (NP (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (PP (IN in) (NP (NP (NP (DT the) (JJ prospective) (NN Nurses) (`` ') (NN Health) (NN Study)) (PRN (-LRB- -LRB-) (NP (NN NHS)) (-RRB- -RRB-))) (CC and) (NP (NP (NN Health) (NN ProfessionalsFollow-up) (NN Study)) (PRN (-LRB- -LRB-) (NP (NN HPFS)) (-RRB- -RRB-))) (NP (NNS cohorts))))))))))))))))) (. .)))
(S1 (S (ADVP (RB Overall)) (, ,) (PP (IN in) (NP (DT the) (NP (NP (NN NHS)) (CC and) (NP (NN HPFS))))) (, ,) (NP (EX there)) (VP (VBD was) (NP (NP (JJ suggestive) (NN evidence)) (PP (IN for) (NP (NP (DT an) (JJ inverse) (NN association)) (VP (VBN associated) (PP (IN with) (NP (NP (NN homozygosity)) (PP (IN for) (NP (NP (DT the) (JJ minor) (NN allele)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (NP (ADJP (ADJP (JJ conditional)) (CC and) (ADJP (ADJP (NP (NN covariate)) (VBN adjusted)) (CC OR) (ADJP (JJ =) (NP (CD 0.63) (, ,) (CD 95) (NN %))))) (NN CI)) (: :) (NP (CD 0.37-1.08)) (: ;) (NP (NP (NN P)) (PP (IN for) (NP (NN heterogeneity) (CD 0.52))) (PP (IN for) (NP (NP (DT the) (NN association)) (PP (IN in) (NP (NP (NNS women)) (CC and) (NP (NNS men)))))))) (-RRB- -RRB-))))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN result)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT the) (VBN increased) (NN drug2)) (VP (VBN associated) (PP (IN with) (NP (NN drug1) (NN genotype))))) (VP (VBZ is) (ADJP (JJ specific) (PP (TO to) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (ADVP (RB Specifically)) (, ,) (NP (NP (DT the) (JJ same) (NN risk) (NN allele)) (PP (IN of) (NP (NP (NP (NP (JJ single) (NN nucleotide) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NN SNP)) (-RRB- -RRB-))) (NN drug1)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN T) (NN allele)) (-RRB- -RRB-))))))))))) (VP (VBZ has) (ADVP (RB recently)) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ minor) (NN allele)) (PP (IN of) (NP (DT each) (NN variant)))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NN drug2)))))) (: ;) (S (NP (NP (DT the) (JJS greatest) (NN risk)) (PP (IN of) (S (VP (VBG developing) (NP (DT the) (NN disease)))))) (VP (VBD was) (VP (VBN conferred) (PP (IN by) (NP (NN drug1))) (, ,) (PP (IN with) (NP (NP (NP (DT an) (JJ allelic) (NNS odds) (NN ratio)) (PRN (-LRB- -LRB-) (NP (NN OR)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (CD 1.31)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (NN CI)) (: :) (NP (CD 1.11) (CC -) (CD 1.56)) (, ,) (S (NP (NN p)) (VP (JJ =) (NP (CD 1.96) (NN x) (CD 10) (-LRB- -LRB-) (CD -3) (-RRB- -RRB-)))) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (NP (NN drug3) (NN disease) (NN stage)) (VP (VBD was) (ADVP (RB marginally)) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (DT the) (NN T) (NN variant))) (PP (PP (IN at) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN p=0.057)) (: ;) (NP (VBN adjusted) (NN p=0.017)) (-RRB- -RRB-)))) (CC but) (PP (RB not) (IN at) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (CD p=0.5)) (: ;) (NP (VBN adjusted) (NP (CD p=0.2)))) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NP (NN Comparison)) (PP (IN between) (NP (NP (NNS subjects)) (PP (IN with) (NP (NP (NN drug3)) (CC and) (NP (DT the) (JJ combined) (NN drug4))))))) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN association)) (PP (PP (IN with) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (CC OR) (NP (NN 1.47)) (, ,) (NP (NP (NN CI) (CD 1.04-2.08)) (: ;) (NP (CD p=0.03))) (-RRB- -RRB-)))) (CC but) (PP (RB not) (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (CD 1.16)) (, ,) (NP (NNP CI) (CD 0.81-1.64) (: ;) (CD p=0.4))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (NP (VBN increased) (NN risk)) (PP (IN for) (NP (NN drug2))) (PP (IN in) (NP (NN Emirati) (NNS subjects))))))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (JJ minor) (NNS alleles)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))))) (VP (VBD showed) (NP (NP (NP (JJ significant) (NNS associations)) (PP (IN with) (NP (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (NP (NP (CD OR=1.48) (, ,) (CD P=2.7) (CC x) (CD 10) (-LRB- -LRB-) (CD -4) (-RRB- -RRB-)) (: ;) (NP (CD OR=1.39) (, ,) (CD P=4.6) (CC x) (CD 10) (-LRB- -LRB-) (CD -4) (-RRB- -RRB-) (: ;) (CD OR=1.70) (, ,) (CD P=9.8) (CC x) (CD 10) (-LRB- -LRB-) (CD -5) (-RRB- -RRB-)) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (JJ combined) (NN sample) (NNS sets)))))) (, ,) (ADVP (RB However)) (, ,) (CC neither) (NP (NN drug4))))) (CC nor) (S (NP (NN drug5)) (VP (VBD showed) (NP (DT a) (JJ significant) (NN association))))) (. .)))
(S1 (S (S (NP (NP (JJ Significant) (NN evidence)) (PP (IN for) (NP (NN association)))) (VP (VBD was) (VP (VBN observed) (PP (IN for) (NP (JJ high) (NN TG))) (PP (IN for) (NP (NP (DT the) (NN T) (NNS alleles)) (PP (IN of) (NP (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN p)) (VP (VBG =) (NP (CD 0.005)))) (CC and) (NP (NP (NN p)) (VP (VBG =) (NP (CD 0.01))))) (-RRB- -RRB-))) (PP (IN in) (NP (NN Mexican) (NN drug3) (NNS families)))))))))) (, ,) (S (NP (NP (DT No) (NN evidence)) (PP (IN for) (NP (NN association)))) (VP (VBD was) (VP (VBN observed) (PP (IN for) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)))) (PP (IN in) (NP (NNP Mexicans)))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBG testing) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PP (IN for) (NP (NP (NN replication)) (PP (IN in) (NP (NN Finnish) (NN drug3) (NNS families)))))))) (, ,) (NP (DT these) (JJ single) (NN nucleotide) (NNS polymorphisms)) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NN drug4))) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NN p)) (ADJP (JJ =) (NP (CD 0.01)))) (CC and) (NP (NN p))) (ADJP (JJ =) (NP (CD 0.007)))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ high) (NN drug3)) (PP (IN in) (NP (NP (NN drug4) (NNS families)) (PP (IN from) (NP (CD two) (JJ different) (NNS populations))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (NN TCF7L2) (NN drug1) (JJ genetic) (NN variation)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (CD One) (JJ representative) (NN variant)) (, ,) (NP (NN drug1)) (, ,)) (VP (VBD was) (ADVP (RB nominally)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PP (PP (IN in) (NP (NP (DT a) (JJ general) (NN model)) (PRN (-LRB- -LRB-) (NP (NP (JJ additive) (NN P)) (ADJP (JJ =) (NP (CD 0.03)))) (, ,) (S (NP (JJ dominant) (NN P)) (VP (JJ =) (NP (CD 0.005)))) (-RRB- -RRB-)))) (CC but) (PP (RB not) (IN in) (NP (NP (DT a) (JJ within-family) (NN analysis)) (PRN (-LRB- -LRB-) (NP (NP (JJ additive) (NN P)) (ADJP (JJ =) (NP (CD 0.2)))) (, ,) (S (NP (JJ dominant) (NN P)) (VP (JJ =) (NP (CD 0.07)))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (JJ several) (NNS variants)) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NN drug2)))))) (: ;) (S (PP (IN in) (NP (JJ particular))) (, ,) (NP (NN drug1)) (VP (VBD was) (VP (VBN associated) (PP (IN in) (NP (ADJP (CC both) (ADJP (JJ general)) (CC and) (ADJP (JJ within-family))) (NNS analyses))) (PRN (-LRB- -LRB-) (CC both) (NP (NP (NN P)) (ADJP (JJ =) (NP (CD 0.0007)))) (-RRB- -RRB-))))) (. .)))
(S1 (S (NP (EX There)) (VP (VBD was) (NP (NP (DT no) (NN association)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (PP (PP (IN in) (NP (NP (DT the) (JJ UK) (JJ case-control) (NN study)) (PRN (-LRB- -LRB-) (NP (NN Cochran-Armitage) (NN test)) (, ,) (S (NP (NN p)) (VP (JJ =) (NP (CD 0.51)))) (-RRB- -RRB-)))) (: ;) (CC nor) (PP (IN with) (NP (NP (JJ symptomatic) (NN status)) (PP (IN in) (NP (NP (DT the) (JJ Finnish) (NN cohort)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (NN 0.36)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (EX there)) (VP (VBD were) (NP (NP (DT no) (NNS relationships)) (PP (IN between) (NP (NP (NP (DT the) (NN TCF7L2) (JJ single) (NN nucleotide) (NN polymorphism)) (NN drug1)) (CC and) (NP (NN drug2))))) (PRN (-LRB- -LRB-) (NP (JJ UK) (NNS cases)) (, ,) (NP (NP (NN p)) (ADJP (JJ =) (NP (CD 0.99)))) (: ;) (NP (NN Finnish) (NNS controls)) (, ,) (NP (NP (NN p)) (ADJP (JJ =) (NP (CD 0.57)))) (: ;) (NP (JJ Finnish) (JJ symptomatic) (NNS cases)) (, ,) (NP (NP (NN p)) (ADJP (JJ =) (NP (CD 0.80)))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN frequency)) (PP (IN of) (NP (DT the) (NN T) (NN allele))) (PP (IN of) (NP (DT both) (NN drug1) (CC and) (NN drug2) (NNS polymorphisms)))) (VP (VBD was) (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (NP (NN drug3) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NP (CD 23) (NN %)) (CC and) (NP (CD 33) (NN %))) (-RRB- -RRB-)))) (PP (VBN compared) (PP (TO to) (NP (NP (DT that)) (PP (IN in) (NP (JJ normal) (JJ glucose-tolerant) (NNS subjects)))))) (PRN (-LRB- -LRB-) (NP (NP (CD 19) (NN %)) (CC and) (NP (CD 28) (NN %))) (: ;) (S (NP (NP (NP (NN P)) (ADJP (JJ =) (NP (CD .001)))) (CC and) (NP (NN P))) (VP (JJ =) (NP (CD .0001)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NP (JJ Normal) (JJ glucose-tolerant) (NNS subjects)) (PP (IN with) (NP (NP (DT the) (NN TT) (NN genotype)) (PP (IN of) (NP (NN drug1)))))) (VP (VBD had) (NP (NP (ADJP (RB significantly) (JJR higher)) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN mean)) (CC +/-) (NP (NN SD))) (, ,) (NP (QP (CD 6.1) (CC +/-) (CD 1.4)) (NN mmol/L)) (-RRB- -RRB-))) (PP (IN than) (NP (NP (DT those)) (PP (IN with) (NP (NP (DT the) (NN GG) (NN genotype)) (PRN (-LRB- -LRB-) (NP (QP (CD 5.6) (CC +/-) (CD 1.0)) (NN mmol/L)) (, ,) (S (NP (NN P)) (VP (JJ =) (NP (CD .011)))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Normal) (JJ glucose-tolerant) (NNS subjects)) (PP (IN with) (NP (NP (DT the) (NN TT) (NN genotype)) (PP (IN of) (NP (NN drug1) (NN polymorphism)))))) (VP (VBD had) (NP (NP (ADJP (RB significantly) (JJR higher)) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN mean)) (CC +/-) (NP (NN SD))) (, ,) (NP (QP (CD 6.0) (CC +/-) (CD 1.3)) (NN mmol/L)) (-RRB- -RRB-))) (PP (IN than) (NP (NP (DT those)) (PP (IN with) (NP (NP (DT the) (NN CC) (NN genotype)) (PRN (-LRB- -LRB-) (NP (QP (CD 5.6) (CC +/-) (CD 1.0)) (NN mmol/L)) (, ,) (S (NP (NN P)) (VP (JJ =) (NP (CD .004)))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (DT the) (NN T) (NN allele)) (PP (IN of) (NP (NP (DT the) (NN drug1) (CC and) (NN drug2) (NNS polymorphisms)) (PP (IN of) (NP (NN TCF7L2) (NN gene)))))) (VP (VBP confer) (NP (NP (NN susceptibility)) (PP (TO to) (NP (NN drug3)))) (PP (IN in) (NP (NNP Asian) (NNP Indians))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN CT/TT) (NNS genotypes)) (PP (IN of) (NP (NN SNP) (NN drug1)))) (ADVP (RB strongly)) (VP (VBD predicted) (NP (NP (JJ future) (NN drug2)) (PP (IN in) (NP (NP (CD 2) (JJ independent) (NNS cohorts)) (PRN (-LRB- -LRB-) (NP (NP (NNP Swedish)) (CC and) (NP (NNP Finnish))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VP (VBP extend) (NP (JJ previous) (NNS observations)) (PP (TO to) (NP (JJ other) (JJ ethnic) (NNS groups)))) (, ,) (CC and) (ADVP (RB strongly)) (VP (VBP confirm) (SBAR (IN that) (S (NP (NN drug1) (NN genotype)) (VP (VBZ is) (NP (NP (DT a) (JJ major) (NN risk) (NN factor)) (PP (IN for) (NP (NP (NN development)) (PP (IN of) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (NN GLP-1-infusion)) (VP (VBN combined) (PP (IN with) (NP (DT a) (JJ hyperglycaemic) (NN clamp))))) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN in) (NP (NN drug3))) (PP (IN in) (NP (NP (NNS carriers)) (PP (IN of) (NP (NP (DT the) (NN risk) (NN allele)) (PP (IN in) (NP (NP (CD two) (NNS variants)) (PRN (-LRB- -LRB-) (NP (NN drug1) (NN drug2) (NN p) (NN <) (CD 0.02)) (-RRB- -RRB-))))))))))) (, ,)))
(S1 (S (S (NP (PRP we)) (VP (VBD analysed) (NP (NP (NP (NP (CD two) (JJ single) (NN nucleotide) (NNS polymorphisms)) (PRN (-LRB- -LRB-) (NP (NNS SNPs)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (, ,)) (PP (IN in) (NP (DT the) (NN transcription) (NN factor) (NP (NP (NN 7-like) (CD 2) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN TCF7L2)) (-RRB- -RRB-))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN drug3)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT Both) (NN TCF7L2) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (-RRB- -RRB-))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NN drug3)))))))) (SBAR (SBAR (WHADVP (WRB when)) (S (VP (VBG adjusting) (PP (PP (IN for) (NP (NN insulin) (NN sensitivity))) (, ,) (CC both) (PP (IN in) (NP (DT the) (JJ whole) (NN cohort))))))) (CC and) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (JJ diabetic) (NNS subjects)) (VP (VBD were) (VP (VBN excluded)))))))) (. .)))
(S1 (S (S (NP (DT The) (ADJP (RBS most) (JJ significant)) (NNS associations)) (VP (VBD were) (VP (VBN observed) (PP (IN with) (NP (NP (NP (NN TCF7L2) (NN intron) (CD 3) (NN SNPs) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (JJ additive) (NN P)) (ADJP (JJ =) (NP (NP (CD 4.10) (CC x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD -6)) (-RRB- -RRB-))))) (, ,) (NP (NNS odds) (NP (NN ratio) (NN -LSB-OR) (-RRB- -RSB-) (CD 1.51))) (: ;) (NP (NP (NP (JJ admixture-adjusted) (NN P)) (PRN (-LRB- -LRB-) (NP (NN a)) (-RRB- -RRB-))) (ADJP (JJ =) (NP (NP (CD 3.77) (CC x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD -6)) (-RRB- -RRB-))))) (-RRB- -RRB-))) (CC and) (NP (NN drug2)))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN P)) (VP (VBG =) (NP (CD 0.001)))) (, ,) (CC OR) (NP (CD 1.30))) (: ;) (NP (ADJP (NN P) (-LRB- -LRB-) (NN a) (-RRB- -RRB-) (JJ =)) (CD 0.003)) (-RRB- -RRB-))))) (, ,) (S (NP (NP (DT The) (JJ 2-SNP) (NN haplotype)) (VP (VBG containing) (NP (DT these) (NNS SNPs)))) (VP (VBD was) (ADVP (RB also)) (VP (VBN associated) (PP (IN with) (NP (NN drug3))) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 3) (NN x) (CD 10) (-LRB- -LRB-) (CD -5) (-RRB- -RRB-)))) (-RRB- -RRB-)))))))
(S1 (S (S (NP (NP (NP (DT The) (ADJP (RB previously) (VBN reported)) (NNS SNPs)) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN of) (NP (DT the) (NN TCF7L2) (NN gene)))) (VP (VP (VBD were) (ADJP (JJ rare))) (CC and) (VP (VBD were) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug3)) (PP (IN in) (NP (DT a) (JJ Chinese) (NN population))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB attribute) (PP (TO to) (NP (NP (DT the) (JJ low) (NNS frequencies)) (PP (IN of) (NP (DT these) (CD two) (NNS SNPs))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN SNP) (NN drug1)) (ADJP (JJ located) (PP (IN in) (NP (NP (DT an) (NN LD) (NN block)) (ADJP (JJ close) (PP (TO to) (NP (NP (DT the) (CD 3) (`` ') (NN end)) (PP (IN of) (NP (DT the) (NN gene)))))))))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NN drug2))) (PRN (-LRB- -LRB-) (S (S (NP (JJ allele-specific) (NN P)) (VP (JJ =) (NP (CD 0.0021)))) (: ;) (S (NP (JJ permuted) (NN P)) (VP (JJ =) (NP (CD 0.03))))) (-RRB- -RRB-))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN TCF7L2) (NN drug1)) (CC and) (NP (NN drug2) (NNS genotypes)))) (PP (IN on) (NP (NN drug3)))))))
(S1 (S (NP (PRP We)) (VP (VBD observed) (NP (NP (DT a) (JJ significant) (NN association)) (PP (IN between) (NP (NP (DT the) (NP (NP (JJ single-nucleotide) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NN SNP)) (-RRB- -RRB-))) (NN drug1)) (CC and) (NP (DT the) (NN microsatellite) (NN drug2)))) (PP (IN with) (NP (NN drug3)))) (PP (IN in) (NP (DT the) (NN Mexican) (NN sample))))))
(S1 (S (S (S (NP (DT The) (NN SNP) (NN drug1)) (VP (VBZ shows) (NP (JJ similar) (NNS trends)))) (, ,) (CC but) (S (NP (NP (PRP$ its) (NN association)) (PP (IN with) (NP (NN drug2)))) (VP (VBZ is) (RB not) (ADJP (RB as) (JJ strong) (PRN (-LRB- -LRB-) (NP (ADJP (NN OR) (JJ =)) (CD 1.39)) (, ,) (S (NP (NN p)) (VP (JJ =) (NP (CD 0.152)))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (PP (IN In) (NP (DT the) (NN DPS))) (, ,) (NP (NP (DT the) (NN TT) (NN genotype)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT an) (VBN adjusted) (JJ 2.85-fold) (NN risk)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (NN CI) (CD 1.17-6.95)) (, ,) (NP (NN p) (JJ =) (NN 0.021)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (JJ incident) (NNS drug2)) (PP (PP (IN in) (NP (DT the) (JJ control) (NN group))) (, ,) (CC but) (PP (RB not) (IN in) (NP (DT the) (NN intervention) (NN group)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN T) (NN allele)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (VBN decreased) (NN drug2))) (PRN (-LRB- -LRB-) (NP (NP (NNS Studies) (CD II)) (, ,) (NP (CD III))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN variant)) (PP (IN of) (NP (NP (NN drug1)) (PP (IN of) (NP (NN TCF7L2)))))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ incident) (NNS drug2)) (PP (PP (IN in) (NP (DT the) (NN DPS))) (CC and) (PP (IN in) (NP (DT a) (JJ separate) (JJ population-based) (JJ cross-sectional) (NN study))))))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VP (VBD genotyped) (NP (NN 6,516) (NNS participants)) (PP (IN for) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (CC and) (VP (VBN analysed) (NP (NP (DT the) (NN role)) (PP (IN in) (NP (NN drug3) (NN susceptibility)))) (S (VP (VBG using) (NP (JJ binary) (NN logistic) (NN regression.)) (S (NP (NP (NN Age)) (, ,) (NP (NN sex)) (CC and) (NP (NN obesity) (NN status))) (VP (VBD were) (VP (VBN examined) (PP (IN as) (NP (NNS covariates))))))))))))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (S (NP (DT All) (VBN investigated) (NNS polymorphisms)) (VP (VBD were) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NN drug2)))))) (, ,) (CC and) (S (NP (NN drug1)) (VP (VBD showed) (NP (NP (DT the) (JJS strongest) (NN association)) (PRN (-LRB- -LRB-) (NP (NP (NN T)) (CC vs) (NP (NN G))) (, ,) (NP (NP (NN chi2)) (ADJP (JJ =) (NP (CD 9.20)))) (, ,) (NP (NN p) (JJ =) (NN 0.0024)) (, ,) (NP (NP (NNS odds) (NN ratio)) (ADJP (JJ =) (NP (CD 1.70)))) (, ,) (S (NP (CD 95) (NN %) (CD CI)) (VP (JJ =) (NP (CD 1.20-2.41)))) (-RRB- -RRB-)))))) (, ,))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NN drug1)) (VP (VBD showed) (NP (NP (NN association)) (PP (IN with) (NP (NP (CD 30) (`` ') (NN Deltainsulin)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT an) (NN interaction)) (PP (IN with) (NP (NP (NN percentage)) (PP (IN of) (NP (NP (NN body) (NN fat)) (PRN (-LRB- -LRB-) (NP (JJ Bonferroni-corrected) (NN P) (JJ =) (NN 0.027)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (NP (NN drug1)) (ADVP (RB also)) (VP (VBD showed) (NP (NP (DT an) (NN association)) (PP (IN with) (NP (NP (NN beta-cell) (NN compensation)) (PP (IN for) (NP (NP (NNS drug2)) (VP (VBN based) (PP (IN on) (NP (NP (CD 30) (`` ') (NN Deltainsulin)) (PP (IN in) (NP (NP (DT an) (NN interaction)) (PP (IN with) (NP (NP (NN percentage)) (PP (IN of) (NP (NP (NN body) (NN fat)) (PRN (-LRB- -LRB-) (NP (JJ Bonferroni-corrected) (NN P) (JJ =) (NN 0.014)) (-RRB- -RRB-))))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD was) (ADVP (RB also)) (VP (VBN associated) (PP (IN with) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (NP (NNS odds) (NN ratio) (NN -LSB-OR) (-RRB- -RSB-) (NN 2.49) (CD -LSB-95) (NN %)) (NP (NN CI) (CD 1.17-5.31) (-RRB- -RSB-))) (: ;) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.018)))) (-RRB- -RRB-)) (PP (IN in) (NP (PRP$ our) (JJ case-control) (NN sample)))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD observed) (NP (NP (JJ nominal) (NN association)) (PP (IN between) (NP (NP (NP (CD four) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (CD three) (NN haplotype) (NNS blocks)) (CC and) (NP (NP (NP (NN drug5)) (, ,) (NP (NP (NN age)) (PP (IN at) (NP (NN diagnosis)))) (, ,) (CC and) (NP (JJ 2-h) (NN glucose) (NNS levels))) (PRN (-LRB- -LRB-) (NP (NN P) (JJ =) (CD 0.001-0.055)) (-RRB- -RRB-)))))))))) (. .)))
